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ABSTRACT 
 
The menopause is a natural transition that occurs at midlife for a woman and is 
accompanied by a number of symptoms which can significantly affect quality of life, the 
most commonly reported being hot flushes. Impaired cognitive function has also been 
observed in menopausal women and natural alternatives to hormone therapy for the 
alleviation of menopausal symptoms are being sought. The aim of this thesis was to 
investigate the effects of soya isoflavones on cognitive function and menopausal 
symptoms in post-menopausal women. 
In an observational study, food diaries were completed by post-menopausal women 
(n=75). Principal component analysis was used to determine dietary patterns and 
associations with cognitive function, as assessed by CANTAB, were investigated. 5 final 
dietary patterns were identified. The ‘meat and dairy’ dietary pattern was associated with 
greater performance in the spatial working memory cognitive test. ‘The social’ dietary 
pattern was associated with negative effects on cognitive performance as was the 
‘potatoes and poultry’ dietary pattern. 
A randomised controlled trial in post-menopausal women (n=101) was conducted to 
investigate the effects of soya isoflavones on cognitive function and menopausal 
symptoms. Participants consumed a volume of soya drink providing a low (10 mg; control 
group), medium (35 mg) or high (60 mg) dose of soya isoflavones daily for a period of 
12 weeks and cognitive function was assessed using CANTAB (spatial working memory, 
spatial span, pattern recognition memory, 5-choice reaction time and match to sample 
visual search). Menopausal symptoms were also assessed using a validated questionnaire. 
Isoflavone supplementation had no effect on the primary outcome measure, cognitive 
function, although consumption of 350ml of soya drink/day (providing 35mg isoflavones) 
significantly reduced hot flushes in post-menopausal women with more severe symptoms 
at baseline. 
An observational study was conducted using focus groups to determine overall 
perceptions towards soya in post-menopausal women and to partly evaluate the soya 
intervention. Post-menopausal women reported barriers and enablers of consumption as 
well as attitudes towards soya products in an Irish and Northern Irish population. The 
main findings from the focus groups include the awareness of soya in the diet and also 
the benefits that can be attained from consuming soya. Main barriers to soya consumption 
include price and lack of knowledge about soya products while enablers of consumption 
include Alpro® being considered a reliable and good brand. 
This thesis questions the potential benefits of soya isoflavones on cognitive function in 
healthy post-menopausal women within 7 years post-menopause. Future studies should 
X 
 
investigate effects in earlier post-menopausal women and/or in those with mild cognitive 
impairment. Soya isoflavone consumption in post-menopausal women had no effect 
ocognitive function although may alleviate vasomotor symptoms in those with more severe 
symptoms at baseline. With the potential risks associated with hormone therapy, soya 
isoflavones may be a natural alternative for the alleviation of vasomotor symptoms. 
XI 
 
ABBREVIATIONS 
 
ANCOVA Analysis of covariance 
ANOVA Analysis of variance 
BMI Body mass index 
BMR Basal metabolic rate 
 
CANTAB Cambridge neuropsychological automated test battery 
 
CONSORT Consolidated Standards of Reporting Trials 
DASH Dietary Approaches to Stop Hypertension 
DB,PMP Double blind 
DHA Docosahexaenoic acid 
 
EPA Eicosapentaenoic acid 
 
Erα Oestrogen receptor 
 
ERβ Oestrogen receptor 
 
FSH Follicle stimulating hormone 
 
HT Hormone therapy 
 
IF Isoflavone 
 
LC-MS/MS Liquid chromatography tandem mass spectrometry 
 
LH Luteinizing hormone 
 
LMP Last menstrual period 
 
MeDi Mediterranean diet 
 
MIND Mediterranean-DASH Diet Intervention for Neurodegenerative Delay 
 
MMSE Mini mental state exam 
 
MTS Match to sample 
 
MUFA Monounsaturated 
 
PA Physical activity 
XII 
 
 
PMW Post-menopausal women 
PRM Pattern recognition memory 
PUFA Polyunsaturated fatty acid 
RDBP Randomised double blind placebo 
RDBP,CO Randomised double-blind placebo, cross over 
RDBP,P Randomised double blind parallel, placebo 
RTI Reaction time 
SERMS Selective oestrogen receptor modulators 
SSP Spatial span 
SWM Spatial working memory 
VMS Vasomotor symptoms 
1 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1 
 
 
General introduction with aims and objectives 
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The Menopause 
Previous research has highlighted the importance of oestrogen for normal cognitive 
processing. The menopause is characterised by the permanent cessation of menses via the 
depletion of oestrogen levels (Freeman and Sherif, 2007) and is defined as 12 months of 
amenorrhea associated with a natural decline in ovarian hormone secretion (Freeman and 
Sherif, 2007). The average age of the menopause differs vastly among women globally 
(Gold, 2011). As oestrogen levels progressively decline from the onset of the menopause, 
women experience a number of symptoms which vary in severity and frequency on an 
individual basis (Bacon, 2017). These symptoms include vasomotor symptoms, more 
commonly described as hot flushes and night sweats, affecting up to 74% of women in 
Europe (Archer et al., 2011). Vasomotor symptoms can severely interfere with daily 
activities including sleep disturbances and are one of the most common symptoms 
experienced by menopausal women (Nelson et al., 2005). In addition, headaches, and 
memory problems are often reported, with heightened symptoms occurring <2years prior 
to and after cessation of the menstrual cycle, although in some women symptoms may 
continue for several years (Shifren et al., 2014). Due to the persistence of hot flushes 
during the menopause, treatment in the form of hormone therapy (HT) is often sought to 
alleviate symptoms. HT is still the most effective treatment for menopausal symptoms, 
particularly hot flushes (NAMS, 2017, NICE, 2015) albeit there are risks associated with 
HT use for some women. Women who commence treatment above the age of 60 years, 
or are more than 10-20 years since menopause onset, are at increased risk of coronary 
heart disease, stroke, venous thrombosis, and dementia (NAMS, 2017). Furthermore, HT 
may not be an option for some women due to contraindications e.g. family history of 
venous thromboembolism (Armeni et al., 2016). Despite HT being a common treatment, 
some women refrain from use due to these associated side effects. Alternative approaches 
for the treatment of menopausal symptoms are therefore needed. 
Menopause and Cognitive Function 
Memory problems are a common complaint in post-menopausal women (Bojar et al., 
2015a). During the menopause, the intensity and duration of symptoms can have an effect 
on cognitive function and progressive declines in episodic memory, working memory and 
executive function have been observed (Bojar et al., 2015a). Following the menopause, 
cognitive function is affected potentially owing to the reduction in endogenous oestrogen 
levels characteristic of this time. Oestrogen is essential for normal brain functioning due 
to the localisation of oestrogen receptors within the brain. Oestrogen exerts 
neuroprotective effects on brain regions responsible for working memory and learning, 
including the hippocampus, hypothalamus, cerebral cortex and pre-frontal cortex 
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(Fournier et al., 2007, Shaywitz et al., 1999, Spencer et al., 2008). A marked increase in 
hippocampal grey matter in post-menopausal women was reported in a short-term 
oestradiol supplementation trial, a finding potentially owing to the abundance of 
oestrogen receptors in this brain region (Albert et al., 2017). 
Soya isoflavones 
Soya isoflavones show promise as dietary compounds that may illicit beneficial effects 
on cognitive function, particularly in post-menopausal women (Cheng et al., 2015). 
Owing to the structural similarity to 17β-oestradiol (Figure 1), isoflavones have the ability 
to bind to oestrogen receptors located within the brain exerting oestrogenic/antiestrogenic 
effects. Isoflavones are classified as selective oestrogen receptor modulators (SERMS), 
having a higher binding affinity for ER-β than ER-α (Kostelac et al., 2003, Kuiper et al., 
1998). Isoflavones bind to the ER much more weakly than oestrogen (Setchell et al., 
2005a) and, in addition to their oestrogenic effects, also exert physiological effects that 
are ER-independent. Soya foods are a unique rich source of isoflavones. The primary soya 
isoflavones, genistein, daidzein and glycitein represent 50,40 and 10% of total isoflavone 
content respectively (Messina, 2016). Owing to similarity in structure to 17β- oestradiol, 
the most abundant circulating female hormone, soya isoflavones mimic many of the 
physiological actions of oestrogens. Dietary isoflavone intake is approximately 25- 
50mg/day in Japanese populations but is <3mg/day in European and western populations 
(Messina et al., 2006). It has been postulated that the lower incidence of menopausal 
symptoms observed in Japanese populations is attributable to soya consumption and 
genetic factors (Adlercreutz et al., 1992). 
 
Equol is an isoflavan produced exclusively through the conversion of daidzein in the 
intestine and is only produced by 30% of western populations (Lampe et al., 1998, 
Rowland et al., 2000, Setchell and Cole, 2006). In contrast, in Japan, Korea and China, 
80% of individuals have the ability to convert daidzein to equol. (Morton et al., 2002, 
Fujimoto et al., 2008). Equol (7-hydroxy-3-(4
’
-hydroxyphenyl)-chroman) exists as two 
isomers, R-(+) equol and S-(-) equol due to its chiral centre. It has been demonstrated that 
humans produce the S-equol isomer via the bacterial conversion of daidzein following 
soya consumption (Setchell et al., 2005b). Inter-individual variation in the production of 
equol has been attributed to differences in genetics, age and gut microflora (Frankenfeld 
et al., 2004, Roosendaal et al., 1997). It has been postulated that the beneficial effects of 
soya isoflavones are dependent on equol producer status, a theory known as the “equol 
hypothesis” (Setchell et al., 2002, Magee, 2011). 
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Soya Isoflavones and cognitive function 
Soya isoflavones may have beneficial effects on cognitive function, predominantly in 
areas of the brain sensitive to circulating endogenous oestrogen, including those 
responsible for memory and frontal lobe function (File et al., 2005, Soni et al., 2014, 
Cheng et al., 2015, Zaw et al., 2017). Isoflavones can cross the blood brain barrier, (Chang 
et al., 2000, Gu et al., 2005) and influence, areas of the brain susceptible to age-related 
cognitive decline such as the hippocampus and prefrontal cortex, (Cheng et al., 2015, 
Kritz-Silverstein et al., 2003) potentially via interaction with oestrogen receptors that are 
localized within these brain regions (Albert et al., 2017). To date, ten randomized 
controlled trials have investigated the effects of soya/isoflavones on cognitive function 
exclusively in post-menopausal women, with only over half of the studies showing 
beneficial effects (reviewed in Zaw et al., 2017). Contrasting findings are likely due to 
the wide variation in study design. Well-designed randomised controlled trials that 
account for covariates such as cognitive measure, age, supplement type/dose, years since 
menopause and severity of symptoms, are necessary in order to accurately determine the 
role of soya isoflavones on cognition in post-menopausal women. The ability to produce 
equol has been postulated to play a role in aiding cognitive function, although evidence 
in this area is limited (Gleason et al., 2009, Henderson et al., 2012). Equol has the ability 
to increase cerebral blood flow potentially exerting beneficial effects on cognition (Yu et 
al., 2016). In a cross-sectional study of older adults, equol producers performed 
significantly better in tests of cognitive function in comparison to equol non-producers 
(Igase et al., 2017). Further research is required in this area exclusively investigating the 
effects of equol producer status on cognitive function as a primary outcome measure to 
allow firm conclusions to be made. 
Soya isoflavones and hot flushes 
Numerous studies have investigated the effect of soya isoflavones, in both food and 
supplement form (Imhof et al., 2018, Tranche et al., 2016), on hot flushes although 
evidence is inconclusive. Hot flushes are thought to be the consequence of the reduction 
in oestrogen in post-menopausal women. In a systematic review and meta-analysis, Taku 
et al., demonstrated that soya isoflavone supplements significantly reduced hot flush 
frequency and severity in comparison to placebo, with supplements providing more than 
18.8 mg of genistein being twice as potent as lower genistein supplements (Taku et al., 
2012). A Cochrane review has also reported that high levels of genistein consistently 
reduce hot flush frequency (Lethaby et al., 2013). The efficacy of isoflavones on hot 
flushes may be dependent on the severity of symptoms at baseline and on the duration of 
supplementation. A recent randomised controlled trial reported modest but significant 
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attenuation in hot flush frequency with 12 weeks supplementation of 100mg isoflavone 
glycosides, with better effects observed in women with ‘severe’ symptoms at baseline 
(Imhof et al., 2018). In addition, a model based meta-analysis (Li et al., 2015) indicated 
slight but slow effects in attenuating menopausal hot flushes with isoflavone 
supplementation compared to oestradiol, reporting a 25% decrease in hot flush frequency 
with a supplementation period of >13.4 weeks required to reach maximal effect. For 
women that refrain from using HT, isoflavones thus offer an alternative for the alleviation 
of hot flushes. 
Beneficial effects of equol on vasomotor symptoms have also been reported within the 
literature. The ability to produce equol has been associated with reduced severity in 
menopausal symptoms. In one observational study, Japanese equol producers reported 
less severe vasomotor symptoms (Uchyama, 2001). After 12 weeks supplementation with 
S-equol, a significant improvement in hot flush frequency and other symptoms was 
reported in a cohort of equol non-producing post-menopausal women (Aso et al., 2012). 
S-equol derivatives of soya isoflavones are recommended by the North American 
Menopause Society (NAMS) for the non-hormonal management of vasomotor symptoms, 
albeit NAMS highlight the need for further research in this area (North American 
Menopause, 2010). 
Diet and cognitive function 
Poor dietary intake has been reported in post-menopausal women (Bojar et al., 2015b). 
Dietary intake has not been directly investigated in relation to cognitive performance in 
post- menopausal women to date, although there is clear evidence linking several key 
nutrients and cognitive processes in the aging population. Cognitive studies have mainly 
focused on individual nutrients such as omega-3 fatty acids (n-3FA) (Gillette-Guyonnet 
et al., 2013), B-vitamins (Porter et al., 2016), antioxidants (Bowman et al., 2012, Gillette- 
Guyonnet et al., 2007, Kesse-Guyot et al., 2011, McDaniel et al., 2003), vitamin D 
(Annweiler and Beauchet, 2013) , zinc (Maylor et al., 2006), and protein (Roberts et al., 
2012, Goodwin et al., 1983). Dietary patterns have been investigated in post-menopausal 
women and associations with sarcopenia (Kaser et al., 2017), obesity (Papavagelis et al., 
2018), bone mineral density (Hardcastle et al., 2011, Karamati et al., 2012, Sugiura et al., 
2011), cardiovascular disease risk (Papavagelis et al., 2018), and metabolic syndrome 
(Silva et al., 2015); although few have investigated the link with cognitive function. 
Nonetheless, the Mediterranean (MeDi), Dietary Approaches to Stop Hypertension 
(DASH) (Pistollato et al., 2018), and Mediterranean-DASH Intervention for 
Neurodegenerative Delay (MIND) (Berendsen et al., 2018, Morris et al., 2015) diets are 
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associated with favourable effects on cognition. Limited data is available in post- 
menopausal women. 
Omega-3 and omega-6 fatty acids (Cooper et al., 2015), folate, vitamin B6 and vitamin 
B12 (Forbes et al., 2015) are highly reviewed in association with cognitive health (Cooper 
et al., 2015). Long term supplementation of these vitamins in randomised trials has 
demonstrated favourable effects on cognitive performance, although these studies 
primarily focus on elderly populations with little focus in post-menopausal women (de 
Jager et al., 2012, Douaud et al., 2013, Durga et al., 2007, Smith et al., 2010). Dietary 
intake in post-menopausal women should be investigated to determine dietary patterns 
which could illicit beneficial effects in terms of cognitive function. 
Consumer attitudes towards soya 
As popularity of soya has risen there has been an increased interest in research, moreover 
favourable effects have been reported in cardiovascular health, cancer and menopausal 
relief (Messina, 2003, Messina, 2014). As there is clear evidence to suggest the various 
health benefits associated with the addition of soya to the diet, further investigation into 
consumer attitudes and opinions of soya is imperative in populations who may benefit 
from its use. One qualitative method that can be used to collect such information from the 
public is via focus groups using thematic analysis. In a study investigating attitudes and 
beliefs towards soya consumption, participants had a healthy perception associated with 
soya, although were unable to explain why they have this opinion (Schyver and Smith, 
2005). Another focus group study has echoed this perception (Tu et al., 2012). These 
findings highlight a lack of knowledge among the public in relation to the health benefits 
of soya food consumption. Further research is thus required in this area. 
AIMS AND OBJECTIVES 
 
The primary aim of this thesis was to investigate the effects of soya isoflavones on 
cognitive function and menopausal symptoms in post-menopausal women. Secondary 
aims were to investigate associations between diet and cognitive function and attitudes 
towards soya consumption. 
 
 
Objectives of this thesis are as follows: 
 
1. To critically review the existing literature investigating the effects of 
soya/isoflavones on cognitive function and hot flushes in post-menopausal women 
encompassing potential mechanisms (Chapter 2). 
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2. To determine if dietary intake in post-menopausal women is associated with 
cognitive function (Chapter 3). 
 
 
3. To determine if consumption of a soya drink impacts cognitive function and 
menopausal symptoms in post-menopausal women (Chapter 4). 
 
 
4. To investigate consumer perceptions of soya foods in relation to post- 
menopausal health and factors influencing soya consumption (Chapter 5). 
 
 
5. Discuss implications of these studies for future research in this area (Chapter 
6). 
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Figure 1: Structure of the female hormone oestradiol and the soya isoflavones genistein 
and daidzein. 
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Abstract 
Hormone fluctuations in women at the time of the menopause can contribute to health-
related changes especially in the years closest to the menopausal transition. This decline 
in oestrogen concentrations can contribute to menopausal symptoms including 
impairment in cognition, especially memory problems. Isoflavones have been 
demonstrated to illicit beneficial effects on cognitive domains as well as relief from 
menopausal vasomotor symptoms. The aim of this review is to determine the effects of 
soya foods/isoflavones on cognitive function and menopausal symptoms in 
postmenopausal women. While the focus of the review is on cognitive function, effects 
on hot flushes will be summarised. Literature demonstrating the effects of isoflavones on 
cognitive function remains conflicting with over half the studies published in this area 
showing positive, medium effects on cognitive domains. Greater effects are observed 
in those who are <10years from their menopausal transition and severity of symptoms at 
this time may be the cofounding factor. 
Summary findings conclude limitations around the literature when summarizing outcome 
findings, more robust methodology is required in future studies. 
 
 
 
 
Key words: vasomotor symptoms, cognition, isoflavones 
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Introduction 
 
For the majority of women, the menopause is a natural process that occurs due to 
ovarian ageing. Menopause is defined as 12 months of amenorrhea and is associated with 
a natural decline in ovarian hormone secretion (Freeman and Sherif, 2007); as ovarian 
production of oestradiol diminishes, there is a marked increase in follicle stimulating 
hormone (FSH) which is used clinically in classifying menopausal status (Bacon, 2017, 
Shifren et al., 2014). The mean age at which the menopause occurs within the UK 
population is 51 years (NICE, 2015) albeit it can occur much earlier than this 
(early/premature menopause) or be induced by medical intervention (Armeni et al., 2016). 
During the menopausal transition many women experience symptoms which vary 
widely in severity and incidence on an individual basis. Hot flushes and night sweats are 
the most commonly reported vasomotor symptoms experienced during menopause, 
affecting up to 74% of women in Europe (Archer et al., 2011). Other symptoms include 
headache, sleep disturbance, joint and muscle pain, effects on mood, urogenital 
symptoms, sexual difficulties and memory problems (Bacon, 2017, NICE, 2015). As 
endogenous levels of oestrogen progressively decrease with the onset of the menopause 
a change in severity of symptoms may be observed (Shaywitz et al., 1999, Spencer et al., 
2008). Heightened severity of symptoms cluster in the 2 years prior to and after cessation 
of the menstrual cycle although for some women symptoms may continue for several 
years (Shifren et al., 2014). Cognitive impairment accompanied with mood disorders are 
frequently observed in peri- and early postmenopausal women. These symptoms 
including complaints relating to impaired memory, difficulty in performing tasks as well 
as depression and anxiety, are more prevalent within the 5 years following the last 
menstrual cycle (Armeni et al., 2016). 
Hormone therapy (HT) remains the most effective treatment for the vasomotor symptoms 
of the menopause (NAMS, 2017, NICE, 2015), however this treatment is not without risk, 
dependent on treatment type, dosage, duration of use, route of administration and timing of 
commencement of treatment (NAMS, 2017). The benefit-risk ratio appears favourable for 
women <60 years of age who commence treatment within 10 years of onset of the 
menopause providing they have no contraindications. In contrast, women who commence 
treatment above the age of 60 years, or more than 10-20 years since menopause onset, are 
at increased risk of coronary heart disease, stroke, venous thrombosis, and dementia 
(NAMS, 2017). Although early observational studies suggested HT might benefit 
cognitive function, two intervention studies, WHIMS-Young (Espeland et al., 2010) and 
KEEPS-Cog (Wharton et al., 2013) have demonstrated that HT initiated early in 
menopause has neither beneficial nor harmful effects on cognition. 
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One large clinical trial, the Women’s Health Initiative showed no effect of hormone therapy 
on cognitive function. This paper was widely criticized for age of the cohort although 
presented enough evidence for further research into the impact of oestrogens on cognition 
within a younger cohort of women in a more recent transition into the menopause 
(Resnick et al., 2009). Despite HT being relatively safe for otherwise healthy young/early 
post-menopausal women, many refrain from HT use due to the associated side effects 
outlined above or due to medical history. Alternative approaches for the treatment of 
menopausal symptoms are therefore needed. 
Dietary soya isoflavones may illicit beneficial effects in postmenopausal women. 
Isoflavones are similar in structure to 17β-oestradiol and thus can bind to the oestrogen 
receptor (ER) exerting oestrogenic/antioestrogenic effects (Kuiper et al., 1998). Soya 
isoflavones show promise in the treatment of menopausal symptoms, in particular in 
alleviating hot flushes (Kurzer, 2008, Messina, 2014b), however research findings have 
been somewhat controversial and one unequivocal finding among studies is the 
substantial placebo effect observed in randomised controlled trials, highlighting the need 
for studies in this area to be sufficiently controlled. The aim of this review is to determine 
the effects of soya foods/isoflavones on cognitive function and menopausal symptoms in 
postmenopausal women. While the focus of the review is on cognitive function, effects 
on hot flushes will be summarized. 
 
Soya Isoflavones 
 
Soya beans are a uniquely rich food source of dietary isoflavones, containing 
approximately 1.2-4.2 mg/g soya protein, with variables affecting exact concentration 
including climate, soil, or level of processing (Pilsakova et al., 2010). Isoflavones are 
classified as selective oestrogen receptor modulators (SERMS), having a higher affinity 
for ER-β than ER-α (Kostelac et al., 2003, Kuiper et al., 1998). Isoflavones bind to the 
ER with much less affinity than oestrogen (Setchell et al., 2005) and also exert 
physiological effects that are ER-independent. Within the soya bean, isoflavones are 
present as biologically inactive glucosides which are hydrolysed following ingestion to 
form active aglycones (Soni et al., 2014). Soya foods contain three main isoflavones; 
genistein, daidzein, and glycitein, representing 50, 40 and 10% of total isoflavone content 
respectively (Murphy et al., 2002). Daidzein can be further metabolized by intestinal 
bacteria to form the nonsteroidal oestrogen equol (Setchell et al., 2002), however not 
everyone has the ability to perform this biotransformation. Approximately 30% of adults 
among western populations (Lampe et al., 1998, Rowland et al., 2000, Setchell and Cole, 
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2006) and 60% of Asian adults (Liu et al., 2010, Tanaka et al., 2009) have the ability to 
convert daidzein to equol following a soya challenge. In 2002 Setchell et al. proposed the 
‘equol hypothesis’, i.e. that the beneficial effects of soya/isoflavones may be dependent 
on equol producer status and this has been the focus of much research in subsequent years 
(Magee, 2011). Dietary isoflavone intake is approximately 25-50mg/day in Japanese 
populations but is <3mg/day in European and western populations (Messina et al., 2006). 
 
Cognitive function 
 
During the menopause, the intensity and duration of symptoms can have an effect on 
cognitive function and progressive declines in episodic memory, working memory, 
executive function (Bojar et al., 2015), planning and mental flexibility and reductions in 
processing speed have been observed (Greendale et al., 2010, Schaafsma et al., 2010). 
Oestrogen is essential for the regulation and utilisation of neurotransmitters essential for 
cognitive functioning and oestrogen receptors are widely distributed throughout the brain. 
Oestrogen exerts neuroprotective effects on brain regions responsible for working 
memory and learning, including the hippocampus, hypothalamus, cerebral cortex and pre- 
frontal cortex (Fournier et al., 2007, Shaywitz et al., 1999, Spencer et al., 2008). One 
recent study using short-term oestradiol supplementation observed an increase in 
hippocampal grey matter in early postmenopausal women, potentially owing to the 
abundance of oestrogen receptors in this brain region (Albert et al., 2017). Impaired 
cognitive function during the menopausal transition may thus be attributed to decreased 
endogenous levels of oestrogen (Tuomisto et al., 2012). 
Recent evidence has demonstrated that dietary soya isoflavones may illicit beneficial 
effects on cognitive function in postmenopausal women. Isoflavones can cross the blood 
brain barrier (Chang et al., 2000, Gu et al., 2005) and due to their structural similarity to 
17β-oestradiol, can exert oestrogenic/antioestrogenic effects on the hippocampus and pre- 
frontal cortex, areas in the brain susceptible to age-related decline (Cheng et al., 2015, 
Kritz-Silverstein et al., 2003). Animal and in vitro models have demonstrated several 
potential neuroprotective mechanisms (both ER-mediated and non-ER mediated) for 
soya/isoflavones and such mechanisms include reduced neuronal loss, inhibition of β- 
amyloid-induced cell death, facilitation of cholinergic transmission, reduced free radical 
generation, anti-inflammatory and antioxidant effects (Soni et al., 2014) and via the 
modulation of mitochondrial function (Yao et al., 2013). Both animal and in vivo studies 
have demonstrated that oestrogens exert neuroprotective effects within the brain 
(Georgakis et al., 2016). The hippocampus and prefrontal cortex are both influenced by 
isoflavones due to the localisation of oestrogen receptors (ERs) within the brain. An 
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increasing number of studies have presented potential effects of plant compounds on 
maintaining cognitive function. 
 
Intervention Studies 
 
To date, ten randomized controlled trials have investigated the effects of soya/isoflavones 
on cognitive function exclusively in postmenopausal women, yielding inconsistent results 
(Table 1). Six studies have shown beneficial effects of isoflavone consumption on 
cognitive function, (Casini et al., 2006, Duffy et al., 2003, File et al., 2005, Henderson et 
al., 2012, Kritz-Silverstein et al., 2003, Santos-Galduroz et al., 2010) with 
supplementation improving cognitive function tests associated with frontal lobe function 
including mental flexibility and planning, (Casini et al., 2006, Duffy et al., 2003, File et 
al., 2005) sustained attention, episodic memory (Santos-Galduroz et al., 2010), visual 
episodic memory (Henderson et al., 2012) and verbal/semantic memory (Kritz- 
Silverstein et al., 2003). 
In the study by Duffy et al. (2003) soya isoflavone supplementation (60 mg/d for 12 
weeks) improved long-term episodic memory, sustained attention and frontal lobe 
function including mental flexibility and planning in comparison to placebo. When these 
authors repeated the study over a shorter duration of 6 weeks, isoflavone supplementation 
again improved frontal lobe function, however no significant effects were observed on 
sustained attention and long-term episodic memory (File et al., 2005). The duration of 
supplementation may thus be important in determining the effects of isoflavones on these 
cognitive domains. These findings are supported by (Casini et al., 2006) reported a 
significant improvement in mental flexibility with the same dose of isoflavone 
supplementation (60mg/d) over a period of 12 months, although the source of isoflavone 
is not clear. In contrast, isoflavone supplementation had no effect on attention in this 
study, nor in the study by (Ho et al., 2007), albeit different tests were used to assess this 
domain in comparison to the earlier studies. Soya isoflavone supplementation (110 mg/d 
for 6 months) significantly improved verbal/semantic memory as assessed by category 
fluency, with an effect size of 0.54 (Kritz-Silverstein et al., 2003). Although logical 
memory and recall also improved with isoflavone supplementation in this study, the effect 
was not significant. Similarly, other studies have observed no significant differences on 
verbal memory/skills between isoflavone and placebo-treated groups (File et al., 2005, 
Fournier et al., 2007, Henderson et al., 2012, Kreijkamp-Kaspers et al., 2004). 
Variations in study design make it difficult to draw comparisons between the limited 
number of studies conducted. One study used both soya milk and a soya isoflavone 
supplement as treatment (Fournier et al., 2007), whereas other studies intervened with 
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isolated soya isoflavones (Casini et al., 2006, Duffy et al., 2003, File et al., 2005, Ho et 
al., 2007, Kritz-Silverstein et al., 2003) or isoflavone-rich intact soya protein (Basaria et 
al., 2009, Henderson et al., 2012, Kreijkamp-Kaspers et al., 2004). Such differences in 
the form of soya tested may impact on isoflavone bioavailability and pharmacokinetics 
(Cassidy et al., 2006). The isoflavone dose administered in the above studies has ranged 
from 60 to 160 mg/day with duration of supplementation ranging from 6 weeks to 2.5 
years. Age range and duration of time since menopause, as well as the method used for 
specifying hormone level varied widely between studies and may partly explain 
inconsistencies in study findings. Re-analyses of findings from the Women’s Health 
Initiative and Women’s Health Initiative Memory Study have demonstrated that 
oestrogen-containing HT may have beneficial effects on cognition in younger women 
who commence HT within 10 years of the onset of menopause. In contrast null or 
detrimental effects were evident in older women who commenced treatment >10 years 
post-menopause (Zhao and Brinton, 2007). Similarly, evidence indicates that those <10 
years post-menopause may gain most cognitive benefit from soya isoflavones. Kritz- 
Silverstein and colleagues (2003) demonstrated that verbal memory was significantly 
improved (versus placebo) in postmenopausal women following 6 months 
supplementation with soya isoflavones (110 mg/day) and in women aged 50-59 years a 
significant improvement was observed in Trails B (a test of visuomotor tracking and 
attention) whereas this effect was not apparent in older women (aged 60-74 years). 
Furthermore, sub-group analysis within the longest (2.5 yrs) intervention trial conducted 
to date (Henderson et al., 2012) indicated that women <10 years post-menopause were 
most likely to show cognitive improvement following soya supplementation. Such 
findings may partly explain why isoflavone supplementation (91 mg/day) had no effect 
on global cognition in this study given that almost half (42%) of the supplemented cohort 
were >10 years post-menopause. Methodologies used in the assessment of cognitive 
function have also been inconsistent between studies and factors such as time of cognitive 
assessment, time since last meal and whether participants were in a fed/fasted state, or if 
the subjects had consumed caffeine prior to testing can influence cognitive performance 
and are not explicit within the current literature. Only a single study to date has 
investigated the effects of soya foods (rather than supplements) on cognitive function 
(Fournier et al., 2007). Although a decline in verbal working memory compared to soya 
supplement and control groups was observed, the study was subject to limitations 
including: subjective compliance; small sample size, lack of power and factors affecting 
cognitive function were not controlled. While a recent meta-analysis of the studies cited 
above concluded that soya isoflavones appear to have a positive effect on improving 
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summary cognitive function and visual memory in postmenopausal women, a huge 
knowledge gap exists within this area (Cheng et al., 2015, Zaw et al., 2017). There is a 
clear need for well-designed controlled trials utilising robust methodologies to assess the 
effects of soya/isoflavones on cognitive function in postmenopausal women.
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Table 1: Human studies investigating the relationship between soya and cognitive function 
 
 
Reference 
Study 
design 
Sample 
Size/Age 
Study 
duration 
Supplementation Cognitive measure Domains Outcomes 
 
(Duffy et 
al., 2003) 
RDBP, 
P 
33 
50-65yrs 
12 weeks 1.Soya supp 
30mg/2 times/day 
2.Placebo(lactose) 
WMS-R: immediate recall 
DMTS-CANTAB 
Short-term episodic memory Isoflavone group showed 
improvement in long term 
recall of pictures and episodic 
memory 
Picture recall Long-term episodic memory 
Category generation Verbal fluency 
Reversals IDED- 
CANTAB 
Frontal lobe-mental flexibility 
SoC-antab Frontal lobe: Planning 
PASAT-1.2 
PASAT-1.6 
Sustained attention 
(Kritz- 
Silverstein 
et al., 
2003) 
RDBP 56 
55-74yrs 
6 months 1.Soya supp 
110mg/day 
2.Placebo 
(pills not 
specified) 
Logical memory and 
recall 
Verbal/semantic memory 
   
Isoflavone supplementation 
showed positive effect on 
Category fluency Verbal/semantic memory verbal memory, and category 
fluency(P=0.03) Trails A and B Executive function 
  
(Kreijkam 
p-Kaspers 
et al., 
2004) 
RDBP 175 
60-65yrs 
12 months 1.Soya protein 
99mg/day 
2.placebo (25.6g of 
total milk protein) 
MMS, Global cognition No association between 
cognitive function and 
isoflavone consumption. 
Auditory Verbal Learning 
Test, immediate recall, 
delayed recall and 
recognition 
Digit Span test, and the 
Doors test; complex 
attention tasks, 
Memory 
Digit Symbol Substitution Complex attention tasks 
Trail making test Executive function 
Verbal fluency, animals 
and occupation, Boston 
naming task 
Verbal skills 
(File et 
al., 2005) 
DB, 
PMP 
50 
51-56yrs 
6 weeks 1.Soya ISF 
supplement 
DMTS-CANTAB Short term episodic memory  
WMS-story recall Logical memory 
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    Novasoya,60 
mg/day 
2.Placebo 
(capsules not 
specified) 
Delayed story recall 
Delayed picture recall 
Long-term episodic memory Isoflavone supplementation 
showed improvement in 
frontal lobe function Category generation Semantic/verbal fluency 
Reversals IDED- 
CANTAB 
Frontal lobe-mental flexibility 
SoC-Cantab Frontal lobe-planning 
PASAT-1.2 
PASAT-1.6 
Sustained attention 
(Casini et 
al., 2006) 
RDBP, 
CO 
78 
49.5yrs 
6 months 1.Aglycone 
supplement 
60mg/day tablet 
40– 45% genistein, 
40– 45% daidzein, 
10–20% glycitein 
2.Placebo 
unspecified 
Digit Symbol test Psychomotor/processing Isoflavone group showed 
better incidental learning and 
mental flexibility and attention 
WAIS 
Digit span test-back recall 
 
Frontal lobe: mental flexibility 
Visual Scanning test Attention 
(Fournier 
et al., 
2007) 
RDBP 79 
48-65yrs 
16 weeks 1. Cow milk and 
ISF supplement, 70 
mg 
ISF/day) 
2. cow milk and a 
placebo 
supplement 
3. soya drink, 
72mg ISF/day and 
placebo 
supplement 
Stroop task Selective attention Isoflavones did not show an 
increase in cog function. Soya 
group had worse performance 
in verbal working memory 
then supplemented and control 
group. 
Benton Visual Retention 
Test 
Memory recall and recognition 
Colour match task Visuospatial working memory 
Digit Ordering Task Verbal working memory 
Digit span 
Corsi block tapping 
Memory span 
(Ho et al., 
2007) 
RDBPP 191 
56-76y 
6 months Supplement 
80mg/day 
Placebo 
(capsules 
not 
specified) 
Hong kong list learning 
test 
Complex figure test-RO 
Learning and memory No association of isoflavone 
consumption on cog function 
across a number of domains 
WMS-R Visual construction and memory 
Trail making test 
Verbal fluency 
Executive function 
Digit span test 
Digit vigilance test 
Attention concentration 
Finger tapping Motor function 
25 
 
 
 
     Rey-osterrieth copy trail Visual perception  
MMSE Global cognitive function 
(Basaria 
et al., 
2009) 
RDBP 93 
46-76y 
12 weeks 1.Supplement 
160mg/day 
Genistein 64mg 
Daidzein 63mg 
Glycitein 34mg 
2.Placebo powder 
(20g milk protein) 
Trail making 
Cube comparison 
Verbal fluency 
Executive/working  
   
No association of Isoflavone 
consumption on cog function 
across a number of domains 
Grooved pegboard 
Identical pictures 
Psychomotor/processing 
(Henderso 
n et al., 
2012) 
RDBPP 350 
45-92y 
30 months Supplement 
91mg/day 
 
Placebo 
milk 
protein 
Trail making test B 
Symbol digit modalities 
test 
Shipley abstraction 
Letter number sequencing 
Block design 
Judgement of line 
orientation 
Category fluency 
Boston naming test 
Executive function Isoflavone group showed 
greater improvement on visual 
memory factor 
California verbal learning 
test, 
Immediate and delayed 
recall 
East boston memory test, 
Immediate and delayed 
recall 
Verbal episodic memory 
Faces 1 and 2,immediate 
and delayed recall 
Visual episodic memory 
(Santos- 
Galduroz 
et al., 
2010) 
RDBP, 
CO 
38 4 months Supplement 
80mg/day 
Placebo 
(tablets ot 
specified) 
Digit span WAIS-3 Visual spatial memory Increased capacity to integrate 
information in isoflavone 
treated group 
Digit Symbol WAIS-3 Agility and attention 
Similarity WAIS-3 Integrate information 
Verbal paired associated 
(WMS-R) 
Episodic memory 
RDBP Randomised double blind placebo, RDBP CO Randomised double blind placebo-controlled trial, RDBP P Randomised double blind placebo paralell, DB PMP 
Double blind double-blind, placebo-matched parallel groups study. 
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Hot Flushes 
 
The wide variety of symptoms, which are associated with the menopause, can be 
classified into three different categories known as somatic, physiological and vasomotor. 
Somatic symptoms are more commonly described as headaches and dizziness, 
physiological symptoms include mood changes, general malaise and lastly vasomotor 
symptoms are the well-known hot flushes and night sweats (Kurzer, 2008, Messina, 
2014a). 
Most prevalent vasomotor symptom more commonly described as hot flushes can 
severely interfere with daily activities including sleep disturbances (Schmidt et al., 2016) 
and are one of the core symptoms experienced by menopausal women classified under 
vasomotor symptoms (Taku et al., 2012). Due to the persistence of hot flushes during the 
menopause, treatment in the form of hormone replacement is often sought to alleviate 
symptoms. A hot flush is a transient event consisting of a sensation of warmth often 
accompanied by sweating, discomfort and anxiety (Zaw et al., 2017). These symptoms 
are thought to be consequential to the natural reduction in endogenous oestrogen levels at 
the time of the menopause (Lambert et al., 2017). Currently 50-80% of menopausal 
women experience episodes of hot flushes, these can occur as frequently as an hourly 
basis during the day or as infrequently as monthly episodes (Bacon, 2017, Freeman and 
Sherif, 2007). Owing to the low prevalence of hot flushes among native Japanese women 
and their high isoflavone consumption, it was proposed that isoflavones may potentially 
alleviate hot flushes due to their oestrogenic effects (Adlercreutz et al., 1992, Messina, 
2014b). A meta-analysis assessing the efficacy of soya isoflavone extracts or synthesised 
isoflavones on the frequency and severity of hot flushes was conducted in peri and post- 
menopausal women. Effects were reported to be more pronounced in a subgroup of 
women who experienced frequent hot flushes up to or more than 5 hot flushes per day, 
and consistent findings among studies in relation to efficacy associate with isolated 
genistein (Crisafulli et al., 2004). A systematic review by Li et al., 2104 reported a 25% 
decrease in hot flush frequency with isoflavone supplementation >13.4weeks period to 
reach maximal effect as well as imhof et al. showing a modest but significant attenuation 
in hot flush frequency with a 100mg supplement of isoflavone glycosides (Imhof et al., 
2018, Li et al., 2015). Daily ingestion from 30-80mg/day of isoflavones for a duration of 
6weeks to 12 months significantly reduced hot flush frequency (Taku et al., 2012). 
Efficacy of soya isoflavones on hot flushes have been consistently reported in clinical 
trials including numerous sources of isoflavones including soya foods, and isolated 
isoflavones (Imhof et al., 2018, Tranche et al., 2016) . As much as a 20% improvement 
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has been shown in the reduction of frequency of hot flushes (Taku et al., 2012). Several 
trials reported statistically significant slow but slight results in reduction of severity and 
frequency of hot flushes with effect more pronounced in those who suffered >5 hot flushes 
a day (Crisafulli et al., 2004). With the use of isoflavones as ongoing therapy for relief of 
vasomotor symptoms there appears to be no negative side effects of isoflavone treatment. 
Isoflavones provide a safe alternative for PMW. 
 
Equol 
 
As noted above, one potential mechanism attributing to the beneficial effects of soya 
isoflavones is via equol production (Magee, 2011). The ability to produce equol has been 
associated with reduced menopausal symptoms. In an observational study Japanese equol 
producers reported less severe menopausal symptoms and a recent double blind placebo 
controlled trial has demonstrated that supplementation of 10mg equol for 12 weeks 
significantly improved hot flush frequency in equol non-producing post-menopausal 
Japanese women (Aso et al., 2012). To date only two studies have investigated the 
relationship between equol and cognitive function in PMW following soya/isoflavone 
supplementation (Gleason et al., 2009, Henderson et al., 2012). In the study of Gleason 
et al. none of the participants were classified as equol producers and this is likely owing 
to the older age of the cohort (Frankenfeld et al., 2004). Henderson et al reported a trend 
for postmenopausal women following sub group analysis women within soya 
supplemented group who were consistent equol producers to have an improved, albeit 
insignificant, global cognition score compared with placebo. Also, a cross sectional study 
showed equol producers have a beneficial effect on cognitive function after soya intake 
vs non producers (Igase et al., 2017). Thus, further studies are required in this area to 
determine if equol producers derive greater benefits from soya consumption as 
highlighted within the report of the (North American Menopause, 2010). 
 
Conclusion 
 
Soya isoflavones have potential to exert beneficial effects on cognition, potentially via 
their interaction with ERs localised within brain regions which play major roles in 
cognition. It appears that supplementation with soya isoflavones for less than 6 months 
irrespective of dose can improve cognitive performance as well as longer duration studies. 
Literature on the effects of isoflavones on cognitive function remains conflicting with 
only over half the studies showing beneficial effects. `With cognitive measures 
consistently targeting areas of the brain which are ER sensitive, frontal lobe functioning 
has received growing attention. Consistent testing of these areas of the brain showing 
significant improvement would suggest that soya isoflavones may benefit frontal lobe 
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function in the menopause. Trials varying in duration from 6 weeks to 30 months have 
both shown to have positive effects on PMW cognitive performance. Greater effects are 
seen in those who are <10years from their menopausal transition and severity of 
symptoms at this time may be the cofounding factor. Inconsistent findings among trials 
may be due to variations in age and time since menopause. There is a prominent reduction 
of ER-β receptors within the ageing brain, thus areas such as the prefrontal cortex may be 
less responsive to oestrogenic compounds in older age. Summary findings concluded by 
only 10 randomised trials has exposed limitations when summarising outcome findings 
for further studies and therefore enhanced study protocols with more stringent and robust 
methodology are required. 
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ABSTRACT 
 
Background: Dietary intake has been linked with cognitive function, yet few studies have 
investigated diet and cognition in post-menopausal women. 
Objective: This study aimed to investigate associations between dietary patterns and 
cognitive function in post-menopausal women. 
Methods: Dietary intake of post-menopausal women (n=75) with an average age of 54y 
was assessed using a 4-day food diary from which dietary patterns were identified using 
principal component analysis. Cognitive function was measured using the Cambridge 
neuropsychological automated test battery (CANTAB). Multiple linear regression 
analysis and Mann Whitney U tests were used to investigate potential associations 
between dietary patterns and cognitive function. 
Results: Factor analysis identified five dietary patterns; ‘hot beverages and breads’, ‘meat 
and dairy’, ‘potatoes and poultry’, ‘healthy’, and ‘social’. The ‘meat and dairy’ dietary 
pattern was negatively associated with spatial working memory (p = 0.009), measured as 
total errors made (β = -0.308; CI = -0.195, -0.029). The ‘potatoes and poultry’ dietary 
pattern was positively associated with five-choice reaction time (p = 0.045), measured as 
reaction time latency in milliseconds, (β = 0.245; CI = 0.000, 0.030). The ‘social’ dietary 
pattern showed a negative association with match to sample visual search (p = 0.017), 
measured as mean correct reaction time in milliseconds (β = 0.289 CI = 0.006, 0.056). 
Conclusion: In post-menopausal women, inclusion of alcohol can have negative effects on 
cognitive performance. Furthermore, intakes of potatoes and poultry can have negative 
effects of cognitive performance. This finding concludes that high intake of meat and dairy 
may have a beneficial effect on cognntive function in post menopausal women. 
 
 
 
 
 
Key words: Dietary patterns; post-menopausal women; cognitive function 
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INTRODUCTION 
 
Memory problems are commonly reported during the menopause (Etgen et al., 2011, 
Sturdee and de Villiers, 2011) and reduced cognitive performance has been observed in 
women at this time (Bojar et al., 2015, Greendale et al., 2010, Schaafsma et al., 2010). 
Oestrogen is essential for normal cognitive processing (Shaywitz et al., 1999, Spencer et 
al., 2008). Higher oestradiol levels in older post-menopausal women have been associated 
with better memory and global cognitive function (Lebrun et al., 2005), as well as greater 
episodic memory (Hogervorst et al., 2004, Ryan et al., 2012). Furthermore, a significant 
association between oestradiol concentration and cognitive dysfunction has been reported 
in healthy post-menopausal women, highlighting a potential benefit of oestradiol 
replacement therapy (Gholizadeh et al., 2018). Thus, impaired cognitive function may be 
attributed to decreased endogenous levels of oestrogen during the menopause (Tuomisto 
et al., 2012). 
Adequate nutritional intake may play a role in slowing the onset of cognitive decline 
(Pistollato et al., 2018). Research has shown the benefits associated with adequate 
nutritional intake in the prevention of Alzheimer’s disease and dementia (Morris et al., 
2015, Berendsen et al., 2018). In elderly individuals showing signs of cognitive 
dysfunction, there occurs an increased risk of Alzheimer’s disease (Goodwin et al., 1983, 
Roberts et al., 2012), in which the Mediterranean diet (MeDi) has shown preventative 
effects counteracting the onset (Morris et al., 2015). An inadequate nutritional intake 
defined by insufficient contribution of micronutrients in the diet has been observed in 
women during the menopausal transition (Bojar et al., 2015), thus dietary intake during 
the menopause may have important consequences in relation to cognitive health. 
Previous studies investigating the relationship between diet and cognition have focused 
mainly on individual nutrients, particularly, omega-3 polyunsaturated fatty acids (n-
3PUFA) (Gillette-Guyonnet et al., 2013), B-vitamins (Porter et al., 2016), antioxidants 
(Bowman et al., 2012, Gillette-Guyonnet et al., 2007, Kesse-Guyot et al., 2011, McDaniel 
et al., 2003), vitamin D (Annweiler and Beauchet, 2013), zinc (Maylor et al., 2006), and 
protein (Roberts et al., 2012, Goodwin et al., 1983). Other diets, associated with a 
healthier lifestyle, have been linked with a slower rate of cognitive decline and dementia 
e.g. the Dietary Approaches to Stop Hypertension (DASH) diet, and a hybrid of the 
DASH (Pistollato et al., 2018), and MeDi (Morris et al., 2015, McEvoy et al., 2017) 
namely the Mediterranean-DASH Diet Intervention for Neurodegenerative Delay 
(MIND) diet (Berendsen et al., 2018, Morris et al., 2015). The MeDi has been postulated 
to play a critical role in cognitive health (Kesse-Guyot et al., 2012). Characterised by a 
higher intake of green leafy vegetables, fish, and nuts, the MeDi has been associated with 
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beneficial effects in relation to physical and cognitive health. Adherence to a MeDi diet 
as investigated by Singh et al., was associated with a 27% reduced risk of developing 
cognitive impairment (Singh et al., 2014), a finding echoed in a meta-analysis by 
Psaltopoulou et al., showing that high adherence to the MeDi is associated with less 
cognitive impairment (Psaltopoulou et al., 2013). Other studies have linked the MeDi 
with a slower rate of cognitive decline (Alvarez-Alvarez et al., 2018, Gonzalez et al., 
2018). Similarly, the original PREDIMED trial, designed to assess the MeDi and health 
outcomes in a cohort of high-risk vascular individuals, showed small but significant 
benefits on global cognition (Martinez-Lapiscina et al., 2013). The MIND diet has shown 
promising results in areas of verbal memory in later life (Berendsen et al., 2018) and has 
also been positively associated with a slower rate of cognitive decline (Morris et al., 
2015). Although evidence consistently demonstrates the beneficial effects of dietary 
components on cognitive function (Berendsen et al., 2018), there is limited data available 
in post-menopausal women. 
The MeDi is often characterised by the high intake of n-3 and n-6 PUFA, highly reviewed 
nutrients in association with cognitive health (Grosso et al., 2014a, Grosso et al., 2014b, 
Hallahan et al., 2016). Nilsson et al., observed an improvement in cognitive function 
following 5-weeks’ supplementation with n-3 PUFA in a cohort of healthy adults aged 51–
72 years (Nilsson et al., 2012). Docosahexaenoic acid (DHA), and eicosapentaenoic acid 
(EPA) have also been postulated to have beneficial effects on cognitive health in aging 
(Bojar et al., 2015, Denis et al., 2013). Folate, vitamin B6 and vitamin B12 are essential 
for normal brain function (Forbes et al., 2015). Folate is essential for the down regulation 
of homocysteine through the enzymatic reaction of methionine synthase to produce 
methyl cobalamin. Methyl cobalamin is required for methylation of homocysteine to 
methionine. Low vitamin B status is associated with increased blood levels of 
homocysteine, which could potentially disturb metabolism and cause cognitive 
impairment (Forbes et al., 2015). Long term supplementation of these vitamins in 
randomised trials has demonstrated favourable effects on cognitive performance, 
although these studies primarily focus on elderly populations (de Jager et al., 2012, 
Douaud et al., 2013, Durga et al., 2007, Smith et al., 2010). It is evident that research is 
needed in the area of B-vitamins and cognitive health particularly in post- menopausal 
women. 
As the nutrients outlined above are not consumed in isolation, this creates limitations in 
ascertaining their specific contribution to cognitive health. Dietary pattern analysis 
overcomes these limitations by accounting for the cumulative effect of nutrients or 
potential interactions among foods (Hu, 2002, Loy and Mohamed, 2013). Previous 
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studies have investigated dietary patterns in post-menopausal women in association with 
sarcopenia (Kaser et al., 2017), obesity (Papavagelis et al., 2018), bone mineral density 
(Hardcastle et al., 2011, Karamati et al., 2012, Sugiura et al., 2011), cardiovascular 
disease risk (Papavagelis et al., 2018), and metabolic syndrome (Silva et al., 2015). Few 
studies have investigated associations with cognitive function. One study explored the 
relationship between dietary patterns and mental health in a cohort of Chinese post- 
menopausal women. Three dietary patterns were identified; ‘processed foods’, ‘whole 
plant foods’, and ‘animal foods’. A higher intake of whole plant foods and a low intake 
of processed foods was associated with a reduced risk of depression and perceived stress. 
A link between depression and a deficit in brain domains responsible for executive 
function, memory, and attention has been identified (Kaser et al., 2017, Citraro et al., 
2015). Furthermore, depression is associated with poorer cognitive function (Murrough 
et al., 2011), indicating that components of these dietary patterns may attribute to 
favourable outcomes in relation to cognitive performance. Another study investigated the 
relationship between dietary patterns and mid-life cognitive performance (Kesse-Guyot 
et al., 2012). Two dietary patterns were established using factor analysis; a ‘healthy’ 
dietary pattern that included fruit, wholegrains, vegetables, fats, nuts and fish and a 
‘traditional’ dietary pattern that included vegetables, vegetable fat, meat and poultry. A 
better global cognition score was associated with the ‘healthy’ dietary pattern and 
adherence to this dietary pattern may help preserve global cognitive function, particularly 
verbal memory. There are a limited number of studies in this area therefore further studies 
are required to investigate the relationship between dietary patterns and cognitive 
function, specifically in post-menopausal women. The aim of this study is to investigate 
the association between dietary patterns and cognitive function in a convenient sample of 
post-menopausal women residing in Northern Ireland. 
 
METHODS 
Study Characteristics 
The present study utilised baseline data from a 12-week randomised controlled trial 
conducted at Ulster University, Coleraine, Northern Ireland. All procedures were 
approved by Ulster University’s Research Ethics Committee (REC/15/0025) and the 
study was registered at www.clinicaltrials.gov (NCT03561662). The study was 
undertaken between the months of October 2015 to June 2018 and was designed to 
examine the effects of soya on cognitive function and menopausal symptoms in post- 
menopausal women. 
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Subjects 
Apparently healthy post-menopausal women within 7 years of their last menstrual cycle 
were considered suitable for inclusion. Exclusion criteria were as follows: not currently 
taking any HRT or isoflavone supplements, not a habitual soya consumer, not currently 
using any psychoactive medication, not suffering from cardiovascular disease, cancer, 
diabetes, thyroid, renal or kidney disease, alcohol or drug abuse and not prescribed any 
antibiotics within the last 3 months. Women were excluded from the study if they had 
cognitive impairment as determined by a Mini Mental State Examination (MMSE) score 
<24; psychiatric distress as determined using a General Health Questionnaire-28 
(Goldberg and Hillier, 1979) score of ≥26; red-green colour blind, assessed via the 
Ishihara test (as CANTAB testing requires colour recognition); abnormal full blood 
profile (assessed via a Sysmex KX21-N, Sysmex Ltd, UK at Ulster University) and/or 
insufficient renal/hepatic performance assessed via kidney and liver function tests 
(assessed photometrically via a Cobas 6000 analyzer [Cobas C501 module], Roche 
Diagnostics at Causeway hospital). 
 
Anthropometric measures 
Trained personnel obtained weight (kg) and height (m) measurements. Standing body 
height was measured using a calibrated stadiometer (SECA, Model 220, Germany). Body 
weight was measured to the nearest 0.1kg using Seca 770 electronic weighing scales 
(Brosch Direct Ltd, Peterborough, United Kingdom), without footwear and heavy 
clothing. Body mass index (BMI) was calculated as weight (kg)/height (m2). A validated 
health and lifestyle questionnaire was used to collect information regarding education, 
smoking, alcohol and physical activity to assess metabolic equivalent tasks (METs) 
hours/week. Estimated basal metabolic rate (BMR) (Kcal/d) was calculated according to 
the following equation for all participants (Henry, 2005). 
 
BMR = 8.18 (weight kg) + 502 (height m) - 11.6 
Dietary Measures 
Dietary intake was assessed by completing a prospective 4 day semi-quantitative food 
diary at baseline (two weekdays and two weekend days; to account for the known variation 
in day-to-day intake) (Stallone et al., 1997). Comprehensive written and verbal 
instructions were given to all participants on the method of recording dietary intake and 
participants were advised not to modify usual dietary habits. Returned food diaries were 
reviewed in order to clarify errors with participants. The nutritional analysis software 
package Nutritics was used to calculate energy and nutrient intakes. Total dietary intake 
41 
 
was generated for each participant, including type, quantity of food eaten, as well as 
energy and nutrient values corresponding to weight of food consumed.  
 
Dietary Patterns: Principal Component Analysis 
A total of 19 food groups and their total consumption over the 4-day period (total g) were 
generated. Foods were grouped according to the types of food or by similarities in nutrient 
content manually using excel. (see Table 1 for food items included in each group). Factor 
loadings for dietary patterns are shown in Table 2. The factors were rotated by an 
orthogonal transformation with the varimax option which maintains uncorrelated factors 
and produces a simpler structure with easier interpretability. Food loading with greater 
than 0.3 on a component were considered for the dietary patterns. The criterion for 
remaining factors included those with an eigenvalue greater than 1 as well as an 
interpretation of the generated scree plot (see Figure 1) showing a break. 
 
Over/Under Reporting of Energy Intake 
Energy intake (kcals/day) for each participant was manually aggregated using SPSS 
based on data collected from Nutritics. Estimated energy intake for each participant was 
assessed and used to determine the number of under reporters, over reporters and 
plausible reporters. The validity of participants’ reported energy intake as calculated from 
the 4 day food diary was assessed using Goldberg et al,. (Goldberg et al., 1991) cut offs 
as outlined by Black (Black, 2000). A physical activity level (PAL) of 1.4 was used as 
recommended based on the age of the cohort validated by Henry et al., (Henry, 2005). For 
the current cohort of post-menopausal women, an EI:BMR of over 2.49 and under 0.78 
was indicative of over and under-reporting, respectively, based on a PAL of 1.4 (Black, 
2000). A total of n=1 were deemed to be ‘over-reporters’, n=8 were deemed to be ‘under 
reporters’ and n=66 were deemed to be ‘plausible reporters’. Overall, the mean reported 
EI for plausible reporters (n=66) was found to be 1607 kcals/day, which was 84% of 
estimated energy requirements (EER; determined by BMR*1.4). In contrast, the mean 
reported EI for under-reporters (n=8) was 1115kcals/day, which was 54% of EER (results 
not shown).  
 
Cognition 
Cognitive function was measured using the Cambridge neuropsychological automated 
test battery (CANTAB), Research Suite; Cambridge Cognition, UK) (CANTAB, 2015). 
Cognitive measures used were designed to target areas of the brain which are susceptible 
to oestrogen related decline. CANTAB has been extensively validated for assessing brain-
to-behaviour relationships in adult populations (Robbins et al., 1998, Robbins et 
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al., 1994), has proven test-retest reliability (Louis et al., 1999) and is deemed suitable for 
use with older adults (Robbins et al., 1994). The following tests were used: spatial 
working memory (SWM), spatial span (SSP), pattern recognition memory (PRM), 5- 
choice reaction time (RTI) and match to sample visual search (MTS). The tests chosen 
activate areas of the brain that are associated with cognitive decline during the 
menopausal transition and that are sensitive to hormonal changes, including the 
hippocampus (Albert et al., 2017) and prefrontal cortex (Shanmugan and Epperson, 
2014). SWM and SSP activate the temporal and frontal lobe regions of the brain; PRM 
activates the temporal lobe, hippocampus and amygdala; RTI, and MTS activate the 
fronto-striatal circuitry (Robbins TW, 1997). The procedure for assessing SSP, RTI and 
MTS are described in detail elsewhere (Simpson et al., 2005). Spatial working memory 
(SWM), a sensitive measure of frontal lobe and executive function, requires retention and 
manipulation of visuospatial information. The test began with 4 coloured squares (boxes) 
shown on the screen. Participants were required, by selecting boxes and using a process 
of elimination, to find one blue ‘token’ in each of 4 boxes (only one token is hidden at a 
time) and use them to fill up an empty column on the right-hand side of the screen. 
Touching any box in which a token has already been found is an error. The trial was then 
repeated three times with 4 boxes and then progressed to four trials with 6 boxes and four 
trials with 8 boxes. The colour and position of the boxes used are changed from trial to 
trial to discourage the use of stereotyped search strategies and a practice test was 
completed prior to testing. The outcome measure was SWM total errors made i.e. the 
number of times a box is selected that is certain not to contain a token and therefore should 
have not been visited by the participant. Visual memory was assessed using the Pattern 
Recognition Memory (PRM) test in a 2-choice forced discrimination paradigm. 
Participants were asked to remember a series of 12 abstract coloured patterns, each 
presented for 3s. They were then presented with a series of 12 pairs of old-new patterns 
and were asked to touch the pattern seen previously in each case. This procedure was 
repeated with a second set of 12 patterns followed by 12 pairs of patterns for recognition. 
The outcome measure was mean correct latency i.e. the mean time (milliseconds) to 
respond correctly. 
 
Statistical Analyses 
All analysis was completed using the statistical package for social sciences (SPSS, 
version 24, IBM, Chicago, IL, USA). Normality tests were carried out for all data, and 
indicated that food group, nutrient intake and cognitive data were not normally 
distributed. Descriptive analysis was carried out and all data is expressed as mean and 
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standard deviation. Non-parametric statistical tests were completed for comparison of 
differences between all participants (n=75) and plausible reporters only (n=66). Multiple 
linear regression analysis was used to examine relationships between dietary patterns, 
nutrients and cognitive function while controlling for factors also known to influence 
cognitive function (age, education). Following calculation for energy misreporting, 
principal component analysis was complete. 
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RESULTS 
The general health and lifestyle characteristics and dietary intake of the participants is 
presented in Table 3. A total of 75 participants successfully completed and returned the 
4-day food diary. A total of 9 (12%) participants were classified as under reporters, 1 
(1.3%) as an over reporter and 65 (86.67%) as plausible reporters. 
 
Identification of Dietary Patterns 
Principal component analysis was carried out with both plausible (n=65) and all 
participants (n=75) and there was no difference in the dietary patterns generated. Principal 
component analysis was completed with all participants (n=75) and resulted in 5 dietary 
patterns, ‘hot beverages and breads’, ‘meat and dairy’, ‘potatoes and poultry’, ‘healthy’, 
and ‘social’. Using19 food groups the dietary patterns generated accounted for 48.76% 
of total variance in the diet of this cohort. The scree plot identified the break point of 
dietary patterns to be retained. The ‘hot beverages and breads’ pattern explained 14.73% 
of the variance. The ‘meat and dairy’ pattern accounted for 10.26% of the variance and 
was made up of meat and dairy, western foods including snacks such as cakes and 
biscuits, eggs, and red meat. The ‘potatoes and poultry’ pattern, characterised by potato, 
snacks and chicken, accounted for 8.67% of the variance. The ‘healthy’ pattern explained 
7.7% of total variance and consisted of healthier dietary choice snacks and alternative 
milks. The ‘social’ pattern accounted for 7.41% of total variance and consisted of alcohol 
and savoury snacks. 
 
Dietary patterns and cognitive function 
Table 4 shows the associations between dietary patterns and cognitive function using 
multiple regression analysis. The “hot beverages and breads” pattern was the most 
commonly consumed dietary pattern among post-menopausal women, although this 
pattern as well as the “healthy” dietary pattern did not present any significant associations 
with cognitive measures. The ‘meat and dairy’ dietary pattern was negatively associated 
with SWM (p = 0.009), measured as total errors made (β = -0.308; CI = -0.195, -0.029). 
The ‘potatoes and poultry’ dietary pattern was positively associated with RTI (p = 0.045), 
measured as reaction time latency in milliseconds, (β = 0.245; CI = 0.000, 0.030), 
representing an effect size small in magnitude. The ‘social’ dietary pattern showed a 
negative association with MTS (p = 0.017), measured as mean correct reaction time in 
milliseconds (β = 0.289 CI = 0.006, 0.056).
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DISCUSSION 
 
Five main dietary patterns were identified in this cohort of post-menopausal women. 
“Meat and dairy”, a dietary pattern associated with intake of protein, was significantly 
associated with a reduction in errors in spatial working memory, representative of a 
greater performance in a measure of frontal lobe function. The ‘potatoes and poultry’ 
dietary pattern was associated with a slower performance time in a cognitive test 
measuring cognitive domains associated with attention and psychomotor speed. Alcohol 
intake represented in the ‘social’ dietary pattern was associated with slower visual 
matching ability and poorer performance in short term visual recognition memory.  
Our findings support previous literature demonstrating that adherence to a diet rich in 
dairy protein is linked to greater cognitive health (LaRue et al., 1997, Roberts et al., 2012). 
These links are associated with activations at the anterior brain region frontal lobe, 
affecting non-verbal learning and verbal memory domains. Our findings indicate that a 
diet rich in protein and dairy is associated with a greater ability to retain and manipulate 
visuospatial information. Similarly, when we considered individual nutrient intake, 
protein intake was associated with a significant improvement in SWM. 
In support of our findings, one longitudinal study (Crichton et al., 2012) demonstrated a 
significant cognitive improvement in multiple brain domains in individuals that consumed 
dairy once a day, compared to those who rarely consume dairy. Beneficial effects on 
global cognitive function, spatial memory, organisation working memory and executive 
function were observed, although it is yet to be investigated what underlying causal 
mechanisms are at play. In contrast, a recent randomised controlled trial investigating the 
association between dairy intake and cognitive function showed no effect, a finding likely 
owing to the fact that baseline comprehensive cognitive performance data were not 
available (Kesse-Guyot et al., 2016). One review reported that increased risk of vascular 
dementia and poorer cognitive function is associated with lower consumption of milk or 
dairy products. In contrast, whole fat dairy products were potentially associated with 
cognitive decline in the elderly, likely due to the saturated fat content. While findings 
suggested that dairy consumption may have a beneficial effect on cognitive function, the 
review highlighted the need for well-controlled, long-term intervention trials to confirm 
this theory (Crichton et al., 2010). Interestingly, a MeDi diet supplemented with dairy 
foods has been shown to improve processing speed in comparison to a low-fat control 
diet in an ageing Australian population (Wade et al., 2018). 
In this study, the “potatoes and poultry” pattern, high in carbohydrates and chicken dishes 
was significantly associated with a poorer performance in RTI, a measure focused on areas 
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of the brain associated with attention and psychomotor speed. The “potatoes and poultry” 
dietary pattern is representative of intakes of carbohydrates and protein (Gibson, 2007, 
Goodwin et al., 1983, Williams and Rollo, 2015). In contrast to our findings, a recent 
review concluded that a high intake of fruit and vegetables, whole grains legumes, pulses 
and potatoes are key for the prevention of cognitive decline (Kiefte-de Jong et al., 2014). 
As discussed above, protein has also been associated with having favourable effects on 
cognitive function (Goodwin et al., 1983, Daly et al., 2015) although evidence in this area 
is novel. 
The “social” dietary pattern in this cohort, which loaded highly for alcohol and savoury 
snacks, was associated with a slower reaction time in MTS, i.e. slower visual matching 
ability and poorer performance in short term visual recognition memory. It has been 
clearly established in the literature that alcohol-dependant individuals are subject to age 
related cognitive decline as seen in neuropathological studies (Harper, 1998). In contrast, 
there is a lack of conclusive findings showing that small to moderate amounts of alcohol 
have a negative effect of cognitive function (Hassing, 2018, Vasiliadis et al., 2018); more 
recent evidence suggests no relationship (Sun et al., 2018). One recent study in a Chinese 
population has demonstrated that alcohol consumption is associated with poorer episodic 
memory and reduction in consumption could help preserve cognitive degeneration in this 
population (Ge et al., 2018). 
Studies investigating associations between dietary intake and cognitive function, as 
dietary patterns or singular nutrient approaches in younger adults are limited. The 
majority of previous studies in this area have been conducted in participants ≥65y whereas 
the mean age of participants in our study was 54y. Also, with the average age of the onset 
of the menopause being 51y of age, findings in elderly cohorts are not representative of 
early post-menopausal women. Cognitive studies in mid-life adults are required, 
particularly focused in post-menopausal women (Bojar et al., 2015). Gardener et al., 
report that executive function and visuospatial brain functions are highly sensitive to 
dietary intake (Gardener et al., 2015); interestingly, these specific areas of the brain are 
highly sensitive to reduced function during the menopause (Bojar et al., 2015). One large 
longitudinal study of generally healthy individuals with no cognitive impairment aged 
60-64y identified that a MeDi was not protective of cognitive decline (Cherbuin et al., 
2011) , this contradictory finding on efficacy of the MeDi is likely owing to variances 
within study designs such as age, severity of cognitive impairment within the cohort, 
dietary and cognitive measures used. 
This study has numerous strengths. PCA is the most common method for obtaining 
dietary patterns. This study also has limitations. This contrast in findings may be 
attributed to the wide variety of tests used to assess cognitive function, study protocols 
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differ vastly also contributing to the contrast in findings among studies in this area. The 
sample size of this cohort is small, dietary data is often representative of a much larger 
sample size. Nonetheless this study has provided novel findings in the area of dietary 
patterns and cognitive function in post-menopausal women. These findings present new 
evidence to consider in further studies which are focused on dietary intake in post-
menopausal women and their potential beneficial effects on cognitive decline. 
CONCLUSION 
 
In conclusion, among the five dietary patterns identified the ‘meat and dairy” dietary 
pattern showed favourable effects on cognitive function, the protein content in this dietary 
pattern is postulated to contribute to these findings. There is a lack of research 
investingating dietary patterns in relation to cognitive health in post- menopausal women. 
Considering the importance of dietary intake on cognition in the elderly, further studies 
should consider the importance of dietary intake and its association within post-
menopausal women. 
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Table 1: Food groups used in dietary pattern analysis 
 
Food Group Food items 
  
Alcohol Alcoholic drinks, spirits wines, larger, stout 
Beverages Coffee, fruit juices, soft drinks, teas, squash, cordials 
Biscuits & Cakes 
Biscuits, cookies, cakes, desserts, candy sweets, 
chocolate, confectionary, non-chocolate confectionary 
Breads Bread, rolls, bagels, tortilla, flat breads, sandwiches 
Cereals & Grains 
Cereal bars, cereals, muesli, crackers, crisps breads, 
flours, pastas, pastry, doughs, pizzas, rice 
Dairy 
Cheeses, cow’s milk, creams, drinking yoghurts, eggs, 
milkshakes, smoothies, processed milks, powders 
Fats & Oils Oils, spreading fats 
Fish 
Canned fish, fatty fish, low fat fish, seafood dishes, 
shellfish 
Fruit Fruit, dried fruit 
Meat Bacon, beef, lamb, meat products, pork 
Miscellaneous 
Food additives, herbs and spices, salts, sauces, sugars, 
syrups, preserves 
Non-dairy Oat milk, soya milk, almond milk, rice milk 
Nuts & Seeds Nuts, seeds, trail mix, almond butter, peanut butter 
Potatoes Potato crips, crisps, potato products, potatoes, 
Poultry Chicken, poultry dishes 
Savoury snacks 
Cous cous, taco shell, prawn crackers, papadums, 
Yorkshire pudding, stuffing, popcorn, breadsticks 
Soup Packet soups, soups 
Vegetables & Legumes 
Beans, peas, lentils, leafy vegetables, mushrooms, fungi, 
roots, tubers, bulbs, vegetable dishes 
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Figure 1: Scree plot indicating cut off for Dietary Patterns. 
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Table 2: Factor loadings for dietary pattern identified by principal component analysis 
(PCA) for n=75 food diaries 
 
Food Group 
Hot 
beverages 
and breads 
Meat and 
dairy 
Potatoes 
and poultry 
 
Health 
 
Social 
Fats & Oils .857 - - - - 
Breads .768 - - - - 
Beverages .485 - - - - 
Meat - .881 - - - 
Dairy - .559 -.377 - - 
Potatoes - - .760 - - 
Poultry - - .722 - - 
Alternative milks - - - .761 - 
Fruit - - - .633 - 
Savoury snacks - - - -.451 .449 
Alcohol - - - - .727 
Biscuits & Cakes - .417 - - -.593 
Cereals & Grains - - - - - 
Miscellaneous - - - - - 
Nuts & Seeds - - - .407 - 
Sauces - - - - - 
Vegetables - .327 - - - 
Soup - - - - - 
Fish - - -.306 - - 
 
% of variance explained 14.73 10.26 8.66 7.7 7.41 
Only food groups with factor loading values of -0.3 or 0.3 were included, some food groups were excluded 
as they did not load onto any factor retained. 
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Table 3: Characteristics of all participants and plausible reporters only 
 
Descriptives 1All participants n=75 1Plausible n=66 
2P 
 
Height, m 1.63  .065 1.63  0.06 .816 
Weight, kg 70.12  13.13 68.79  11.89 .588 
BMI, kg/m2 26.42  5.24 26.03  4.46 .673 
Age, y 54.07  3.8 54.49  3.72 .635 
Alcohol, units/wk 8.07  9.81 8.70  10.28 .710 
Education, % 
 
Primary 
 
 
1 
 
 
2 
 
Secondary 41 41 
 
Tertiary 56 56 .992 
PA, METs/week 181.34  66.28 181.11  67.57 .990 
LMP, mo 36.96  21.12 38.31  21.14 .840 
FSH, IU/ml 87.97  30.46 89.67  29.84 .708 
 
BMI, body mass index, METs, metabolic equivalents, PA, physical activity, LMP, time since last menstrual period, FSH, 
follicle stimulating hormone 
1mean ± SD 
2No significant differences were observed between all reporters and plausible reporters of dietary intake as determined using a 
Mann Whitney U 
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Table 4: Multiple regression analysis of dietary pattern predictors of cognitive function in post-menopausal women (all participants). 
Hot beverages and breads Meat and dairy Potatoes and poultry Healthy Social 
Cognitive test2    
β 95%CI β 95%CI β 95%CI β 95%CI β 95%CI 
 
RTI .156 -.005, 0.24 -.070 -.018, .010 .245 .000, .030* -.088 -.019, .009 .136 -.006, .022 
SSP -.036 -.027, 0.020 .112 -.012, .033 .032 -.021, .027 .005 -.022, .023 -.074 -.030, 016 
SWM -.095 -.125, 0.56 -.308 -.195, -.029* .076 -.065, .122 .169 -.024, .146 -.003 -.090, .087 
PRM -.033 -.025, 0.019 -.206 -.040, .001 -043 -.027, .019 .033 -.018, .024 -.002 -.022, .021 
MTS .043 -.022, 0.031 .062 -.019, .032 .126 -.013, .042 -.052 -.031, .020 .289 .006, .056* 
2RTI, five-choice reaction time measured as reaction time latency (milliseconds); SSP, spatial span measured as longest sequence length recalled correctly; SWM, spatial working memory measured as total errors made; PRM, 
pattern recognition memory measured as mean correct latency (milliseconds); MTS, match to sample visual search measured as mean correct reaction time (milliseconds). 
*significant results p<0.05 
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ABSTRACT 
 
Purpose: Cognitive decline is commonly reported during the menopausal transition, with 
memory and attention being particularly affected. The aim of this study was to investigate 
the effects of a commercially available soy drink on cognitive function and menopausal 
symptoms in postmenopausal women. 
Methods: 101 postmenopausal women, aged 44-63 years, were randomly assigned to 
consume a volume of soy drink providing a low (10 mg/day; control group), medium (35 
mg/day) or high (60 mg/day) dose of isoflavones for 12 weeks. Cognitive function (spatial 
working memory, spatial span, pattern recognition memory, 5-choice reaction time and 
match to sample visual search) was assessed using CANTAB. Menopausal symptoms 
were assessed using Greene’s Climacteric Scale. 
Results: No significant differences were observed between the groups for any of the 
cognitive function outcomes measured. Soy drink consumption had no effect on 
menopausal symptoms overall, however when women were stratified according to the 
severity of vasomotor symptoms (VMS) at baseline, women with more severe symptoms 
at baseline in the medium group had a significant reduction (P=0.001) in VMS post- 
intervention (mean change from baseline score: -2.15 ± 1.73) in comparison to those with 
less severe VMS (mean change from baseline score: 0.06 ± 1.21). 
Conclusions: Soy drink consumption had no effect on cognitive function in 
postmenopausal women. Consumption of ~350ml/d (35mg IFs) for 12 weeks 
significantly reduced VMS in those with more severe symptoms at baseline. This finding 
is clinically relevant as soy drinks may provide an alternative, natural, treatment for 
alleviating VMS, highly prevalent among western women. 
Keywords: isoflavones, CANTAB, menopausal symptoms, hot flush, hot flash, equol 
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INTRODUCTION 
 
Cognitive decline is commonly reported by peri- and post-menopausal women and 
deteriorations in memory, attention and processing speed have been observed during the 
menopausal transition (Kok et al., 2006; Schaafsma et al., 2010; Epperson et al., 2013; 
Maki and Henderson et al., 2016). These effects have been attributed to a reduction in 
circulating oestrogen concentrations (Shanmugan and Epperson, 2014) albeit, this has 
been contested (Henderson., 2008). Hormone therapy (HT) remains the most effective 
treatment for vasomotor menopausal symptoms (VMS) (North American Menopause 
Society, 2017) and early observational studies supported a beneficial effect of HT on 
cognitive function (Mc Carrey and Resnick, 2015). Two recent intervention studies have 
demonstrated that HT initiated early in menopause has neither beneficial nor harmful 
effects on cognition (Espeland et al., 2013; Wharton et al., 2014). Furthermore, despite 
HT being commonly prescribed for otherwise healthy young/early post-menopausal 
women, many refrain from HT use due to the health risks associated with HT use in older 
women (North American Menopause Society., 2017; Marjoribanks et al., 2017). 
Alternative, natural approaches for the treatment and prevention of menopausal 
symptoms are thus being sought. 
Dietary soy isoflavones (IFs) have been reported to be efficacious in the treatment of hot 
flushes (Taku et al., 2012) and to have the potential to enhance cognitive function in 
postmenopausal women, having the ability to cross the blood brain barrier in small 
amounts (Chang et al., 2000; Gu et al., 2005). Genistein and daidzein, the main IFs present 
in the soy bean, can bind to oestrogen receptors (ERs), and are classified as selective ER 
modulators, having a higher affinity for ER-β than ER-α  (Kuiper et al., 1998; Oseni et al., 
2008). ERs are localised throughout the adult brain including the hippocampus, where 
ER7 is more highly expressed in comparison to ER777 and are also localised within 
the prefrontal cortex (Shanmugan and Epperson, 2014). These areas are important for 
learning, memory, attention and higher-order cognitive function and are particularly 
susceptible to age-related decline (Burke and Barnes, 2006). Both  ER-mediated  and 
non- ER mediated neuroprotective effects have been demonstrated for soy/IFs using in 
vitro and animal models (Yao et al., 2013; Soni et al., 2014;). Nevertheless, 
randomized controlled trials investigating the effects of soy/IFs on cognitive function 
in postmenopausal women have yielded inconsistent findings, with some showing 
positive effects on cognitive function (Duffy et al., 2003; Kritz-Silverstein et al., 2003; 
File et al., 2005; Casini et al., 2006; Santos-Galduroz et al., 2010) and others 
demonstrating null/negative effects (Kriejkamp-Kaspers et al., 2004; Fournier et al., 
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2007; Ho et al., 2007; Basaria et al., 2009). Two recent comprehensive reviews (Soni et 
al 2014; Zaw et al., 2017) have highlighted several variations in study design that have 
likely contributed to these disparate outcomes including: age; time since menopause; 
habitual soy/IF intake; IF dose, duration, bioavailability and metabolism and cognitive 
function assessment. To date only one study has investigated the effects of soy/IFs on 
cognitive function in postmenopausal women using a food (soy milk) (Fournier et al., 
2007) rather than a supplement. There is, therefore, a need for additional, well-designed 
studies to further assess the effects of IFs on cognitive function. 
In line with the ‘critical window hypothesis’ of HT and cognitive function that postulates 
that optimal effects are evident with early initiation (Maki, 2013), limited evidence 
suggests that younger postmenopausal women (< 60 y) may gain more cognitive benefit 
from soy IFs in comparison to their older counterparts (Kritz-Silverstein et al., 2003). It 
has also been postulated that the effects of soy on health may be determined by an 
individual’s equol producer status (Setchell et al., 2002). S-equol, a potent ligand for 
ER77 is an isoflavan formed exclusively via the bacterial conversion of daidzein in the 
intestine (Setchell et al., 2005) and is only produced by ~30% of western populations 
following a soy challenge (Lampe et al., 1998; Rowland et al., 2000; Setchell and Cole et 
al., 2006). The ability to produce equol has been associated with reduced VMS (Newton 
et al., 2015). Furthermore, S-equol supplementation alleviates hot flushes (Aso et al., 
2012) and S-equol derivatives of soy IFs are now recommended by the North American 
Menopause Society for the non-hormonal management of VMS (North American 
Menopause Society, 2015), who have highlighted the need for further studies in this area. 
The aim of this study was to investigate the effects of a commercially available soy drink 
on cognitive function and menopausal symptoms in postmenopausal women. 
SUBJECTS AND METHODS 
 
Design 
 
This 12-week parallel group, randomised, controlled trial was conducted between 
October 2015 and May 2018. All procedures were approved by Ulster University’s 
Research Ethics Committee (REC/15/0025) and the study was registered at 
www.clinicaltrials.gov (NCT03561662). Participants were recruited throughout the 
province of Ulster and screening, baseline and post-intervention appointments were 
conducted before and after the 12-week intervention either at the university, the 
participant’s home or at a location convenient for the participant. The duration of 
intervention was based on previous intervention studies in postmenopausal women that 
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have demonstrated that soy IF supplementation (60 mg/d) for 6 weeks significantly 
improves frontal lobe function (File et al., 2005), with significant improvements in 
sustained attention and long-term episodic memory additionally observed when 
supplementation is extended to 12 weeks (Duffy et al., 2003). The primary outcome of 
the study was effect on cognitive function and the secondary outcome was effect on 
menopausal symptoms. Sub-analysis investigated the effect of the intervention based on 
severity of VMS at baseline and also investigated cognitive function and menopausal 
symptoms according to equol producer status. 
Participants 
 
Eligible participants were apparently healthy women within 7 years post menopause (i.e. 
1-7 y since last menstrual period). Postmenopausal status was confirmed based on a serum 
concentration of follicle-stimulating hormone (FSH) >30 mIU/ml (assessed via 
electrochemiluminescence immunoassay on a Cobas 8000 analyzer [Cobas 602 module], 
Roche Diagnostics at Antrim Area hospital). Exclusion criteria included: surgically 
induced menopause; habitual consumers of soya foods (> 2 serves/week); current use of 
HT or IF supplements; antibiotics use within the previous 3 months; current use of 
psychoactive medication; presence or history of cardiovascular disease, cancer, diabetes, 
thyroid, renal or kidney disease, alcohol or drug abuse; cognitive impairment as 
determined by a Mini Mental State Examination score <24; psychiatric distress as 
determined using a General Health Questionnaire-28 (Goldberg and Hillier, 1979) score 
of ≥26; red-green colour blind, assessed via the Ishihara test (as CANTAB testing requires 
colour recognition); abnormal full blood profile (assessed via a Sysmex KX21-N, Sysmex 
Ltd, UK at Ulster University) and/or insufficient renal/hepatic performance assessed via 
kidney and liver function tests (assessed photometrically via a Cobas 6000 analyzer 
[Cobas C501 module], Roche Diagnostics at Causeway hospital). 
Intervention 
 
An independent clinical trials manager used MINIM software (Minim, 2017) to 
randomise recruited women to one of three treatment groups with an allocation ratio of 
1:1:1 Participants were asked to consume soy drinks (Alpro®) providing a low (10 
mg/100ml), medium (35 mg/350ml) or high (60 mg/600ml) dose of IFs daily for a period 
of 12 weeks and could choose from different flavours of drink (original, unsweetened, 
chocolate or strawberry). Limited evidence suggests that IFs consumed in divided doses 
may be more effective in alleviating menopausal symptoms than a single dose (Kurzer, 
2008; Crawford et al., 2013), thus women were advised to spread their intake throughout 
the day. The group that consumed the lowest dose of IFs was considered a low dose 
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control group as beneficial effects of soy IFs on postmenopausal health have previously 
been observed in intervention studies at much higher doses (Messins, 2014); furthermore, 
it was not possible to obtain a placebo control drink. Previous soy/IF intervention studies 
on cognitive function in postmenopausal women have used doses ranging from 60 – 160 
mg IFs per day (Duffy et al., 2003; Kritz-Silverstein et al., 2003; File et al., 2005; Casini 
et al., 2006; Santos-Galduroz et al., 2010; Henderson et al., 2012; Kreijamp-Kaspers et 
al., 2004; Fournier et al., 2007; Ho et al., 2007; Basaria et al., 2009). This study utilised 
a dose that was achievable in a commercially available soy drink and at a volume that 
was easily incorporated into an individual’s daily diet. Compliance was monitored by 
measuring plasma concentrations of soy IFs. Total genistein, daidzein and equol 
concentrations were assessed using LC-MS/MS by LGC Limited (Cambridgeshire, UK). 
Equol producers were defined as those with a plasma equol concentration of > 20nmol/L 
(5 7g/L) (Setchell and Cole, 2006). 
Dietary intake, anthropometrics and general health and lifestyle 
 
Weight (kg) and height (cm), were measured at baseline and used to calculate BMI 
[weight (kg)/height (m)2]. Body weight was measured to the nearest 0.1kg using Seca 770 
electronic weighing scales (Brosch Direct Ltd, Peterborough, United Kingdom), without 
footwear and heavy clothing. Standing body height was measured to the nearest 0.1cm 
using a Seca 220 stadiometer (Seca Ltd, Hamburg, Germany). The participant stood 
without footwear, with their heels together, hands and arms hanging relaxed, and 
measurements were taken with the Frankfurt plane in a horizontal position. Dietary intake 
was assessed at baseline and post-intervention using a four-day food diary. Participants 
received instructions on how to complete the diary from a trained researcher and dietary 
intake was analysed using Nutritics nutritional analysis software (Nutritics, Research 
Edition v5.031). A general health and lifestyle questionnaire was completed by 
participants at baseline and provided information on age, gender, marital status, education 
level, occupation, smoking habits, alcohol use, dietary habits and physical activity. 
Blood collection and processing 
 
Fasted blood samples were collected by a trained phlebotomist before and after 
intervention for the analysis of serum FSH and plasma IF concentrations. Participants 
were instructed to fast from 10pm the night prior to blood sampling and water intake was 
encouraged. Fasted blood samples were obtained from the antecubital fossa using a 21- 
gauge butterfly needle and 8mL serum and 9mL ethylenediametetraacetic acid (EDTA) 
plasma vacutainer tubes (Greiner Bio-One GmbH, Kremsmunster, Austria). Following 
inversion, serum samples were allowed to clot for >60 min and plasma samples placed in 
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refrigeration until full blood profile analysis. Following this, all tubes were centrifuged at 
2200rpm for 15 min at 4°C to allow separation of whole blood into its respective 
components. Following separation, serum and plasma samples were divided into aliquots 
and stored at -80°C until further analysis. 
Cognitive function 
 
Pre- and post-intervention cognitive function was assessed in the morning, after 
participants had consumed a standard, caffeine-free, breakfast. Cognitive function was 
assessed using the Cambridge Neuropsychological Test Automated Battery (CANTAB 
Research Suite; Cambridge Cognition, UK) (CANTAB, Cambridge Cognition 2015). 
CANTAB has been extensively validated for assessing brain-to-behaviour relationships 
in adult populations (Robbins et al., 1994; Robbins et al., 1998), has proven test-retest 
reliability (Louis et al., 1999) and is deemed suitable for use with older adults (Robbins 
et al., 1998). The following tests were used: spatial working memory (SWM), spatial span 
(SSP), pattern recognition memory (PRM), 5-choice reaction time (RTI) and match to 
sample visual search (MTS). The tests chosen activate areas of the brain that are 
associated with cognitive decline during the menopausal transition and that are sensitive 
to hormonal changes, including the hippocampus (Albert et al., 2017) and prefrontal 
cortex (Shanmugan and Epperson, 2014). SWM and SSP activate the temporal and frontal 
lobe regions of the brain; PRM activates the temporal lobe, hippocampus and amygdala; 
RTI, and MTS activate the fronto-striatal circuitry (Robbins et al., 1997). The procedure 
for assessing SSP, RTI and MTS are described in detail elsewhere (Simpson et al., 2005). 
Spatial working memory (SWM), a sensitive measure of frontal lobe and executive 
function, requires retention and manipulation of visuospatial information. The test began 
with 4 coloured squares (boxes) shown on the screen. Participants were required, by 
selecting boxes and using a process of elimination, to find one blue ‘token’ in each of 4 
boxes (only one token is hidden at a time) and use them to fill up an empty column on the 
right-hand side of the screen. Touching any box in which a token has already been found 
is an error. The trial was then repeated three times with 4 boxes and then progressed to 
four trials with 6 boxes and four trials with 8 boxes. The colour and position of the boxes 
used are changed from trial to trial to discourage the use of stereotyped search strategies 
and a practice test was completed prior to testing. The outcome measure was SWM total 
errors i.e. the number of times a box is selected that is certain not to contain a token and 
therefore should have not been visited by the participant. 
Visual memory was assessed using the Pattern Recognition Memory (PRM) test in a 2- 
choice forced discrimination paradigm. Participants were asked to remember a series of 
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12 abstract coloured patterns, each presented for 3s. They were then presented with a 
series of 12 pairs of old-new patterns and were asked to touch the pattern seen previously 
in each case. This procedure was repeated with a second set of 12 patterns followed by 
12 pairs of patterns for recognition. The outcome measure was mean correct latency i.e. 
the mean time (milliseconds) to respond correctly. 
Menopausal symptoms 
 
The Greene Climacteric Scale (Greene, 2008) was used to assess menopausal symptoms 
at baseline and post-intervention. This 21-item scale provides three main independent 
measures of psychological, somatic and vasomotor symptoms. Participants were asked to 
indicate the extent to which they were currently bothered by the list of symptoms on a 
scale from 1 ‘not at all’ up to 4 ‘extremely’. 
Statistical analyses 
 
An a priori power calculation was conducted using spatial working memory total errors 
data obtained from the study of Thompson et al. (Thompson et al., 2005). Based on the 
probability of a type 1 error (7) = 0.05 and a Power of 0.9, 41 participants were required 
in each group to be able to reject the null hypothesis that the population means of the 
treatment groups are equal. To allow for dropouts, we aimed to recruit 150 women to the 
study. All statistical analyses were performed using the Statistical Package for the Social 
Sciences (SPSS) with significance set at P < 0.05 throughout (IBM SPSS Statistics for 
Windows, version 24.0, IBM Corp, Armok NY). Only those participants that had 
completed cognitive testing at both baseline and post-intervention were included in the 
analysis. Intention-to-treat analysis was also performed including all participants 
randomised at baseline and did not change the primary outcome findings. The Shapiro- 
Wilk test was used to determine whether data followed a normal distribution and skewed 
variables were log-transformed to attain a normal distribution prior to analysis or analysed 
using non-parametric statistical tests. Transformations were applied to SWM, SSP, PRM, 
RTI and MTS data. Descriptive statistics were used to present participant characteristics 
at baseline. The effect of intervention on the primary outcome measures of cognitive 
function (SWM, SSP, PRM, RTI and MTS) were analysed using an analysis of covariance 
(ANCOVA) with baseline measures included as covariates. The secondary outcome 
measure of menopausal symptoms was analysed using a Kruskal-Wallis test. IF 
concentrations were compared between groups using a Kruskal-Wallis test with post-hoc 
analysis conducted using a Mann-Whitney U test. Two outliers with post-intervention 
genistein concentrations of > 800 ng/ml in the low dose treatment group and one in the 
high dose group (baseline genistein of 275 ng/ml) were removed prior to statistical 
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analysis of IF concentrations between groups. Sub-analysis was conducted to determine 
if the effect of the intervention on cognitive function and menopausal symptoms was 
significantly different between equol producers and non-producers using a Mann- 
Whitney U test. This test was also used in sub-analysis to investigate the effect of the 
intervention on VMS stratifying women according to severity of VMS at baseline. Dietary 
intake pre- and post-intervention was analysed using the Wilcoxin Signed Rank test. 
RESULTS 
 
A total of 101 postmenopausal women completed the study and were included in the final 
analysis. Participant progress through the study is illustrated in the CONSORT diagram 
(Moher et al., 2012) in Figure 1. Baseline demographic characteristics of the study 
participants are shown in Table 1. There was no significant difference at baseline between 
the groups for any of the characteristics presented. Table 2 shows the effect of the 
intervention on cognitive function; no significant differences were observed between the 
groups for any of the cognitive function outcomes measured (RTI, SSP, SWM, PRM, 
MTS). The soy drink had no effect on menopausal symptoms overall (Table 3), however, 
when women were stratified according to the severity of their VMS (hot flushes and night 
sweats) at baseline by splitting into two groups above/below mean, women with more 
severe VMS at baseline in the medium group had a significant reduction in symptoms 
after consuming the soy drink for 12 weeks, in comparison to those with less severe 
symptoms at baseline (Table 4). Furthermore, this observed reduction in symptoms was 
significantly greater in comparison to that observed in women with more severe VMS at 
baseline in the low dose control group (P = 0.015, Mann-Whitney U test) and the high 
dose group (P=0.044). 
Compliance, as assessed via plasma IF concentrations appeared good (Table 5), albeit 
some women found it difficult to consume the instructed volume of soy drink in the high 
dose group, with seven women failing to complete the intervention for this reason. Blood 
samples were available for IF analysis for 95 participants at baseline and 87 post- 
intervention. IF concentrations were not significantly different between groups at 
baseline. As expected, post-intervention genistein concentration was significantly higher 
in the medium (P = 0.007) and high (P = 0.013) dose groups in comparison to the low 
dose group. Post-intervention daidzein was also significantly higher in the medium 
(P=0.006) and high (P=0.029) dose groups versus the low group. There was no significant 
difference in post-intervention IF concentrations between the medium and high dose 
groups. Some 28.7% of the cohort were classified as equol producers with n=7, n=9 and 
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n=9 participants classified as equol producers within the low, medium and high dose 
groups respectively. In sub-analysis cognitive performance was not significantly different 
according to equol status (Table 6) albeit, within the high dose group, spatial working 
memory improved in equol producers (change from baseline -9.44 ± 15.69, n=9) in 
comparison to non-producers (2.36 ± 13.24, n=23), though this effect did not reach 
significance (P = 0.066). VMS were significantly lower in equol producers in comparison 
to non-producers at both baseline (3.67 ± 1.01 vs 4.49 ± 1.60, P = 0.022) and post- 
intervention (2.96 ± 1.04 vs 3.86 ± 1.67, P = 0.046). 
Energy intake, carbohydrate, protein and total fat intake were not significantly different 
between the low, medium and high dose groups at baseline or post-intervention (Table 
7). In the high dose group, protein and total fat intake (expressed as % energy intake) 
were significantly lower post-intervention in comparison to baseline. Using the Goldberg 
cut-off technique (57), 12.8% and 15.7% of participants were identified as mis-reporters 
at baseline and post-intervention respectively. Of these, 3 were within the low, 2 within 
the medium and 5 within the high dose groups at baseline with 6 within the low, 2 within 
the medium and 3 within the high dose groups post-intervention. 
DISCUSSION 
 
In the current study, consumption of a soy drink for 12 wks, providing 35 or 60 mg of 
IFs/d, had no effect on visual memory, working memory or attention, in apparently 
healthy postmenopausal women in comparison to consumption of a low dose control 
providing 10 mg IFs/d. Menopausal symptoms were unaffected by soy drink consumption 
albeit, sub-analysis identified a potential beneficial effect of soy IFs in women with more 
severe VMS at baseline. In contrast to our primary findings, File et al. (File et al., 2005) 
observed an improvement in frontal lobe function (mental flexibility and planning) when 
healthy postmenopausal women, of similar age range to the current study, consumed an 
IF supplement (60 mg/d) for 6 wks in comparison to a placebo. This group previously 
performed a similar study investigating the effect of 12 wks supplementation (Duffy et 
al., 2003) and, in addition to improvements in frontal lobe function, long-term episodic 
memory and sustained attention significantly improved. Using the same dose of IFs as 
that of our high dose group (60 mg/d, 6 mo), Casini et al. observed an improvement in 
psychomotor performance as assessed by the Digit Symbol test in a placebo-controlled 
crossover study (Casini et al., 2006). In contrast, we observed no improvement in 
psychomotor speed as assessed via RTI albeit, the duration of supplementation in our 
study was shorter. In line with our findings, Casini et al. observed no significant effect on 
attention as assessed by the Visual Scanning test or on mental flexibility assessed by the 
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Digit Span test. Similarly, other studies that have assessed memory/attention using the 
Digit Span Test have observed no significant effects of IF supplementation (Santos- 
Galduroz et al., 2010; Kreijkamp-Kaspers et al., 2004; Fournier et al., 2007; Ho et al., 
2007). In the only study conducted within an Asian population, Ho et al. found no effect 
of IF supplementation (80 mg/d for 6 mo) on Digit Span or other standard 
neuropsychological tests in healthy Chinese postmenopausal women (Ho et al., 2007). A 
notable difference of this study, however, was the mean habitual soy IF intake of 20 mg/d. 
Additional studies that report improvements in cognitive function with soy IF 
supplementation have used much higher doses and have intervened over a longer duration 
than that used in the current study (Krtiz-Silverstein et al., 2003; Santos-Galduroz et al., 
2010; Henderson et al., 2012). Kritz-Silverstein et al. observed a significant improvement 
in verbal memory, as assessed by category fluency, following supplementation with 110 
mg/d IFs for 6 mo (Kritz-Silverstein et al., 2003). In women aged 50-59 y a significant 
improvement was observed in Trails B, a test of visumotor tracking and attention, whereas 
this effect was not apparent in older women (60-74 y), suggesting that younger 
postmenopausal women may especially benefit from soy IFs. This finding is supported 
by Kreijkamp-Kaspers et al. who observed no significant effects on cognitive function, 
including Trailmaking B, in a cohort of older postmenopausal women, aged 60 – 75 y, 
following supplementation with 99 mg IFs daily for 12 mo (Kreijkamp-Kaspers et al., 
2004). In the longest intervention trial conducted to date, supplementation of 91 mg IFs 
daily for 2.5 years had no effect on global cognition, executive function or verbal episodic 
memory in healthy postmenopausal women albeit, an improvement in a visual memory 
factor was observed (Henderson et al., 2012). In contrast to our study, there was a wide 
age range in this study (45 – 92 y) with almost half of the cohort > 10 years post 
menopause; sub-analysis suggested such women were less likely to show cognitive 
improvement and this may, therefore, have influenced the null findings in this study. 
Similar to our findings, Basaria et al. found no effect of 12 wks IF supplementation on 
cognitive function; albeit they did not assess visuospatial function and the IF dose used 
was 3 – 5 times higher than that used in the current study (Basaria et al., 2009). 
To our knowledge, only one other study has investigated the effects of IFs on 
postmenopausal cognition in the form of a soy drink (Fournier et al., 2007). In this study, 
consumption of IFs via a drink (72 mg/d) or a supplement (70 mg/d) over 16 wks did not 
improve short-term memory, long-term memory, working memory or selective attention 
as assessed using tests similar to those used in our study. The soy milk group showed a 
poorer performance in verbal working memory in comparison to the supplement and 
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control groups; albeit this study was subject to limitations including subjective 
compliance, lack of power and lack of controls, owing to the quasi-experimental design. 
Variations in study design make it difficult to draw direct comparisons between the 
findings of our study and previous work. Although two studies utilised CANTAB to 
assess cognitive function (Duffy et al., 2003; File et al., 2005), neither used the same tests 
as the current study. Given the wide range of methodologies currently available to assess 
cognitive function, there is a need to identify a standard method and testing suite to enable 
better comparison between studies and reliably inform scientific knowledge in this area. 
We did not reach our recruitment target of 41 participants/group, largely due to 
participants not meeting the stringent inclusion criteria (of note was the substantial 
number of postmenopausal women currently on antidepressants) however, the study was 
still adequately powered (80% power) to detect significant effects. Reference ranges are 
not provided for the CANTAB tests used for healthy populations however, our data 
concur with a previous study in healthy older women (Lenehan et al., 2016). 
In agreement with previous literature, 28.7% of our study cohort were equol producers 
(Lampe et al., 1998; Rowland et al., 2000; Setchell and Cole, 2006). Limited evidence 
suggests that the ability to produce equol may confer beneficial effects on cognitive 
function following soy intake (Igase et al., 2017), potentially via increased cerebral blood 
flow (Yu et al., 2016). We did not observe any significant differences in cognitive 
performance following intervention between equol producers and non-producers 
although, within the high dose group, improvements in spatial working memory in 
producers versus non-producers was approaching significance. Our findings support 
those of Henderson et al. (Henderson et al., 2012) who observed a nonsignificant trend 
towards improved global cognition in consistent equol producers. Similar to Henderson’s 
study, the sample size in the current study was likely too small to adequately investigate 
the role of equol in cognitive performance and further research in this area is warranted. 
In agreement with our findings, previous studies, including 2 that used the same scale as 
that in the current study (Duffy et al., 2003; File et al., 2005), have reported no effect of 
IF supplementation on menopausal symptoms (Duffy et al., 2003; File et al., 2005; Ho et 
al., 2007). Basaria et al. observed an improvement in menopausal symptoms using the 
Menopause-specific Quality of Life questionnaire however, the dose used in this study 
was very high (160 mg/d) (Basaria et al., 2009). A recent meta-analysis has demonstrated 
that soy IF supplementation can significantly reduce hot flush frequency and severity in 
comparison to placebo, with supplements containing > 18.8 mg of genistein being most 
effective (Taku et al., 2012). In support of these findings, our study has shown that women 
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with more severe VMS at baseline showed a significant improvement in symptoms 
following consumption of 35 mg IFs/d (providing ~18 mg genistein) in comparison to 
those consuming 10 mg/d. This observation was not replicated in the high dose group, 
possibly due to the sample size, thus further studies are required to confirm these findings. 
Our findings in the medium group are in agreement with an open-label crossover study 
that demonstrated a commercial soy drink (ViveSoy®), providing ~50 mg IFs per day for 
12 wks, improved climacteric symptoms including hot flushes in peri/postmenopausal 
women (Tranche et al., 2016). Previous research on the effects of soy foods on 
menopausal symptoms is limited (Levis and Griebeler, 2010) and our findings warrant 
further study in this area. In support of the role of S-equol in the alleviation of VMS 
(Newton et al., 2015), equol producers in the current study had significantly lower VMS 
scores throughout in comparison to non-equol producers. 
Strengths of this study include the use of digital cognitive assessment, CANTAB. 
Cognitive assessment was strictly controlled with participants consuming the same 
standard caffeine-free breakfast prior to testing at both timepoints. Time since menopause 
was kept within a defined limit of < 7 y and compliance was closely monitored. The main 
limitations of the study were the absence of a placebo control and the non-blinded study 
design. Nonetheless, the low dose control drink provided only 10 mg IFs/d, an amount 
well below that typically consumed in Asian populations (~25 – 50mg/d) (Messina et al., 
2006) and well below the lowest dose previously used in intervention studies on cognitive 
function in postmenopausal women (60 mg/d) (Duffy et al., 2003; File et al., 2005; Casini 
et al., 2006). Given that we used a commercially available soy drink in the current 
intervention study, we were limited with regard to the dose of IFs that could be tested. 
Nonetheless, it is important to investigate the effects of soy foods in addition to IF 
supplements as consumers may gain additional nutritional benefits from consuming soy 
food as part of a healthy balanced diet (Messina, 2016). Furthermore, IF pharmacokinetics 
are similar following ingestion of soy foods and IF supplements (Setchell et al., 2011). 
In conclusion, a commercially available soy drink had no effect on cognitive function in 
postmenopausal women. Consumption of ~350ml/d (providing 35 mg IFs) for 12 wks 
significantly reduced VMS in those women with more severe symptoms at baseline, a 
finding with potential clinical relevance that warrants further research given the high 
prevalence of VMS in western women (Archer et al., 2011; Thurston et al., 2011). 
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TABLE 1 
 
Baseline participant characteristics1,2. 
 
Soy IF treatment group 
Measure3 Low (n=35) Medium (n=37) High (n=29) 
Age, y 53.69 ± 3.724 53.86 ± 3.28 53.72 ± 4.62 
Height, m 1.61 ± .065 1.64 ± .062 1.63 ± .073 
Weight, kg 70.32 ± 12.36 71.48 ± 13.85 72.91 ± 14.86 
BMI, kg/m2 26.97 ± 5.22 26.76 ± 5.73 27.37 ± 5.77 
Non-Smokers (%) 94.12 100 100 
Alcohol, units/wk 
Education level (n) 
7.64 ± 6.58 11.73 ± 12.60 7.44 ± 10.21 
Primary 0 1 0 
Secondary 19 13 12 
Tertiary 15 21 16 
PA, METs/week 165.17 ± 56.32 184.70 ± 57.48 192.74 ± 76.98 
LMP, mo 31.97 ± 19.05 39.33 ± 21.99 39.38 ± 23.25 
FSH, IU/ml 83.02 ± 34.44 88.79 ± 28.33 85.84 ± 33.84 
GHQ-28 16.91 ± 4.82 14.73 ± 5.48 15 ± 4.6 
MMSE 29.17 ± .79 29.03 ± 1.07 29.21 ± .73 
1 Characteristics were not significantly different between treatment groups. 
2FSH, follicle stimulating hormone; GHQ-28, General Health Questionnaire-28; LMP, time since last menstrual period; 
METs, metabolic equivalents; MMSE, Mini Mental State Examination; PA, physical activity 
3 Data on smoking, alcohol use, education and physical activity was unavailable for 4 participants (n = 1, n = 2 and n= 1 in 
the low, medium and high dose groups respectively) as they failed to complete the health and lifestyle questionnaire. 
4 mean ± SD (all such values with the exception of smoking and education) 
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Table 2 
 
Cognitive function of postmenopausal women at baseline and following 12 weeks’ soy drink intervention1. 
 
 
 
Treatment group 
Low (n=35) Medium (n=37) 
High (n=29) 
 
 
Cognitive test2 Baseline Week12 change from baseline Baseline Week 12 change from baseline Baseline Week 12 change from baseline 
RTI 373.66 ± 51.833 367.06 ± 59.34 -6.60 ± 55.11 345 ± 45.66 354.15 ± 67 9.15 ± 55.07 349.33 ± 61.70 363.99 ± 70.79 14.66 ± 52.64 
SSP 5.51 ± 1.06 5.77 ± 1.14 0.25 ± 1.22 5.65 ± 1.18 5.68 ± 1.23 0.03 ± 1.55 5.62 ± 1.18 5.76 ± .83 0.14 ± 1.36 
SWM 33.86 ± 19.09 29.11 ± 16.95 -4.74 ± 15.74 28.7 ± 17.59 28.92 ± 17.85 0.22 ± 17.42 30.45 ± 16.04 27.90 ± 16.08 -2.55 ± 15.07 
PRM 2054.25 ± 395.87 2083.14 ± 544.32 28.89 ± 417.47 2138.94 ± 587.38 1903.244 ± 434.09 -235.7 ± 557.83 1920.65 ± 458.59 1969.56 ± 568.19 48.91 ± 565.60 
MTS 2836.70 ± 732.05 2518.54 ± 735.28 -318.16 ± 585.35 2846.98 ± 796.82 2456.46 ± 606.2 -390.52 ± 814.11 2694.54 ± 597.66 2535.90 ± 607.23 -158.64 ± 572.23 
1 No significant differences were observed between the groups for any of the outcomes measured using an ANCOVA to compare post-intervention (week 12) cognitive function with baseline measures as 
covariates. 
2RTI, five-choice reaction time measured as reaction time latency (milliseconds); SSP, spatial span measured as longest sequence length recalled correctly; SWM, spatial working memory measured as total 
errors made; PRM, pattern recognition memory measured as mean correct latency (milliseconds); MTS, match to sample visual search measured as mean correct reaction time (milliseconds). 
3 mean ± SD (all such values) 
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baseline baseline baseline 
 
 
 
 
Table 3 
 
Menopausal symptoms at baseline and following 12 weeks’ soy drink intervention1. 
 
Treatment group Low (n=34) Medium (n=35) High (n=27) 
 
Greene’s Climacteric scale Baseline Week12 change from baseline Baseline Week 12 change from baseline Baseline Week 12 change from baseline 
Psychological score 18.29 ± 4.002 17.47 ± 4.37 -0.83 ± 5.10 18.51 ± 4.92 16.40 ± 4.11 -2.11 ± 4.19 17.02 ± 3.55 15.93 ± 3.59 -1.10 ± 3.89 
Vasomotor score 4.46 ± 1.58 3.97 ± 1.73 -0.49 ± 1.18 4.50 ± 1.54 3.49 ± 1.27 -1.01 ± 1.84 3.54 ± 1.22 3.37 ± 1.69 -0.17 ± 2.02 
Somatic score 9.79 ± 1.81 9.29 ± 2.28 -0.49 ± 2.50 9.71 ± 2.30 9.49 ± 2.13 -0.23 ± 2.68 9.77 ± 2.64 9.26 ± 3.37 -0.51 ± 3.52 
Total score 34.72 ± 5.37 32.76 ± 6.52 -1.96 ± 6.83 34.87 ± 7.31 31.29 ± 6.10 -3.58 ± 6.87 32.52 ± 6.42 30.52 ± 7.91 -2.00 ± 8.62 
1 No significant differences were observed between the groups for any of the symptoms assessed as determined using a Kruskal-Wallis test. 
2 mean ± SD (all such values) 
 
 
Table 4 
 
Effect of soy drink intervention on vasomotor symptoms stratifying women according to severity of symptoms at baseline.  
Treatment group 
Low (n=34) Medium (n=35) 
High (n=27) 
 
 
Vasomotor 
symptoms at 
baseline 
Baseline Week12 
change from
 
P1 
Baseline Week 12 
change from
 
P 
Baseline Week 12 
change from P
 
Less severe 3.37± 0.902 3.05 ± 0.97 -0.32 ± 1.06  
0.290 
3.22 ± 0.73 3.28 ± 1.18 0.06 ± 1.21  
0.001 
2.64 ± 0.50 3.14 ± 2.11 0.50 ± 1.99  
0.096 
More severe 5.83 ± 1.10 5.13 ± 1.81 -0.70 ± 1.33a 5.85 ± 0.83 3.71 ± 1.36 -2.15 ± 1.73b 4.51 ± 0.99 3.62 ± 1.12 -0.89 ± 1.88a 
1 Mann-Whitney U test comparing change from baseline of those women with more severe vasomotor symptoms at baseline to those with less severe symptoms within groups 
2mean ± SD (all such values) 
a,b values with different superscript letters across a row are significantly different (Kruskal-Wallis with post-hoc Mann-Whitney U Test) 
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Table 5 
 
IF concentrations at baseline and following 12 weeks’ soy drink intervention. 
 
Treatment group Low Medium High 
 
 Baseline Week12  Baseline Week 12  Baseline Week 12 
(n=32) (n=32)  (n=35) (n=32)  (n=28) (n=23) 
genistein (ng/ml) 10.01± 22.071 82.75 ± 124.62a  9.83 ± 24.25 168.71 ± 166.81b  6.40 ± 9.27 216.71 ± 305.36b 
daidzein (ng/ml) 5.03 ± 11.88 20.44 ± 30.82a 
 2.29 ± 4.37 39.20 ± 36.9b 
 2.50 ± 3.34 49.82 ± 66.49b 
equol (ng/ml) 1.76 ± 6.01 3.81 ± 8.17a 
 BLD2 9.43 ± 19.84a 
 0.42 ± 1.30 11.69 ± 19.23a 
1 mean ± SD (all such values) 
a,b values with different superscript letters across a row are significantly different (Kruskal-Wallis with post-hoc Mann-Whitney U Test) 
2 BLD, below limit of detection 
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Table 6 
Effect of soy drink intervention on cognitive performance stratifying women according 
to equol producer status. 
 
 
Cognitive 
Change from baseline 
 
Equol non-producers Equol producers2 P3 
 
 
 
 
 
 
 
 
 
 
 
 
1RTI, five-choice reaction time measured as reaction time latency 
(milliseconds); SSP, spatial span measured as longest sequence length 
recalled correctly; SWM, spatial working memory measured as total errors 
made; PRM, pattern recognition memory measured as mean correct latency 
(milliseconds); MTS, match to sample visual search measured as mean 
correct reaction time (milliseconds). 
2 defined as plasma equol concentration > 20nmol/L (51g/L) 
3independent samples t-test or Mann-Whitney U test for non-parametric data 
4 mean ± SD (all such values) 
 
test1  
n=62 
 
n=25 
  
RTI 6.23 ± 54.984 -6.23 ± 41.30 0.764 
SSP 0.21 ± 1.34 0.12 ± 1.42 0.735 
 
SWM -1.82 ± 15.34 -6.16 ± 16.36 0.245 
 
PRM -45.58 ± 533.00 -62.66 ± 557.10 0.453 
 
MTS -363.39 ± 675.51 -163.99 ± 630.38 0.234 
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Table 7 
Dietary intake at baseline and following 12 weeks’ soy drink intervention.1,2 
Treatment group 
 
Low 
Medium 
 
High 
 
 
 Week12 Baseline Week 12 Baseline Week 12  
Baseline (n=27) P3   P  P 
 (n=28) (n=27) (n=21) (n=24) (n=21)  
 
Energy (Kcal/d) 
 
1532 ± 451.724 
 
1506 ± 526.37 0.715 
 
1623 ± 549.91 
 
1792 ± 665.34 
 
0.845 1562 ± 501.51 
 
1731 ± 583.89 
 
0.163 
Carbohydrate (g/d) 165.52 ± 47.76 154.21 ± 46.65 0.144 165.67 ± 44.26 162.43 ± 50.24 0.500 173.38 ± 63.37 170.00 ± 54.52 0.472 
Protein (g) 74.74 ± 42.49 72.39 ± 24.59 0.726 75.85 ± 33.37 71.90 ± 28.28 0.184 77.21 ± 27.46 70.71 ± 32.31 0.139 
Fat (g) 61.07 ± 25.96 59.86 ± 18.31 0.935 59.56 ± 16.74 65.40 ± 23.34 0.887 61.21 ± 23.32 59.00 ± 25.08 0.868 
Carbohydrate (% EI) 44.32 ± 9.85 45.74 ± 28.91 0.068 42.52 ± 8.99 37.60 ± 7.82 0.184 44.26 ± 5.31 41.00 ± 11.35 0.744 
Protein (% EI) 15.55 ± 2.55 18.28 ± 12.52 0.563 15.27 ± 3.42 15.37 ± 5.84 0.500 15.46 ± 2.13 13.59 ± 3.67 0.018 
Fat (% EI) 42.76 ± 17.35 47.89 ± 25.98 0.503 42.11 ± 11.52 38.67 ± 12.85 0.112 46.94 ± 19.53 37.71 ± 13.52 0.022 
1Nutrient intake did not differ between the groups at either baseline or post-intervention (Kruskal-Wallis test). 
2 EI, energy intake 
3 Wilcoxin Signed Rank Test comparing week 12 to baseline within groups 
4 mean ± SD (all such values) 
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Figure Caption 
 
Fig.1 CONSORT diagram of participant flow. A total of 394 women were assessed for 
eligibility with 279 excluded due to not meeting the inclusion criteria (n=146) or not 
wishing to participate in the study (n=133). Remaining postmenopausal women were 
randomised to receive a soy drink (Alpro®) and asked to consume a volume providing 
either 10 mg (n=39), 35 mg (n=38) or 60 mg (n=38) IFs daily. A total of 14 participants 
were lost to follow up owing to illness (n=3) unrelated to the intervention, antibiotic use 
(n=2), no longer wishing to participate (n=1), family illness (n=1) or being unable to 
consume the soy drink (n=7). A total of 101 women completed the study and were 
included in the final analysis 
Excluded (n=279) 
Not meeting inclusion criteria (n=146) 
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Allocated to 10mg/day (n=39) 
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Breast Cancer (n=1) 
Analysed (n=35) Analysed (n=37) Analysed (n=29) 
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Abstract 
 
The number of studies evaluating consumer perceptions is increasing as understanding 
consumer acceptance is a key aspect of consumer choice and attitude. Soya foods have 
many proven health benefits for the general population, and specifically for 
postmenopausal women, albeit soya consumption among western populations is low. The 
aim of this study was to evaluate the attitudes of post-menopausal women to soya 
consumption following an intervention study. Three focus groups were conducted in post- 
menopausal women who had recently participated in a randomised trial where they 
consumed a specified volume of a soya drink (Alpro®) every day for 12 weeks. Focus 
groups were designed to represent individuals from each of the three treatment groups 
within the study; group 1 consumed 100 ml/day, group 2 consumed 350 ml/day and group 
3 consumed 600ml/day. Focus groups included discussion on overall knowledge of 
Alpro® soya, attitude towards soya drinks, advantages and disadvantages of adding soya 
to the diet and enablers/barriers to soya consumption. Eight common themes were 
identified using thematic analysis. Barriers to soya consumption included the image of 
soya, lack of familiarity with the product, and sugar content of the products. Advantages 
of soya included the healthfulness and fortification of micronutrients. Soya consumption 
was perceived to be associated with allergies, a healthful change in lifestyle or adoption 
of a vegetarian diet. Educating consumers about soya and improving the image of soya 
may increase consumption in western populations. 
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Introduction 
 
Clinical and epidemiological evidence demonstrates beneficial effects of soya foods and 
isoflavones on post-menopausal health, specifically breast cancer, cardiovascular disease, 
cognitive function and menopausal vasomotor symptom relief (Casini et al., 2006, Duffy 
et al., 2003, File et al., 2005, Messina, 2014). The North American Menopause Society 
recommends S-equol derivatives of soya isoflavones for the non-hormonal management 
of vasomotor symptoms (North American Menopause, 2010). 
As there is clear evidence of health benefits associated with the addition of soya to the 
diet, further investigation into consumer attitudes and opinions of soya is imperative in 
populations who may benefit from its use. In spite of health claims and benefits associated 
with soya consumption, intake still remains low in western populations in comparison to 
Asian populations. Isoflavone intake is approximately 25-50mg/day in Japanese 
populations but is <3mg/day in European and western populations (Messina et al., 2006; 
Bai et al, 2014; Zamora Ros et al 2012). Therefore, a clear understanding of motivators 
and barriers to soya consumption is imperative. Investigating barriers and enablers of soya 
consumption alongside evaluation of a soya intervention with qualitative methods using 
a systematic approach allows for key information from participants to be utilised. 
Focus groups are useful for collecting valuable information from the public/research 
participants and can be utilised to investigate consumer attitudes and to evaluate 
interventions in order to produce more effective research protocols (Leung et al., 2019). 
This method involves using valuable data around methodology and participants’ 
perceptions of research trials. The use of this systematic approach, incorporating thematic 
analysis, to evaluate human intervention trials is imperative for development of future 
research trials, particularly randomised trials, in ascertaining the quality of results. Many 
interventions are complex, made up of multiple components, and delivered on multiple 
levels (Mackenzie et al., 2018). Understanding the use of a systematic approach may 
improve evaluation of complexities within study designs (De Silva et al., 2014) thus 
improving the design of future studies. The evaluation process ensures for the 
development in the administration of adequate more robust interventions to attain robust 
results. Intervention evaluations implicate changes such as different methodology, 
educating people about benefits of soya, awareness of soya in menopause, sample size, 
study type/design, intervention time period, and methods of data collection, ensuring 
effective trials to address the relevant clinical question (Fletcher, 2002). Changes to 
intervention methods, which can be adopted through evaluation, successfully address 
research question issues that arise. 
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Evaluating interventions requires sophisticated methods in order to establish what has 
been achieved and how it has been achieved, uncovering strengths and weaknesses. 
Further investigating whether the most effective methods were used and whether it was 
conducted in the most effective way are all outcomes of evaluating interventions and have 
the potential to have a major impact in future trials adopting similar approaches and 
outcomes (Richard A. Krueger, 2009). These methods include, observing a change in 
attitudes, discussing research questions, observing behaviour changes and interpreting 
written questionnaires. Assessing an intervention process involves comprehensive 
evaluation of what occurred during implementation and creating a judgement on efficacy. 
Effectiveness is evaluated through assessing questions; did you achieve your 
goal/outcome as quickly as possible and cost efficiently (Kitzinger, 1995). A good 
theoretical understanding is required of how the intervention causes change, therefore 
weaker components can be addressed and changed (Craig and Petticrew, 2013). 
Achieving the outcome may for instance not have been carried out as efficiently as 
possible so therefore this needs to be evaluated so that changes can be implemented. Self- 
evaluation and feedback are fundamental in assessing interventions. Receiving feedback 
is essential in monitoring performance and can be carried out in many ways through 
questions and anonymous feedback (Scriven, 2010, Parry-Langdon et al., 2003, Craig et 
al., 2008). 
This evaluation process is imperative in research interventions influencing future more 
robust studies. Impacts arising from this process include improving your own practice; 
helping others improve their practice through breaking down your own evaluation; 
justifying your methodology and providing evidence to support as well as identify any 
unplanned or unexpected findings that may be significant for future trials (Scriven, 2010). 
Evaluating interventions has an impact on public health, medical evidence and future 
studies which rely heavily on efficacy of intervention impact, therefore this process is 
imperative and has major impact on research, effectiveness, and implementation of trials. 
A limited number of focus group studies have been conducted to date investigating 
attitudes and opinions towards soya. Schyver et al, 2005., investigated attitudes and 
beliefs towards soya in consumers vs non consumers (Schyver and Smith, 2005). Major 
themes identified were: barriers to soya consumption; promotors of soya consumption; 
perceived health attributes of soya and suggestions on how to increase soya consumption. 
Sub-themes generated highlighted: soya’s overall image, availability and cost as well as 
ways to increase overall soya consumption through consumer attitudes. The main barriers 
to soya consumption were price, not knowing how to prepare it and the unfavourable 
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image of soya. The main promoter of consumption was the initiation of a major change 
in lifestyle of individuals. Participants were aware of the healthfulness perception 
associated with soya, similar to findings in a focus group study investigating attitudes to 
soya in French and Vietnamese cohorts. In this study by Tu et al., (Tu et al., 2012) 
however, individuals were not sure why soya was perceived as healthy. A commonality 
among focus group studies conducted on soya is the association with the product being 
produced exclusively for vegetarians or those who have an intolerance to dairy milks. 
Price was also a determinant of soya consumption among the Vietnamese cohort, 
particularly in comparison to dairy product prices. Similarities among these focus groups 
show the importance for more focus groups to be conducted in this area. Furthermore, 
findings have highlighted the need for education on the health benefits of soya for the 
population. 
This focus group study was designed in order to evaluate the attitudes of post-menopausal 
women towards consumption of soya and to partly evaluate the overall effectiveness of a 
12-week soya drink intervention in which participants had recently participated. 
Materials and methods 
 
The present study utilised participants from a 12-week randomised trial conducted at 
Ulster University, Coleraine, Northern Ireland. All procedures were approved by Ulster 
University’s Research Ethics Committee (REC/15/0025) and the study was registered at 
www.clinicaltrials.gov (NCT03561662). The study was undertaken between the months 
of October 2015 to June of 2018 and was designed to examine the effects of soya on 
cognitive function and menopausal symptoms in post-menopausal women. Women aged 
44-63 y, within 7 y post menopause were randomly assigned to consume a volume of 
Alpro® soya drink providing a low (10 mg isoflavone; control group), medium (35 mg 
isoflavone) or high (60 mg isoflavone) dose of isoflavones daily for a period of 12 wks. 
Women that completed the intervention study were invited to participate in the focus 
group study. Focus groups were designed to represent individuals from each of the three 
treatment groups from the intervention. Each focus group consisted of 2-5 participants. 
Focus groups were held in a suitable room in the university and refreshments were 
provided. Focus groups were led by a trained researcher and assisted by a research 
assistant. The outline of the focus groups is provided in Table 1. The focus groups were 
audio-recorded and then transcribed verbatim. All responses were kept anonymous. 
 
Participants 
Eligible participants were apparently healthy women within 7 years post menopause 
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(i.e. 1-7 y since last menstrual period). Baseline characteristics are shown in table 1. 
Postmenopausal status was confirmed based on a serum concentration of follicle-
stimulating hormone (FSH) >30 mIU/ml (assessed via electrochemiluminescence 
immunoassay on a Cobas 8000 analyzer [Cobas 602 module], Roche Diagnostics at 
Antrim Area hospital). Exclusion criteria included: surgically induced menopause; 
habitual consumers of soya foods (> 2 serves/week); current use of HT or IF 
supplements; antibiotics use within the previous 3 months; current use of psychoactive 
medication; presence or history of cardiovascular disease, cancer, diabetes, thyroid, 
renal or kidney disease, alcohol or drug abuse; cognitive impairment as determined by 
a Mini Mental State Examination score <24; psychiatric distress as determined using 
a General Health Questionnaire-28 (Goldberg and Hillier, 1979) score of ≥26; red-
green colour blind, assessed via the Ishihara test (as CANTAB testing requires colour 
recognition); abnormal full blood profile (assessed via a Sysmex KX21-N, Sysmex Ltd, 
UK at Ulster University) and/or insufficient renal/hepatic performance assessed via 
kidney and liver function tests (assessed photometrically via a Cobas 6000 analyzer 
[Cobas C501 module], Roche Diagnostics at Causeway hospital). Women who 
participated in the focus groups were health conscious individuals who maintained a 
healty lifestyle.  
Focus groups were used as the method of data collection as they provide insight into 
topics and perceptions about soya drinks that otherwise may not have been known. Focus 
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groups have the ability to produce opinions from similar groups of people at the same 
time. 
Data Collection 
 
Open ended questions were used based on the information we were interested in clarifying 
about soya products through the focus groups (Table 2). Focus groups included discussing 
familiarity with soya drinks, advantages/disadvantages, continued consumption 
likelihood, enabling factors of consumption, barriers to soya consumption and lastly, did 
soya drinks aid in menopausal symptoms. Audio recorded transcripts were transcribed 
manually verbatim. Transcriptions were reviewed by a research assistant to verify that 
recording had been transcribed correctly. Researchers met to debrief on the content 
discussed to identify emerging themes. 
Thematic Analysis 
 
Thematic analysis is a widely-used qualitative analytical method (Roulston, 2001) 
particularly in psychology, used in identifying, analysing and reporting themes within 
data (Tuckett, 2005). Qualitative approaches are incredibly diverse, thematic analysis is 
one of the foundational methods for qualitative analysis. Thematic analysis is carried out 
through a step by step process considering all elements of data collected in focus groups. 
This theory driven approach was conducted by two researchers in parallel, coding and 
identifying concepts based on themes generated, agreeing on interpretation of the 
material. The thematic analysis process advised by Braun and Clarke (Braun, 2006, 
Clarke and Braun, 2013) was carried out in the current study. Phases involved in thematic 
analysis include; familiarising yourself with the data and understand the research 
question. This is carried out by reviewing data to ensure that initial ideas and prominent 
themes are recorded in writing. Steps involved in this process include generating initial 
codes, coding interesting features across the whole data set collating important themes, 
and lastly, defining these themes. This process allows for ongoing analysis generating 
clear themes producing the report, this is the final analysis of selected extracts, relating 
to research question and literature. 
The first step of thematic analysis is when the analyst begins to identify, look for 
reoccurring patterns of meaning, of interest in the data. Unlike statistical analysis, writing 
ideas and potential coding is integral of thematic analysis, with a constant back and forth 
between the entire dataset representing the flexibility in this method of data investigation. 
Qualitative analysis guidelines are not rules, although following basic phases allows 
application to fit the research question. With this recursive process moving back and forth 
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across phases of data analysis it allows for the development over time (Clarke and Braun, 
2017). Researchers have used this method to explore a wide variety of experiential 
research questions which vary in sample size, data collection, methods and meaning 
generation (Clarke and Braun, 2013). By using thematic analysis it generates a link in 
concepts and opinions among participants and allows data to be comparable to other data 
collected from other studies (Alhojailan, 2012). Another strength of utilising thematic 
analysis is allowing full submersion of data and eradicating precipitous conclusions from 
the onset of analysis. Overall thematic analysis allows you to gather a clear logical 
understanding over narrative data which allows for interpretation of participants’ thoughts 
and conveys their experience in relation to themes generated and the overall research 
question. Furthermore, a greater understanding of participants’ attitudes and reflections 
on specific issues through this method prevents calculating unambiguous words or 
statements for expressing ideas and generates a more robust understanding of attitudes 
within specific cohorts (Alhojailan, 2012). 
Results and discussion 
 
Intervention Evaluation 
 
It was evident through evaluation of the intervention that women had a heightened 
awareness of soya. Women expressed they will be continuing to consume soya and would 
even recommend it to a friend. The intervention also successfully encouraged women to 
incorporate soya into the diet in many different ways, ie. tea/coffee and cereals. Women 
also expressed they had a relaxed feeling from taking part in the study, therefore the 
intervention process was successful in terms of generating a further willingness within 
volunteers to contribute to further research in the future. It was also evident, regardless 
of dose, through the focus group evaluation that participants felt 12 weeks was a long 
period of time to be consuming daily doses of soya drink. This may be owing to the fact 
that larger doses of soya hindered daily consumption and therefore it was concluded that 
future studies in this area should combine supplements and soya drink to attain the dose 
required for effect within interventions. The soya drink was also referred to as a “filling” 
drink and larger doses were difficult to consume on a daily basis, this confirms the need 
to consider a change in methodology in terms of the supplement matrix used in 
interventions using soya supplementation. 
Attitudes and perceptions of soya 
 
The analysis resulted in 8 final themes (see Table 3); knowledge of Alpro® products; 
impressions of soya products; advantages of Alpro® soya in diet; disadvantages of 
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Alpro® soya in diet; continue to consume; enablers to consumption; barriers to 
consumption and menopausal symptoms. Combined thematic analysis from all three 
focus groups was carried out and results were amalgamated due to the consistencies that 
were evident throughout each of the focus groups. The major findings of our study 
identified consumer attitudes towards soya including barriers to regular consumption, 
enablers of continued use a healthful impression and an unhealthful impression. There 
are a limited number of studies utilising focus groups to investigate perceptions towards 
soya and also little evidence in the area of post-menopausal women. Two focus group 
studies have been conducted in post-menopausal women investigating perceptions and 
experience of the menopause (Fox-Young et al., 1999) and women’s decision making at 
the time of the menopause (Alfred and Kazakov, 2006), neither of which mention soya in 
relation to the menopause. 
Knowledge of Soya products 
 
Sub themes generated from this major theme included overall familiarity with soya 
products. This sub theme represents the overall opinions and attitudes gathered from post- 
menopausal women and encompasses whether soya was known to participants or not. 
Women who were aware of soya further mentioned whether they had tasted the product 
or not. Familiarity of soya milk was low among the three focus groups, see Table 3. Soya 
was unknown to an equal number of those who were familiar with the product with very 
few previously tasting the product before. There was some familiarity with soya desserts 
among the focus groups. There was a small number of women throughout the three focus 
groups who had tried soya before. 
Impressions of Soya products 
 
Two sub themes were generated from overall impressions of soya milk, these include 
healthful impression and flavour. In addition, women expressed a consistent healthful 
impression of soya and interestingly soya was perceived as a product which is a “healthy 
alternative” for vegetarians or those with allergies (see Table 3), an alternative to dairy 
products, as well as improving women’s health, all similar findings which were reported 
in previous focus group studies reporting attitudes and beliefs about soya (Schyver and 
Smith, 2005, Tu et al., 2012). Both of these focus group studies express benefits of soya 
on menopausal health. One participant during the focus groups stated; 
“I had some vague awareness of soya being used as an alternative to dairy” 
 
Although there was an awareness that soya products are healthful, no one was able to 
report benefits associated with cardiovascular disease. Participants had a vague 
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understanding that soya may be good for menopausal symptoms as well as have a 
beneficial effect in terms of memory and have lower calories that dairy milk. Participants 
debated about the flavours of the soya drinks (see Table 3 discussed as sub theme flavour). 
Quotes below from participants during focus group discussion about flavour indicated a 
differing opinion; 
“I didn’t like it to taste” 
 
“I like those creamy sort of flavours” 
 
Participants agreed that one of the sole enablers to consumption was the flavour of the 
original soya drink. Although there was concern about the sweetness of strawberry and 
chocolate flavours available, the “creamy” flavour of the original soya drink was the 
greatest factor in increasing consumption. Further discussion about the flavoured 
products identified concerns in relation to content of sugar and an unnatural taste. 
Advantages of adding soya to the diet 
 
There were several sub themes generated throughout the focus groups considering 
advantages of adding to the diet. These included “fortification”; “source of protein”, and 
“reducing dairy farming”. A common finding among all of the focus groups was the “feel 
good factor” (see Table 3) or participation in an intervention which potentially could 
benefit other women. Contribution to research and taking part in a study was considered 
one of the main advantages of adding soya to the diet. Soya products were also perceived 
to be a good source of micro nutrients essential for the diet, such as vitamin-D and 
calcium, as well as a good source of protein. Although this was mentioned, participants 
did enquire with researchers what the difference was in protein content between whole 
milk and the soya drink. In addition, it was eluded to that soya consumption enhanced 
breast size, prevented cancer, and was a good source of isoflavones for the prevention of 
menopausal symptoms. 
Disadvantages of adding soya to the diet 
 
Many of the participants thought that soya added to the diet was filling and so associated 
it with weight gain (see Table 3), one response below from a participant highlights this; 
“I had said to (name omitted) that I thought I had put on weight” 
 
One of the other main disadvantages of adding soya to the diet was that it was not 
preferred in tea or coffee over whole milk. As many of the women only consumed dairy 
milk in tea and coffee, it was mentioned that it was difficult to add a milk alternative to 
the diet when they did not habitually drink milk. 
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“I didn’t like it in tea and coffee” 
Consumption in the diet 
 
Although there was a mixed opinion about soya during the intervention, many of the 
participants agreed that they would and already have recommended soya products, 
particularly if they knew it would help with menopausal symptoms (see Table 3). As part 
of the intervention, women incorporated soya into their diet in many ways. Participants 
mostly added it into their diet by using it in tea and coffee and breakfast cereals. There 
are many other ways that soya was introduced into the diet including drinking as a shake, 
drinking in lattes, or as a snack on the go.  
Enablers to consumption 
 
One major theme generated “incorporation into the diet” presented common ways in 
which women added soya to the diet. Below are several quotes from participants during 
the focus group that indicate ways in which they incorporated soya into the diet; 
“I would use mine as a milky coffee, I actually preferred the soya in coffee now” 
“Yea I put it in to make my porridge, half milk half water” 
One of the strongest enablers for consumption of soya was the brand itself, participants 
associated Alpro® soya with a good brand associated with healthy foods. Many of the 
participants would buy soya specifically when it was on offer. Carton sizes played a 
crucial role in enabling consumption of soya due to lack of users in a household. If there 
was a smaller carton size available in local shops they would buy soya more frequently 
(see Table 3). Buying 1L cartons for single users in homes eluded to increase of waste of 
the product. When more people are consuming the product in the home it is a massive 
enabler for consumption. Longer shelf-life products as well as flavour are also enabling 
consumption of soya. 
Barriers to consumption 
 
Sub themes that were generated through thematic analysis under barriers to consumption 
include cost; sugar content, and a bad impression of soya brand (see Table 2). The 
identified barriers to consumption are similar to those of Schyver et al., who reported that 
price, controversy over processing, genetically modified factors and interaction with 
thyroid stimulation inhibited use of soya products (Schyver and Smith, 2005). One 
participant stated that she felt that the product was too expensive; 
“It’s expensive I think; to me I think it’s kind of expensive” 
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A finding echoed in a focus group conducted in Vietnamese and French cohorts (Tu et 
al., 2012) to investigate cultural influences of soya, with price identified as a barrier. One 
of the major findings in these focus groups was the price barrier of soya drinks of then 
eluding to the product as expensive and only even buying when it is on offer. Also, 
association with the amount of soya milk that was consumed throughout the study became 
a barrier to consumption, being asked to consume 100-600ml/day proved difficult for 
some of the participants. Sugar content of the product was a clear barrier to consumption 
as participants did not want to add sugar to their diet but were unaware as to the content 
in soya. One particular participant made the following statement in relation to their 
impression on sugar content; 
“Too much sugar I, you know I stayed away from the sugar” 
 
Unfamiliarity of the product was also identified as a barrier to consumption; 
 
“I think the soya puts people off” 
 
Some concern was expressed relating to the controversy over processing of soya and 
concerns of genetically modified products and interaction with the thyroid, similar to 
findings from Scyhver et al., (Schyver and Smith, 2005). Although this was a concern, 
participants were unaware that Alpro® products are not genetically modified. 
Menopausal symptoms 
 
Sub themes which appeared included symptom free; unaware if menopausal symptoms 
were affected and hot flushes returning after the study. In two focus group studies in post- 
menopausal women and attitudes to soya (Alfred et al., 2006, Fox-Young et al., 1995), 
recognition of some benefits during the menopause was highlighted, other than knowing 
it can be of some benefit, participants in neither of the two studies were able to indicate 
why this might be the case. In this study, although participants understood that soy is a 
healthful food, (Messina and Messina, 2003) prior to taking part in the study, they had 
little knowledge of the potential beneficial effects on the menopause. Some of the ladies 
did report that they were symptom free while consuming the soya milk and equally others 
were unaware if they could ascertain symptom free spells with the soya drinks (see Table 
3), expressed by one participant through the following quote; 
“while I was on it yes I was quite I was quite free of menopausal symptoms” 
 
Women felt that soya helped alleviate hot flushes, provided more energy and it was even 
found that soya made some women feel more relaxed. 
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To conclude, results reported are very similar to those reported by Tu et al., and Scyhver 
et al., and generate the following understanding about soya consumption (Schyver and 
Smith, 2005, Tu et al., 2012). Soya is perceived as a healthier option to many other dairy 
choices and those who are making lifestyle changes are more likely to change to soya 
milk than at any other time. Soya is predominately seen as a replacement drink for those 
who have allergies or intolerances to dairy milks and also for vegetarians (Schyver and 
Smith, 2005). Prior to an intervention with soya drinks women wouldn’t have 
recommended soya to a friend or even tried it themselves to alleviate menopausal 
symptoms or as a health choice. Also, participants are more likely to continue with 
consumption of soya if they knew that it helped with menopausal symptoms. Soya is 
rising in popularity as an area of focus in dietary interventions and parameters of health. 
Product development and Public health 
In relation to the themes generated from this thematic analysis there can be a number of 
influencing factors in realtion to public health and product development. Despite the 
healthfulness of soya known to the public some of the strongerst influencing factors for 
consumption were price and familiarity of the product. This finding shows that the 
development stage of planning and processing in product development requires extensive 
communication on the beneficial factors associated with soya consumption. On a wider 
public health standpoint meaningful collaboratve effort for effective communication with 
the public on the intake of soya is essential, particularly in a cohort of post menopausal 
women. 
Conclusion 
 
Through the evaluation of the intervention it is evident that future interventions should 
consider using a soya supplement along with a soya food in order to accomplish greater 
compliance from participants. Consumption of the soya drink was well received in 
relation to the intervention although it is clear that the higher dose of soya has an 
implication on satiety and therefore a reduced desire to consume all of the recommended 
dose. Evaluation of the intervention successfully highlighted awareness of benefits of 
soya and incorporation of soya into the diet. Soya is continuously being investigated in 
relation to different parameters of health, however, acceptance as a valuable food in 
reducing potential health risks has yet to be concluded. Main barriers to soya consumption 
include price and lack of knowledge about soya products while enablers of consumption 
include Alpro® being considered a reliable and good brand. Introducing education about 
soya products is required in relation to nutrient content and sugar content in order to 
reduce barriers to consumption. Consumption of soya in western populations still remains 
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low and use is limited to particularly health conscious individuals interested in 
maintaining a healthy lifestyle. Post-intervention, individuals confirmed they would 
continue to consume soya due to the health benefits associated with its use that they were 
unaware of prior to taking part in the study. Therefore, increasing overall awareness of 
the healthfulness of soya may increase consumption in western populations. 
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Table 1: Baseline participant characteristics presented for the focus group participnats as mean 
and standard deviation. 
 
Measure All participants 
(n=10) 
Age, y 55.20 ±3.05 4 
Height, m 1.63 ± .051 
Weight, kg 70.69 ± 14.33 
BMI, kg/m 26.51 ± 5.92 
Alcohol, units/wk 
Education level (n) 
1 ± 0 
PA, METs/week1 
161.17 ± 63.42 
1METs, metabolic equivalents; MMSE, Mini Mental 
State Examination; PA, physical activity 
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Table 2: Showing the line of questioning and probes used in focus group discussions 
of soya with post-menopausal women. 
 
Q1 
Before you joined the women's health study, were you familiar with Alpro® 
soya products? 
Had you tasted/bought them previously? 
Before you joined the women's health study what was your overall impression of 
Q2 
soya products? 
What do you think of their healthfulness? 
Why? 
Why did you want to/not want to consume them? 
What encouraged you to take part in the study? 
 
Q3 What do you feel are the advantages of adding Alpro® soya products to your diet? 
What did you think of the flavours offered on the study? 
How did you incorporate the soya products into your regular diet? 
Did you experiment with different ways of adding the Alpro® drinks 
to your diet? 
Did the products help in any other way? 
What do you feel are the disadvantages of adding Alpro® soya products to your 
Q4 
diet? 
Q5 Will you continue to consume these products? 
 
What factors or circumstances would enable you to use Alpro® soya products in 
Q6 the 
future? 
 
Q7 Do you feel the Alpro® products helped with your menopausal symptoms? 
In what way? 
Is there anything further you would like to tell us about your use of Alpro® 
Q8 
products as part of this study?
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Table 3: Showing major themes and sub themes of the three focus groups conducted in post-menopausal women. 
 
Main theme F Quotes from focus groups 
Knowledge of Alpro® products   
Familiarity with Soya milk 9 “Soya milk in the shops, you know” 
No 9 “Nope never used them” 
Familiarity with Soya Desserts 4 “Actually, the wee soya custards and soya desserts” 
Yes 3 “Yes” 
Previously tasted 3 “I tried it before” 
Impressions of Soya products   
Healthful impression 
Dairy alternative 4 “I had some vague awareness of soya being used as an alternative to dairy” 
Allergies 4 “vegetarian's sort of ate them” 
“I would’ve thought with people who always have allergies and stuff like that” 
Improved menopausal symptoms 3 “I think it definitely helped with the hot flushes” 
Lower incidence of menopausal 
symptoms in Japanese women 
3 “um it being very big in Japanese, and Japanese ladies don’t suffer menopausal symptoms, that they had 
soya in the rest of their diet” 
Low calorie 2 “is the soya milk lower in calories than ordinary milk or not” 
Improved memory 1 “I don’t know that it helped my memory, I think my memory is particularly bad so maybe that the 
reason” 
Flavour 
Too sweet 8 “and maybe the fact that it was a little bit sweet
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Nice creamy flavour 7 “I like those creamy sort of flavours I like, you know I don’t know I like, I think there’s a nice comforting 
  um, if you had it as a warm drink” 
  “Yea because, the fresh one was much creamier, and a nicer taste” 
Unsweetened favourable flavour 5 “And I like the unsweetened and the chocolate” 
  “So no I buy the unsweetened soya milk now” 
Disliked strawberry flavour 4 “The strawberry didn’t taste very natural, because it was a very strong, very sweet, not as sweet as the 
  chocolate, or sweeter than the chocolate sorry, sweeter than the chocolate” 
Disliked chocolate flavour 4 “I didn’t go near the chocolate or anything because I thought probably too much sugar” 
Disliked unsweetened flavour 4 “I didn’t like to taste” 
Vanilla favourable flavour 3 “because even the vanilla one was delicious really like a little milkshake but it was good” 
Advantages of Alpro® Soya in diet 
  
Contribution to research 8 “I think if I heard benefits coming out of the research I would certainly tell everybody” 
  “Maybe it’s just because you were doing a survey and taking part in something and other people were 
  doing it” 
Fortified with vitamin-D 6 “I think it had Vit D, didn’t it, did it have vitamin D or calcium?” 
Feel good factor 4 “I think that must be a good thing but also, it am it just expands your whole way of thinking about your 
  intake of food you know” 
  “a feel good factor with taking it too” 
Good source of protein 3 “well I think, the protein point of view” 
  “its replacing or giving me proteins that I didn’t have before then it means that it’s worth keeping it up” 
Bigger breast 2 “but the size of me here was getting bigger” 
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 “My bust did get bigger for sure” 
Reduced cattle in dairy farms 2 “you know and I think overall that’s always going to be a good thing, just in terms of environmentally 
  keeping dairy cattle and beef cattle isn’t a great thing” 
Prevention of cancer 1 “it was then the introduction to soya, and whether an enzyme was released in the gut and it was for the 
  prevention of cancer” 
Good source of isoflavones 1  
Disadvantages of Alpro® Soya in diet 
Filling to consume 7 “It’s quite filling anyway” 
Weight gain 4 “I had said to (name omitted) that I thought I had put on weight when I was, during the time that I was 
drinking it” 
Dislike taste when added to tea and 
coffee 
Continue to consume 
4 “I didn’t like it in tea and coffee” 
“it did feel different in tea or coffee; I didn’t mind it too much in tea but I didn’t like it in coffee” 
 
Recommend to a friend 8 “I have recommended it since, told people about the study” 
“I have recommended it since” 
With cereal products 7 “I ended up just drinking it mostly and made porridge and put it in the odd thing” 
 
Drink as a milkshake 
 
5 
“Yea I put it into, make my porridge half milk/half water” 
“and maybe the fact that it was a little bit sweet, I said earlier it’s kinda like have a little milkshake, it 
 
Chai latte 
 
4 
was a little bit sweet and delicious really” 
“but a chai latte now I would always have in soya” 
Milk substitute 3 “I didn’t try any other milk substitutes” 
109 
 
 
Incorporation into the diet 
Tea/coffee 21 “I did have it in tea as well and coffee” 
“I would use mine as a milky coffee, I actually preferred the soya in coffee now” 
Drank in a glass 10 “I didn’t find it a problem drinking that amount as such” 
“it was just sorting it out and remembering to drink it” 
Drank throughout the day 8 “I just kind of paced it throughout the day” 
Handy on the go snack 3 “the wee cartons are handy to have in the car when you’re on the move” 
“know I would buy them and they’re handy” 
Enablers to consumption 
Alpro®; Good brand 10 “I would agree with that, you know that I think Alpro® is a good brand and I associate it with healthy 
food and a good product” 
“I thought it’s the one if I were out and there were lots of brands, I would be looking for the Alpro®” 
Price if the product if on offer 9 “I only buy it when it’s on offer” 
“I’d be the same” 
Choice of different carton sizes 
available 
Other family members who also 
consume Soya milks 
4 “yea and I think that’s really good to see that there is a range of size of the packaging” 
 
“also the size of the package, that’s a great size (500ml) because you know if you live on your own” 
Longer shelf life 3 “I have to say if it’s on offer I’d buy a couple of cartons of it you know because it probably has a slightly 
longer shelf life” 
Flavour 3 “You it has that sort of, slight nuttyish flavour which I really liked
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Barriers to consumption  
Expensive 22 “It’s expensive I think; to me I think it’s kind of expensive” 
  “Yes, I only buy it when it’s on offer” 
A lot to consume 17 “I think, you have an idea what the quantity is going to be, and then when it comes to it the actually 
  reality of taking it, it’s slightly different” 
  “It was quite a lot” 
Sugar content of flavoured drinks 10 “Too much sugar I, you know I stayed away from the sugar” 
  “The strawberry didn’t taste very natural, because it was a very strong, very sweet” 
Bad impression of Soya brand 6 “I think the soya puts people off” 
GMO product 5 “Well I don’t like genetically modified products because it worries me” 
Alpro® brand 4 “I don’t know maybe it’s the name Alpro® that isn’t very nice” 
  “I think the soya puts people off” 
Weight gain 3 “Huge weight gain” 
Association with thyroid function 2 “I have this worry about the thyroid problem so I just thought I’ll be a bit cautious” 
Sole user in the household 1 “Because I’d be the only one consuming it in our house now buying the big carton, it’ll be going off by 
  the time I would get through it” 
Menopausal symptoms   
Symptom free 5 “While I was on it yes I was quite free of menopausal symptoms” 
  “Mine’s coming to an end anyway I think that I didn’t connect it possibly with the previous menopause 
  symptoms that I had” 
Unaware 4 “and I didn’t know anything at all about soya product” 
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Hot flushes returned after the study 4 “While I was on it yes I was quite free of menopausal symptoms” 
  “Mine’s coming to an end anyway I think that I didn’t connect it possibly with the previous menopause 
  symptoms that I had” 
Hot flushes 2 “I think it definitely helped with the hot flushes” 
No difference 2 “I don’t see really any difference” 
  “I just didn’t feel It made a huge difference to me so I didn’t sort of feel I could say you must try this it 
  makes a big difference” 
More energy 2 “I don’t know I just in the day it made me more energetic, or just something you know that” 
Feeling more relaxed 1 “I think I did feel more relaxed” 
F, Frequency at which the relevant statement was mentioned during all three focus groups 
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CHAPTER 6 
General discussion and future directions 
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The effects of soya isoflavones (IFs) on cognitive function and menopausal symptoms 
has received much attention due to their similarity in structure to the endogenous 
circulating oestrogen 17 - oestradiol. As highlighted within the literature review 
presented in Chapter 2, there is a lack of well-designed studies investigating the effects 
of isoflavones on cognitive function in post-menopausal women. This thesis therefore 
aimed to address this research gap by conducting a robust human intervention study to 
investigate the effects of a soya isoflavone food intervention on the cognitive performance 
and menopausal symptoms of post- menopausal women (Chapter 4). Food diaries 
collected during the intervention study were utilised to investigate associations between 
dietary patterns and cognitive function in post-menopausal women (Chapter 3). Post- 
menopausal women were invited to take part in focus groups to evaluate their attitudes 
towards consumption of soya during a 12-week intervention and also to partly evaluate 
the overall effectiveness of this intervention (Chapter 5). 
 
Absence of a determined dose which consistently represents an improvement in cognitive 
function with isoflavone supplementation led to the intervention method used in Chapter 
4. The majority of studies to date have used varied supplementation doses/types ranging 
from 60-160mg isoflavones/day, creating difficulty in comparing studies. Therefore, in 
the intervention study (Chapter 4), 10mg IFs/d 100ml was used as a low dose control 
group, 35 mg IFs/d 350ml as a medium dose and 60 mg IFs/d 600ml as a high dose, 
allowing comparison to be made among treatment groups. The quantities of soya 
consumed throughout the study were considered manageable by participants although it 
was highlighted that the high dose 60 mg IFs/d (600ml) was perhaps too large of a 
quantity for some post menopausal women, therefore this could be a limitation to the 
study as this was the highest treatment group. Chapter 4 has presented no significant 
differences among the three groups for any of the cognitive function outcomes measured 
following a 12- week soya intervention. Soya drink consumption had no effect on overall 
menopausal symptoms, although when women were stratified based on severity of their 
vasomotor symptoms at baseline, those who suffered with more severe symptoms in the 
medium group at baseline had a significant reduction in vasomotor symptoms post 
intervention in comparison to those with less severe vasomotor symptoms. Therefore, 
future studies should aim to recruit stratifying women based on severity of vasomotor 
symptoms and or recruitment of peri menopausal women (Li et al., 2010) who may be 
more symptomatic as symptoms cluster within the first two years before and after 
menopausal transition (Shifren et al., 2014). In support of these findings on vasomotor 
symptoms, a recent meta- analysis has demonstrated that isoflavone supplementation 
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containing > 18.8 mg of genistein, in comparison to a placebo group, can significantly 
reduce hot flush frequency and severity (Taku et al., 2012). It is also important to 
investigate the effects of soya foods in addition to isoflavones supplements as consumers 
may gain additional nutritional 
benefits from consuming soya foods as part of a healthy balanced diet (Messina, 2016). 
Furthermore, isoflavone pharmacokinetics are similar following ingestion of soy foods 
and isoflavone supplements (Setchell et al., 2011). The critical window hypothesis in 
relation to hormone therapy and cognitive function postulates that optimal effects are 
evident with early initiation (Maki, 2013), limited evidence suggests that younger 
postmenopausal women (< 60 y) may gain more cognitive benefit from soya isoflavones 
in comparison to their older counterparts (Kritz-Silverstein et al., 2003). Cognitive 
assessment was strictly controlled through providing a standard caffeine- free breakfast 
prior to testing at both timepoints. Post-menopausal status of women was defined and 
limited to <7 years since last menstrual cycle. Limitations of the study include absence of 
a placebo control, large quantity of soya in the high dose group and the non-blinded study 
design. Difficulties in relation to recruitment were also a limitation to the study as there 
were a large number of women who were not experiencing a natural menopause who 
were prescribed antidepressants for their vasomotor symptoms. Nonetheless, the control 
group consumed only 10mg/IF/d, a quantity much lower than amounts consumed in Asian 
populations. Also the dose of soya isoflavones used was limited due to the use of a 
commercially available soya drink. 
  
In Chapter 3, it was found that high dietary intakes of meat and dairy may be associated 
with improved frontal lobe function. It was also found that a high intake of alcohol is 
associated with poorer visual recognition memory function. Consumption of potatoes and 
poultry is associated with poorer performance in response accuracy. Factor analysis 
identified five final dietary patterns; ‘hot beverages and breads’, ‘meat and dairy’, 
‘potatoes and poultry’, ‘healthy’, and ‘social’. The ‘hot beverages and breads’ and 
‘healthy’ dietary patterns were not significantly associated with any of the 5 cognitive 
outcome measures. Vitamin D, LCPUFA, and B vitamins have been postulated to play a 
role in cognitive health and performance. These particular micronutrients were associated 
with beneficial effects on cognitive function being positively associated with reduced 
errors in SWM, representing frontal lobe function. This study has numerous strengths. 
The method used to assess cognitive function CANTAB. Additionally, Principal 
component analysis, PCA, is the most common method for obtaining dietary patterns. 
This study also has limitations. Study protocols differ vastly in relation to cognitive 
function measures which contributes to the contrast in findings among studies in this area. 
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Self-reporting food diaries are prone to bias or misreporting. The sample size of this 
cohort is small, dietary data is often representative of a much larger sample size. 
Nonetheless this study has provided novel findings in the area of dietary patterns and 
cognitive function in post-menopausal women. These findings present new evidence to 
consider in further studies which are focused on dietary intake in post-menopausal women 
and their potential beneficial effects on cognitive decline. 
 
In Chapter 5 a mixed method design is introduced and provides pragmatic advantages 
when exploring the complex research questions in the focus groups. This qualitative data 
provides a deep understanding through focus group responses, and statistical analysis 
which provides detailed analysis. Chapter 5 has presented evidence on methods which 
could potentially increase soya consumption in western populations and possible ideas to 
develop future interventions focusing on investigating soya. Through qualitative method 
thematic analysis, 8 final themes were generated encompassing: knowledge of Alpro 
products; impressions of soya products; advantages of Alpro soya in the diet; 
disadvantages of Alpro soya in the diet; likelihood of continued consumption; enablers to 
consumption; barriers to consumption and menopausal symptoms.The results observed 
in the focus group could also explain the observed reduction in protein and fat intake (as 
%EI) within the high dose group at the end of the intervention as intake of soya was 
considered by participants to be “very filling” Major contributors to soya consumption 
was healthfulness of the product as well as impact on nutritional intake through 
fortification  or specific use for vegetarians. Soya is considered a healthy addition to any 
diet. Barriers to soya consumption included the image of soya, lack of familiarity with the 
product, and sugar content of the products. Overall, increased awareness of the benefits 
of soya and educating the public about soya may contribute to increased consumption in 
western populations. A strength of this study was the use of thematic analysis as a 
qualitative method to determine themes within the data. The use of focus groups and 
individuals who recently added soya to their diet was also a strength of this study. 
Limitations include the choice of questions in order to evaluate the intervention and small 
number of participants who attended the focus groups. 
 
Limitations and scope for further research 
 
All participants (Chapter3, 4, and 5) typically consisted of middle-aged post- 
menopausal Caucasian women residing in Ireland, at the early stages of menopausal 
transition therefore it is not possible to generalise these results to other demographics 
such as non-Caucasian post-menopausal women and those of the same age but not 
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entering menopause. Aside from limitations discussed within each chapter, general 
limitations should be acknowledged. With a significant number of women excluded from 
the intervention based on the stringent exclusion criteria as mentioned in Chapter 4, it 
was discovered that a large number of women were currently administered anti- 
depressants for both mental health and menopausal symptoms (although not reported in 
the thesis). These women were excluded based on the exclusion criteria although this 
generates a concern that our cohort may not be completely representative of post- 
menopausal women residing in Ireland and Northern Ireland. The exclusion criteria were 
based on confounding measures of cognitive function. It may have been interesting to 
recruit these women on anti-depressants and generate a comparison among women on 
anti-depressants vs those not on anti-depressants, to see if those on anti-depressants 
gained more benefit from isoflavone supplementation. Indeed, recent literature suggests 
soya may have a role in the management of depression (Messina and Gleason, 2016). 
Although, depression is associated with cognitive dysfunction and therefore controlling 
results of CANTAB assessment may be problematic (Kaser et al., 2017). Also, with the 
absence of a placebo group and the non-blinded design as well as use of commercially 
available soya which limited dose alternatives, future studies could investigate a 
combination of isoflavone supplements and soya foods specifically in western 
populations. Chapter 3 examined dietary patterns associated with cognitive function 
using 4-day cumulative food diaries. Dietary information was collected prior to 
commencing the intervention, and it has been well established the bias which is associated 
with self-reported dietary data. 
As cognitive function was the primary outcome of the intervention, women were not 
recruited based on menopausal symptom status; recruitment stratified by severity of 
menopausal symptoms may have presented with greater benefits from isoflavone 
supplementation. Future studies should aim to recruit post-menopausal women who 
suffer from more severe vasomotor symptoms >5 hot flushes/day. 
 
Finally, this thesis has proposed a number of new research questions highlighted in the 
following areas for future research: 
 
• Do isoflavones have a greater effect on women suffering 5 hot flushes/day, do 
they derive greater benefits on cognitive function? 
 
• Do women taking anti-depressants derive greater health benefits from isoflavone 
supplementation and effects on cognitive function and menopausal symptoms? 
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• In early menopausal women, how does earlier commencement of 
isoflavones/soya drink impact on menopausal symptoms? 
 
 
Overall, results presented in this thesis suggest that isoflavone supplementation may not 
impact cognitive function in post-menopausal women within 7 years of menopausal 
transition. Future studies should investigate effects on early postmenopausal women who 
report memory problems as a result of the menopause or in those with mild cognitive 
impairment. Secondary analysis indicates that isoflavone consumption significantly 
reduced vasomotor symptoms in those with more severe symptoms at baseline. This 
should be corroborated by additional intervention trials assessing the effects of isoflavone 
supplementation using vasomotor symptoms as the primary outcome measure. 
Administration of isoflavones should be considered in food and supplementation form to 
ascertain their effect on menopausal symptoms in early menopause. 
121 
 
 
Bibliography 
 
Kaser, M., Zaman, R. & Sahakian, B. J. 2017. Cognition as a treatment target in depression. 
Psychol Med, 47, 987-989. 
Kritz-Silverstein, D., Von Muhlen, D., Barrett-Connor, E. & Bressel, M. A. 2003. Isoflavones 
and cognitive function in older women: the SOy and Postmenopausal Health In Aging 
(SOPHIA) Study. Menopause, 10, 196-202. 
Li, Y., Liu, K., Lei, W. & Zhang, K. 2010. [Effect of soy isoflavones on peri-menopausal 
symptom and estrogen]. Wei Sheng Yan Jiu, 39, 56-9. 
Maki, P. M. 2013. Critical window hypothesis of hormone therapy and cognition: a scientific 
update on clinical studies. Menopause, 20, 695-709. 
Messina, M. 2016. Soy and Health Update: Evaluation of the Clinical and Epidemiologic 
Literature. Nutrients, 8. 
Messina, M. & Gleason, C. 2016. Evaluation of the potential antidepressant effects of soybean 
isoflavones. Menopause, 23, 1348-1360. 
Roberts, R. O., Roberts, L. A., Geda, Y. E., Cha, R. H., Pankratz, V. S., O'connor, H. M., 
Knopman, D. S. & Petersen, R. C. 2012. Relative intake of macronutrients impacts risk 
of mild cognitive impairment or dementia. J Alzheimers Dis, 32, 329-39. 
Setchell, K. D., Brown, N. M., Zhao, X., Lindley, S. L., Heubi, J. E., King, E. C. & Messina, M. 
J. 2011. Soy isoflavone phase II metabolism differs between rodents and humans: 
implications for the effect on breast cancer risk. Am J Clin Nutr, 94, 1284-94. 
Shifren, J. L., Gass, M. L. & Group, N. R. F. C. C. O. M. W. W. 2014. The North American 
Menopause Society recommendations for clinical care of midlife women. Menopause, 
21, 1038-62. 
Taku, K., Melby, M. K., Kronenberg, F., Kurzer, M. S. & Messina, M. 2012. Extracted or 
synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: 
systematic review and meta-analysis of randomized controlled trials. Menopause, 19, 
776-90. 
121 
 
 
 
 
 
 
 
 
 
APPENDIX 1 
Confirmation of ethical approval 
122 
 
 
 
 
Chapter 4 confirmation of ethical approval 
 
 
 
 
 
123 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 2 Nutritional content of soya drinks used 
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Typical Values Typical Values per 100 ml 
Energy 161 kJ / 39 kcal 
Fat 1.8 g 
of which - 
Saturates 0.3 g 
Carbohydrate 2.5 g 
of which - 
Sugars 2.5 g 
Fibre 0.5 g 
Protein 3.0 g 
Salt 0.08 g 
Vitamins: - 
D 0.75 µg* 
Riboflavin (B2) 0.21 mg* 
B12 0.38 µg* 
Minerals: - 
Calcium 120 mg* 
Iodine 22.5 µg* 
* = 15% of the nutrient reference values - 
These values are approximate due to the 
variations which occur in natural ingredients 
- 
Lactose nil 
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Typical Values Typical Values per 100 ml 
Energy 260 kJ / 62 kcal 
Fat 1.8 g 
of which - 
Saturates 0.3 g 
Carbohydrates 7.6 g 
of which - 
Sugars 7.6 g 
Fibre 0.5 g 
Protein 3.3 g 
Salt 0.14 g 
Vitamins: - 
D 0.75 µg* 
Riboflavin (B2) 0.21 mg* 
B12 0.38 µg* 
Minerals: - 
Calcium 120 mg* 
Lactose nil 
*= 15% of the nutrient reference 
values 
- 
These values are approximate due to 
the variations which occur in natural 
ingredients 
- 
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Typical Values Typical Values per 100 ml 
Energy 326 kJ / 78 kcal 
Fat 2.1g 
of which - 
Saturates 0.6g 
Carbohydrate 10.9g 
of which - 
Sugars 9.3g 
Fibre 1.0g 
Protein 3.3g 
Salt 0.14g 
Vitamins: - 
D 0.75µg* 
Riboflavin (B2) 0.21mg* 
Vitamin B12 0.38µg* 
Minerals: - 
Calcium 120mg* 
* = 15% of the nutrient reference values - 
These values are approximate due to the 
variations which occur in natural ingredients. 
- 
Lactose nil 
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APPENDIX 3 
Copies of questionnaires 
• • 
IMini mental State 
Page.1 
111111111 
 • 
1.0rientation 
• 
What is today's date? 
What is the year? 
What is the month? 
What day is today? 
What season is it? 
What is the name of this place? 
What floor are we on? 
correct D 
D 
D 
D 
D 
D 
What is the name of the town we are in? 
D 
D 
DWhat county are we in? 
What country are we in? 
2.lmmediate recall 
D 
D Incorrect 
D 
D 
D 
D 
D 
D 
D 
D 
D 
Ask subject to repeat these words. Allow 1 second per word, and up to 6 trials. 
Score 3 points if correct first time, 2 if correct the second time, and one if correct the 
third time. Ask patient to keep the three things in mind. 
Ball 
Flag 
Tree 
recall D D not recall 
D 
D 
3.Attention and concentration. 
D 
D 
Ask the patient to take seven from 100, then seven from the result and so on for five 
subtractions. Score 1 point for each correct answer. 
93 Correct D D Incorrect 
86 D D 
79 D D 
72 D D 
65 D D 
4.Memory recall. 
Ask the patient to recall the three objects from 2. 
Ball Correct D D Incorrect 
Flag 
Tree 
D D 
5.Language. 
D D 
Show two familiar objects and ask to name. 
Pen Correct D D Incorrect 
Watch Correct D D Incorrect 
Ask the patient to repeat the sentence "No ifs, ands or buts" 
Correct D D Incorrect 
Ask the patient Please take th paper in your left hand. 
Correct D D Incorrect 
Fold it in half. 
Correct D D Incorrect 
Put the paper on the floor. 
Correct D D Incorrect 
Appendix 1 Mini Mental State Examination
• • 
• • 
Ask the patient to read the following instructions "CLOSE YOUR EYES". 
Correct D Incorrect D 
Ask patient to write simple sentence, with a subject, verb and should make sense. 
Correct D Incorrect D 
Visual reconstruction. 

Ask patient to copy a picture of intersecting pentagons. 

Correct D Incorrect D 
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Close your eyes. 

Appendix 1 Mini Mental State Examination
Please read this carefully: 
We should like to know if you have had any medical complaints, and how your health has 
been in general, over the past few weeks. Please answer ALL the questions on the following 
pages simply by underlining the answer which you think most nearly applies to you. 
Remember that we want to know about present and recent complaints, not those that you 
had in the past. 
It is important that you try to answer ALL the questions. Thank you very much for your 
cooperation. 
HAVE YOU RECENTLY: 
AI. Been feeling perfectly well and in good health? 
Not No more Rather more Much more 
at all than usual than usual than usual 
A2. Been feeling in need of a good tonic? 
Not 1\10 more Rather more Much more 
at all than usual than usual than usual 
A3. Been feeling run down and out of sorts? 
Not No more Rather more Much more 
at all than usual than usual than usual 
A4. Felt that you are ill? 
Not No more Rather more Much more 
at all than usual than usual than usual 
AS. Been getting any pains in your head? 
Not No more Rather more Much more 
at all than usual than usual than usual 
A6. Been getting a feeling of tightness or pressure in your head? 
Not No more Rather more Much more 
at all than usual than usual than usual 
A7. Been having hot or cold spells? 
Not 1\10 more Rather more Much more 
at all than usual than usual than usual 
B1. Lost much sleep over worry? 
Not No more Rather more Much more 
at all than usual than usual than usual 
B2. Had difficulty in staying asleep once you are off? 
Not No more Rather more Much more 
at all than usual than usual than usual 
B3. Felt constantly under strain? 
Not No more Rather more Much more 
at all than usual than usual than usual 
B4. Been getting edgy and bad-tempered? 
Not No more Rather more Much more 
at all than usual than usual than usual 
BS. Been getting scared or panicky for no good reason? 
Not No more Rather more Much more 
at all than usual than usual than usual 
B6. Found everything getting on top of you? 
Appendix 2. General Health Questionnaire-28 (GHQ-28)
Not No more Rather more 
at all than usual than usual 
B7. Been feeling nervous and strung-up all the time? 
Not l'Jo more Rather more 
at all than usual than usual 
C1. Been managing to keep yourself busy and occupied? 
Not No more Rather more 
at all than usual than usual 
C2. Been taking longer over the things you do? 
Not No more Rather more 
at all than usual than usual 
C3. Felt on the whole you were doing things well? 
Not No more Rather more 
at all than usual than usual 
C4. Been satisfied with the way you've carried out your task? 
Not No more Rather more 
at all than usual than usual 
CS. Felt that you are playing a useful part in things? 
Not No more Rather more 
at all than usual than usual 
C6. Felt capable of making decisions about things? 
Not No more Rather more 
at all than usual than usual 
C7. Been able to enjoy your normal day-to-day activities? 
Not No more Rather more 
at all than usual than usual 
01. Been thinking of yourself as a worthless person? 
Not No more Rather more 
at all than usual than usual 
02 . Felt that life is entirely hopeless? 
Not No more Rather more 
at all than usual than usual 
03. Felt that life isn't worth living? 
Not No more Rather more 
at all than usual than usual 
Much more 
than usual 
Much more 
than usual 
Much more 
than usual 
Much more 
than usual 
Much more 
than usual 
Much more 
than usual 
Much more 
than usual 
Much more 
than usual 
Much more 
than usual 
Much more 
than usual 
Much more 
than usual 
Much more 
than usual 
04. Thought of the possibility that you might make away with yourself? 
Not l'Jo more Rather more Much more 
at all than usual than usual than usual 
05. Found at times you couldn't do anything because your nerves were too bad? 
Not No more Rather more Much more 
at all than usual than usual than usual 
06. Found yourself wishing you were dead and away from it all? 
Not No more Rather more Much more 
at all than usual than usual than usual 
07. Found that the idea of taking your own life kept coming into your mind? 
Not No more Rather more Much more 
at all than usual than usual than usual 
Appendix 2. General Health Questionnaire-28 (GHQ-28)
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Appendix 3     
The effect of soya foods on cognitive function and menopausal symptoms in 
postmenopausal women. 
 
Screening Questionnaire 
 
Name: _________________________         Date of Birth:__________________ 
 
1. Can you confirm that your last menstrual period was at least 12 months but not longer 
than 5 years ago? 
 
Yes      No      
 
2. How long ago (approximately) did you experience your last menstrual cycle (period)? 
 
____________________________ 
 
3. Did you go become menopausal as the result of surgery (i.e. removal of both ovaries)? 
 
Yes      No       
4. Do you currently consume soya foods? 
 
Yes      No       (go to Q6) 
 
5. If you answered ‘yes’ to Q4 how often would you consume soya foods per week? 
 
< once per week     1-2 times per week    > 2 times per week   
 
6. Are you currently on hormone therapy? 
 
Yes      No      
 
7. Are you currently taking soya/isoflavone supplements?  
Yes      No      
 
8. Have you taken an antibiotic within the last 3 months?  
Yes      No      
 
9. Are you currently taking medication for the treatment of a psychiatric condition? 
 
Yes      No        (go to Q11)    
   version 1 (02 Feb 2015) 
      
10. If you answered ‘yes’ to Q9 which medication(s) are you currently taking?  ________________________________________________  
11. Do you suffer from or have a history of any of the following conditions:   
cardiovascular disease   
cancer   
diabetes   
thyroid disease   
renal disease   
kidney disease   
alcohol or drug abuse      
Thank you for taking the time to complete this questionnaire. 
 
 
 
Researcher’s signature ____________________ 
 
Date___________________ 











• 
• 
• 
• 
Life style questionnaire. 
The questionnaire is all about your general life style. 

The researcher will have a quick look through the questionnaire when you have finished, and 

will help you with any sections that you have had trouble with. 

1- General information. 
What is your date of birth? _'_'_. Age__(in years). 
What is your gender? male D D female 
1-1 Marital status. 
Please specify what your marital status is at present, tick the approprate box? 
Married D 
Fulltime relationshipD 
Separated D 
Divorced D 
Widowed D 
Single D 
Do you have any children? yesD Dna 
If yes, how many children do you have? 
1-2 Education. 
Can you indicate by ticking the appropriate boxes which of the following you have attended? 
Yes No 
No education D 0 
Primary education 0 0 
Secondary education D D 
Tertiary education D D 
(University, Higher or further education college) 
At what age did you leave school? 

1-3 Occupation. 

Please indicate which of the following boxes best desribe your present working situation. 

Yes No 
Retired D 0 How long is it since you retired? 
What was your main occupation? 
Still working full time 
Still working part time 
D 
D 
D 
D 
What is your current occupation? 
What is your current occupation? 
Unemployed D D What was your main occupation? 
Give a brief description of the duties under taken by you as part of the job named above. 
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Who else lives in your house with you? 
Yes No 

No one. 00 

Spouse/partner. 00 

Children. 00 

Relatives. 00 

Pets. 0 0 

Others. (not relatives) 0 0 

2-Living Habits. 
2-1Smoking Habits. 
Which of the following statements best describes you? (please tick one box only). 
I smoke every day. 0 
I smoke occasionaly, but not every day. 0 
I used to smoke daily, but don't smoke at all now. 0 
I used to smoke occasionally, but don't smoke at all now. 0 
I have never smoked. 0 
If you have never smoked, please go to question 2-2 Alcohol, page 4. 
If you used to smoke, go to the next set of questions, page 3. 
If you smoke at all, please answer the the following questions. 
Howald were you when you started to smoke? 
What do you usually smoke? (Please tick one box only). 

Cigarettes with filter. 0 

Cigarettes without filter. 0 

Hand rolled cigarettes. 0 

Cigars. 0 

Pipe. 0 

Other (Please specify) . 0 

How often would you smoke the following? 
Cigarettes 
Cigars 
Pipe 
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Can you indicate how many of the following you would smoke on a weekly basis? 
~<;)
,,<;) 
rr><::­rr><::­ ;s;s <;) 
";}<;) b<<;) ~ ~q, ~~ ,,~ 
" 
,,"3 ~q, 
<::-0 ,q, ~o
" 
." ~ b<" 
Cigarettes. D D D D D D D 
Cigars. D D D D D D D 
Pipe. D D D D D D D 
If you smoke more than 50 of any of the above per week, specify what it is you smoke and how 
many you smoke per week. 
If you used to smoke, but have now stopped, please answer the following questions. 
How old were you when you started smoking? 
How old were you when you gave up smoking? 
What did you usually smoke? (please tick one box only). 
Cigarettes with filter tip. D 
Cigarettes with no filter. D 
Hand rolled cigarettes. D 
Cigars. D 
Pipe. D 
Other (please specify). D 
How often did you smoke the following? 
q,<" i'-"" q,q,~"" 0<::­q,"" . ~"" o~ ~ ~<' 
Cigarettes. D D D D 
Cigars. D D D D 
Pipe. D D D D 
Can you indicate how many of the following you used to smoke on a weekly basis? 
~<;)
,,<;) 
rr><::­
rr><::- ;s;s <;) ~ b<<;) ~ ~q,~q, ~~ ,,~ ,,":l ,,':3
." " 
~o<::-0 ,q, ~ b<
" Cigarettes. D D D D D D D 
Cigars. D D D D D D D 
Pipe. D D D D D D D 
If you used to smoke more than 50 of any of the above per week, specify what you smoked and 
how many you smoked per week. 
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2-2 Alcohol. 
Are you a non-drinker or a teetotaller? yes 0 o no If yes , go to section 3 Dietary habits, 
page 6. 
How often do you usually drink alcohol? Please tick only one box. 
everyday 0 
4-6 times per week 0 
2-3 times per week 0 
once a week 0 
once a fortnight 0 
once a month 0 
less than once a month 0 
How often would you drink the following drinks? Please give an answer for each type of drink. 
Each box represents the following answers. 
1 = everyday. 5= once a fortnight. 
2= 4-6 times a week. 6= once a month. 
3= 2-3 times a week. 7= less than once a month. 
4= once a week. 8= never. 
1 2 3 4 5 6 7 8 
Beer 0 0 0 0 0 0 0 0 
Spirits 0 0 0 0 0 0 0 0 
Red wine 0 0 0 0 0 0 0 0 
White wine 0 0 0 0 0 0 0 0 
Liqueurs 0 0 0 0 0 0 0 0 
Shandy 0 0 0 0 0 0 0 0 
Alcopops 0 0 0 0 0 0 0 0 
Other ~ 0 0 0 0 0 0 0 (please speci 
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In relation to the answers you have given in the previous question, about how often you drink 
particular drinks, could you state if these are usually pub measures, glasses, bottles or cans? 
C,v~'lI 
'lI'li 
~ c,c, ~'lI . ~ 'li'" 0­~ ~'li ~'< Ci 'Q . ~ 
Beer. D D D D D 
Spirits. D D D D D 
Red wine. D D D D D 
White wine. D D D D D 
Liqueurs. D D D D D 
Shandy. D D D D D 
Alcopops. D D D D D 
Other (Please specify). D D D D D 
How many of these measures would you usually have for each drink, on each occasion you 
drink it? ~o ~'lI 
,,~ 
"f"" "f'O '\~ C?l 0\ 
Beer. D D D D D 
Spirits. D D D D D 
Red wine. D D D D D 
White wine. D D D D D 
Liqueurs. D D D D D 
Shandy. D D D D D 
Alcopops. D D D D D 
Other (Please specify) . D D D D D 
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3 Dietary Habits. 
1. Do you prepare your own meals? DDDDD 
2. Do you eat alone? DDDDD 
3. How often do you eat a cooked meal?(Please tick one box only) 
Everyday. D 
Regularly (once or more a week). D 
Occasionally (less than once a week) . D 
Never (less than once a month) . o 
4. What do you do with the leftovers from a meal? Yes No 
Throw them away. DO 
Reheat them always. DD 
Reheat them sometimes. DO 
Never reheat them, I eat them cold . DO 
Give to dog. DO 
Other (please specify). DO 
Yes No 
5. Are you on a special diet? DD 
If yes, answer the following questions. 

If no, go to question 6, page 7. 

What kind of diet is it? 

Low salt. 
 DD 
Low fat. DD 
Low calorie. DD 
Weight reduction. OD 
Other (please specify). OD 
How long have you been on this diet? 

less than 6 months. DD 

7 -12 months. DD 

1-3 years . DD 

more than 3 years DD 

(please specify how long) 

Page : 6 
111111111 
Appendix 5. Health and Lifestyle Questionnaire.
• 
• 
• 
• 
Who prescribed the d 
Doctor. 
you? Please select only one answer. 
o 
Dentist. 0 
Dietician/Nutritionist. 0 
Yourself. 
Other 
o 
specify). 0 
Do you buy ready 
If yes, are they: 
Chilled. 
Frozen. 
Canned. 
Other. 
(please specify) 
Yes No 
o 
o 
you have difficulty chewing? 
8. you have dentures? 
9. you wear your dentures for 
Yes No 
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4. Physical Activity. 
This part of the questionnaire is divided into three sections. 
Section 4-1 , asks about your physical activity patterns in and around the house. 
Section 4-2 , asks about physical activity patterns at work. This section does not have to 
be completed by people who have not worked at any stage during the past year. 
Section 4-3, Asks about re'creational activities engaged in during the past year. 
4-1 Home activities. 
Sleeping scale. 
Please select the correct answer for you which describes your sleeping patterns at different 
times of the night and day. 
a. Average time sleeping over the past year. 
During the night. 
Less than 6 hours. D 
6-8 hours . D 
8-10 hours. D 
More than 10 hours. D 
Average time sleeping over the past year. 
In the afternoon or during the day. 
None D 
Less than 30 minutes D 
30mins to 1 hr. D 
1-2 hours. D 
more than 2 hours. D 
b. Average time spent sleeping during each day: 
Laying in a bed . D D D O D D D 
Sitting in an armchair. D DOD D D D 
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Getting about - apart from going to work. 

Please put a tick in the correct box. 

I travel by car most or all of the time. 

I travel by public transport most or all of the time. 

Are you a car owner/driver? 

I work from home. 

Yes No 
00 
00 
00 
00 
Average number of journeys per week, other than travelling to work - by :- (Please tick the 
appropriate box). 
Bicycle 
Walking ooooon 
TV or video viewing. 

Please tick the most appropriate answer for you. 

Hours of TV or video watched per day: 

Weekdays: 
Before6pm. 0 0 D DOD 
After6pm. D D D D n 0 
Weekends: 
Before6pm. 0 D D D D 0 

After6pm. D D D D D 0 
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Stair climbing at home. 
Please tick the box that corresponds to the number of times you climb up a flight of stairs 
(approximately 10 steps) each day at home. 
None. [] 
1-5 times a day. [] 
6-10 times a day. [] 
11-15timesaday. [] 
16-20 times a day. [] 
More than 20 times a day. [] 
Activities in and around the home. 
Give an approximate idea of the number of hours each week you have undertaken the following 
activities, during the last year. Put a tick in the box that correspond with the correct answers for 
you. 
Activities in the home: 
Preparing food, cooking and washing up. 
Shopping for food and groceries. 
Shopping and browsing in shops for other items 
(eg clothes, toys). 
Cleaning the house. 
Doing the laundry and ironing. 
Caring for pre-school children and babies at home 
(not as paid employment) . 
Caring for handicapped, elderly or disables people at 
home (not as paid employment). 
[][][][][][][] 
[][][][][][][] 
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4-2 Activity at work. 

Please answer this section only if you have been in paid employment at any time during the 

past year or if you have carried out regular orgainsed voluntary work during the past year. 

If you have not worked in the past year, go to section 4-3 dealing with recreation, page 13. 
Types of work during the past year. 

We would like to know what full or part time jobs you have done in the past year. For example, 

someone who worked full time for 6 months, then retired and took a voluntary job for 6 hours a 

week should complete these questions. 

Have you worked during the past twelve months? yesO Ona 
How many hours per week would you normally have worked during the past twelve months? 
How many months in the past year did you do this work? 
Activity levels at your work. 

Now we would like you to take the total number of hours you worked per week and divide them 

up according to your activity level. 

First of all, read each of the following categories and tick either Yes or No. Then go back 

through the list and record the number of hours per week that you spent on each activity. 

The number of hours spent in each activity should add up to the number of hours that you 

worked in your job, as you stated above. 
Activities at work. Yes No Hours. 
Sitting lig ht work. o 0 
(eg. desk work, or driving a car or truck) 
Sitting moderate work. o o 
(eg. working heavy levers or driving a 
mower or fork lift truck) 
Standing - light work. o o (eg. lab technician work or working at a shop counter) 
Standing - moderate work. o o 
(eg. fast rate assembly line work) 
Standing - moderate/heavy work. o o 
(eg. masonary/painting) 
Walking at work - carrying nothing heavier than a briefcase. D D 
(eg. moving about a shop) 
Walking - carrying something heavy. o o 
Moving, pushing heavy objects weighing over 751bs. o o 
If you do other activites that are not included here, please tell us about them and state the 
number of hours spent on these activites. 
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Stair or step climbing at work. 
Please indicate, by ticking the the number of times you climb up the 
following at work. 
A flight of stairs (10 
Climb a ladder. 
How many miles is it from your home to your job? 

How many times a week do you travel from home to your job? 

How do you normally travel to your 
By car. 
By works or public transport 
By bicycle. DD 
Walking. DD 
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4-3 Recreation. 
The following questions ask about how you spend your leisure time. Please indicate how often 
you did each activity on average over the past year. For activities that are seasonal, ego cricket 
or mowing the lawn, please put the average frequency during the season when you did the 
activity. 
Please indicate the average length of time that you spent doing the activity on each occasion. 
Example 
You would complete the table below: 
If you had mowed the lawn every fortnight in the grass cutting season and took 1 hour 
and 10 minutes on each occassion. 
If you went walking for pleasure for 40 minutes once a week. 
Please give an answer for the average time you spend on each activity and the number of times 
you did that activity in the past year. 
Activity Hours Mins. Number of times you did the activity in the 
past year. 
None Less than once a 2-3 times once a 2-3 times 4-5 times 
once a month month a month week a week a week 
Mowing the lawn. 1 10 / 
Walking for pleasure. 40 / 
Complete question below in the same way. 
Please give an answer for the average time you spend on each activity and the number times 
you did that activity in the past year. 
Activity Hours Mins. 
Swimming. 

Back packing/ 

mountain climbing. D D D D D D D 0 

Walking for pleasure. D D 0 DOD D D 
(do not include walking as means 

of transportation as this is included in the previous sections) 

Walking the dog. DDDDDDDD 
Cycling. (you should not DDDDDDDD 
include cycling as a means oftransportation) 
D D D D D D D 
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Please give an answer for the average time you spend on each activity and the number 
of times you did that activity in the past year. 
Hours Mins. Number of times you did the activity in 
Activity. the past year. 
Mowing the lawn. 
Watering the grass/lawn 
in summer. DDDDDDDD 
Digging, shovelling or 
chopping wood . DDDDDDDD 
Weeding/pruning . DDDDDDDD 
DIY (eg. carpentry, home or DDDDDDDD 
car maintanance) . 
High impact aerobics, 
step aerobics. D DOD D D D D 
Other types of aerobics. D D D D D D D D 
Exercises with weights. D D D D D D D D 
Conditioning exercises. D D D D D D D D 
(eg . using an exercise bike or rowing 
machine). 
Floor exercises. (eg. stretching, __ D D D D 0 D O D 
bending, keep fit). 
Dancing . D D D D 0 D D D 
Jogging. D D DOD DOD 
ODD D D D D DBowling. 
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Please give an answer for the average time you spent on each activity and the number of 
times you did that activity in the past year. 
Activity. Hours. Mins. Number of times you did the activity in the 
past year. 
Tennis/Badminton. 

Squash. 

Table tennis. 

Golf. 

Football, rugby or 

hockey. (during the season). 

Cricket.(during the season). 

Rowing. 

Netball, volleyball, basketball._ 

Fishing. 

Horse riding. 

Snooker, billiards, darts. 

Play musical instrumentlsing._ 

Ice skating. 

Sailing, wind surfing, boating._ 

Winter sports. 

D D D D D D D D 

D D D D D D D D 

D D D DOD D D 

D D D DOD D D 
D D D D D D D D 
D D D D D D D D 
D D D D D D D D 
D D D D D D D D 
D D D D D D D D 
DDDDDDDD 
D D D D D D D D 
D D D D D D D D 
D D D D D D D D 
D D D D D D D D 
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P\ease an answer for the average time you spent on each activity and the number of 
you did that activity in the past year. 
Activity. Hours Mins. 	 Number of times you did the activity in the 
past year. 
~ 
<$'0 ~ 
'b 	 q}:­0'" 	 ~e
"e ~ q}:­0'" ",,'b ~0 r:,,'b 0 
'S''b'" 	 . ~'O c,'b.....;;;.<$' '1> 
..;s ~,::.e 	 ,,0Martial boxing 	
",0 ,e",,"" rv"-' I).{V:! 0"''00'" 
wrestling. D 
Playing chess. D 
Knitting. D D 	 D 
Computer. 	 D D 
D D 
Volunteer activities. D 
Other exercises/activities. 
--	
D 
(please specify). 
You have now finished this questionnaire - Thank You. 
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Green's 21-item Menopause Symptom Checklist. 

Please indicate the extent to which you are bothered at the moment by any of these 

symptoms, by placing a tick in the appropriate box. 
1 = Not at all. 
2 = a little bit. 
3 = quite a bit. 
4 = extremely. 
Symptoms. 
1. Feeling tired and Jacking in energy. 1 [ 2 [ 3[ 4[ 
2. Heart beating strongly or quickly . l[ 2 l 3[ 4[ 
3. Feeling tense or nervous. l[ 2 [ 3[ 4[ 
4. Difficulty in sleeping. 1 [ 2 [ 3[ 4[ 
5. Excitable. 1l 2 [ 3[ 4[ 
6. Attacks of panic. l[ 2 [ 3[ 4[ 
7. Difficulty in concentrating. l[ 2 [ 3[ 4[ 
8. Loss of interest in most things. 1 [ 2 [ 3[ 4[ 
9. Feeling unhappy or depressed. l[ 2 [ 3[ 4[ 
10. Crying spells. l[ 2 [ 3[ 4[ 
11. Irritability. l[ 2 l 3[ 4[ 
12. Feeling dizzy or faint. 1l 2 l 3[ 4[ 
13. Pressure or tightness in head or body. 1l 2 [ 3[ 4[ 
14. Parts of the body feel numb or tingling. l[ 2 [ 3[ 4[ 
15. Headaches. 1 [ 2 [ 3[ 4[ 
16. Muscle and joint pain. l[ 2 [ 3[ 4[ 
17. Loss of feelings in hands or feet. l[ 2 [ 3l 4[ 
18. Feelings of suffocation. 1 [ 2 [ 3[ 4[ 
19. Hot flushes. I[ 2 [ 3[ 4[ 
20. Sweating at night. l[ 2 [ 3l 4[ 
21. Loss of interest in sex. l[ 2 [ 3[ 4l 
Appendix 6. Green's 21-Item Menopause Symptom Questionnaire.
Appendix 1: CASP-19 Questionnaire 
Here is a list o/statements that people have used to describe their lives or how they/eel. 
We would like to know how often, i/at all, you think this applies to you. 
Tick one box on each line 
Often Some­
times· 
Not 
often· 
Never 
1 2 3 4 
1 My age prevents me from doing the things I would like to 
2 I feel that what happens to me is out of my control 
3 I feel free to plan for the future 
4 I feel left out of things 
5 I can do the things that I want to do 
6 Family responsibilities prevent me from doing what I want 
to do 
7 I feel that I can please myself what I do 
8 My health stops me from doing things I want to do 
9 Shortage of money stops me from doing things I want to 
do 
10 I look forward to each day 
11 I feel that my life has meaning 
12 I enjoy the things that I do 
13 I enjoy being in the company of others 
14 On balance, I look back on my life with a sense of 
happiness 
15 I feel full of energy these days 
16 I choose to do things that I have never done before 
17 I feel satisfied with the way my life has turned out 
18 I feel that life is full of opportunities 
19 
-. 
I feel that the future looks good for me 
-_._-_ .. - -------­
" 
Appendix 7. CASP-19 Questionnaire
• • 
• • 
The PANAS 
This scale consists of a number of words that describe different feelings and emotions. Read each 
item and then mark the appropriate answer in the space next to the word. Indicate to what extent 
you feel this way right now, that is, at the present moment. Use the following scale to record 
your answers. 
1 2 3 4 5 
very slightly a little moderately quite extremely 
a bit 
interested 
distressed 
excited 
upset 
strong 
guilty 
scared 
hostile 
enthusiastic 
proud 
irritable 
alert 
ashamed 
inspired 
nervous 
determined 
attentive 
jittery 
active 
afraid 
~ ~ 0­~" -?~ e;.-4..1\.;:\~ ~ '0"; ~ ~ f...'li ~ ~0
r;:\Cj .-§:0 ~0 .1\.0 ~0 
40 ~~ ~O ~ 0-f 
00 0 00 
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Appendix 8. PANAS 
• • 
• • 
!PERCEIVED STRESS SCALE 

Instructions 
The questions in this scale ask you about your feelings and thoughts during the last month. 
In each case, you will be asked to indicate how often you felt or thought a certain way. Although 
some of the questions are similar, there are differences between them and you should treat each 
one as a separate question. The best approach is to answer each question fairly quickly. That is, 
don't try to count up the number of times you felt a particular way, but rather indicate the alternative 
that seems like a reasonable estimate. 
For each question choose from the following alternatives: 
O=never 

1 =almost never 

2=sometimes 

3=fairly often 

4=very often 

1. 	In the last month, how often have you been upset because of 

something that happened unexpectedly? 

2. 	In the last month, how often have you felt that you were unable to 

control the important things in your life? 

3. 	In the last month, how often have you felt nervous or stressed? 
4. 	In the last month, how often have you dealt with irritating life hassles? 
5. 	In the last month,how often have you felt that you were effectively 

coping with important changes that were occurring in your life? 

6. 	In the last month, how often have you felt confident about your ability 
to handle your personal problems? 
7. 	In the last month,how often have you felt that things were going your way? 
8. 	In the last month, how often have you found that you could not cope 
with all the things that you had to do? 
9. 	In the last month, how often have you been able to control irritations 
in your life? 
10. In the last month, how often have you felt that you were on top of things? 
11. In the last month, how often have you been angered because of 
things that happened that were outside of your control? 
12. In the last month, how often have you found yourself thinking about things 
that you have to accomplish. 
13. 	In the last month, how often have you been able to control the way you 
spend your time? 
14. In the last month, how often have you felt difficulties were piling up so high 
that you could not over come them? 
CIDDDD 

DDDDD 

DDDDD 

DDDDD 

DDDDD 

DDDDD 

DDDDD 

DDDDD 

DDDDD 

DDDDD 
DDDDD 
DDDDD 
DDDDD 
DDDDD 
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Appendix 9. Perceived Stress Scale.
• • 
• • 
ICOPE 

We are interested in how people respond when they confront difficult or stressful events in their lives. 
There are lots of ways to try deal with stress. This questionnaire asks you to indicate what you 
generally do and feel when you experience stressful events. Obviously, different events bring out 
somewhat different responses, but think about what you usually do when you are under a lot of 
stress. 
Then respond to each of the following items by choosing one number for each, using the response 
choices listed just below. 
1=1 usually don't do this at all. 2=1 usually do this a little bit. 
3=1 usually do this a medium amount. 4=1 usually do this a lot. 
Please try to respond to each item separately in your mind from each other item. Choose your 
answers thoughtfully, and make your answers as true FOR YOU as you can. Please answer every 
item. There are no right or wrong answers, so choose the most accurate answer for YOU - not what 
you think "most people" would say or do. Indicate what YOU usually do when YOU experience a 
stressful event. 
1.1 turn to work or other substitute activities to take my mind off things. 
2. I concentrate my efforts on doing something about the situation I'm in. 
3. I say to myself "this isn't real. 
4. I use alcohol or drugs to make myself feel better. 
5. I get emotional support from others. 
6. I give up trying to deal with it. 
7. I take action to try and make the situation better. 
8. I refuse to believe that it has happened . 
9. I say things to let my unpleasant feelings escape. 
10. I get help and advice from other people. 
11. I use alcohol or other drugs to help me get through it. 
12. I try to see it in a different light, to make it seem more positive. 
13. I critize myself. 
14. I try to come up with a strategy about what to do. 
15. I get comfort and understanding from someone. 
16. I give up the attempt to cope. 
17. I look for something good in what is happening . 
18. I make jokes about it. 
19. I do something to think about it less, such as going to the movies, watching 
TV, reading, daydreaming, sleeping or shopping . 
20. I accept the reality of the fact that it has happened . 
1 2 3 4 
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Appendix 10. Brief-COPE.
• • 
• • 
Respond to each of the following items by choosing one number for each, using the response choices 
listed just below. 
1=1 usually don't do this at all. 2=1 usually do this a little bit. 
3=1 usually do this a medium amount. 4=1 usually do this a lot. 
21 . I express my negative feelings .' 
22 . I try to find comfort in my religion or spiritual beliefs . 
23. I try to get advice or help from other people about what to do. 
24. I learn to live with it. 
25. I think hard about what steps to take. 
26. I blame myself for things that happened. 
27. I pray or meditate. 
28. I make fun of the situation . 
1 2 3 4 
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Abstract
Purpose Cognitive decline is commonly reported during the menopausal transition, with memory and attention being 
particularly affected. The aim of this study was to investigate the effects of a commercially available soy drink on cognitive 
function and menopausal symptoms in post-menopausal women.
Methods 101 post-menopausal women, aged 44–63 years, were randomly assigned to consume a volume of soy drink 
providing a low (10 mg/day; control group), medium (35 mg/day), or high (60 mg/day) dose of isoflavones for 12 weeks. 
Cognitive function (spatial working memory, spatial span, pattern recognition memory, 5-choice reaction time, and match 
to sample visual search) was assessed using CANTAB pre- and post-the 12 week intervention. Menopausal symptoms were 
assessed using Greene’s Climacteric Scale.
Results No significant differences were observed between the groups for any of the cognitive function outcomes measured. 
Soy drink consumption had no effect on menopausal symptoms overall; however, when women were stratified according 
to the severity of vasomotor symptoms (VMS) at baseline, women with more severe symptoms at baseline in the medium 
group had a significant reduction (P = 0.001) in VMS post-intervention (mean change from baseline score: − 2.15 ± 1.73) in 
comparison to those with less severe VMS (mean change from baseline score: 0.06 ± 1.21).
Conclusions Soy drink consumption had no effect on cognitive function in post-menopausal women. Consumption of 
~ 350 ml/day (35 mg IFs) for 12 weeks significantly reduced VMS in those with more severe symptoms at baseline. This 
finding is clinically relevant as soy drinks may provide an alternative, natural, treatment for alleviating VMS, highly prevalent 
among western women.
Keywords Isoflavones · CANTAB · Menopausal symptoms · Hot flush · Hot flash · Equol
Introduction
Cognitive decline is commonly reported by peri- and post-
menopausal women and deteriorations in memory; attention 
and processing speed have been observed during the meno-
pausal transition [1–4]. These effects have been attributed 
to a reduction in circulating estrogen concentrations [5]; 
albeit, this has been contested [6]. Hormone therapy (HT) 
remains the most effective treatment for vasomotor meno-
pausal symptoms (VMS) [7] and early observational studies 
supported a beneficial effect of HT on cognitive function 
[8]. Two recent intervention studies have demonstrated that 
HT initiated early in menopause has neither beneficial nor 
harmful effects on cognition [9, 10]. Furthermore, despite 
HT being commonly prescribed for otherwise healthy 
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young/early post-menopausal women, many refrain from 
HT use due to the health risks associated with HT use in 
older women [7, 11]. Alternatively, natural approaches for 
the treatment and prevention of menopausal symptoms are 
thus being sought.
Dietary soy isoflavones (IFs) have been reported to be 
efficacious in the treatment of hot flushes [12] and to have 
the potential to enhance cognitive function in post-menopau-
sal women, having the ability to cross the blood brain barrier 
in small amounts [13, 14]. Genistein and daidzein, the main 
IFs present in the soy bean, can bind to estrogen receptors 
(ERs), and are classified as selective ER modulators, having 
a higher affinity for ER-β than ER-α [15, 16]. ERs are local-
ised throughout the adult brain including the hippocampus, 
where ERβ is more highly expressed in comparison to ERα 
[17], and are also localised within the prefrontal cortex [5]. 
These areas are important for learning, memory, attention, 
and higher order cognitive function, and are particularly sus-
ceptible to age-related decline [18]. Both ER-mediated and 
non-ER-mediated neuroprotective effects have been demon-
strated for soy/IFs using in vitro and animal models [19, 20]. 
Such mechanisms include reduced neuronal loss, inhibition 
of β-amyloid-induced cell death, facilitation of cholinergic 
transmission, reduced free radical generation, anti-inflam-
matory and antioxidant effects [19, 21], and via the modula-
tion of mitochondrial function [20]. Furthermore, a high soy 
diet [22] and soy isoflavone supplementation [23] has been 
shown to improve cognitive function in men. Nevertheless, 
randomised-controlled trials investigating the effects of soy/
IFs on cognitive function in post-menopausal women have 
yielded inconsistent findings, with some showing positive 
effects on cognitive function [24–29] and others demonstrat-
ing null/negative effects [30–33]. Two recent comprehen-
sive reviews [19, 34] have highlighted several variations in 
study design that have likely contributed to these disparate 
outcomes including: age; time since menopause; habitual 
soy/IF intake; IF dose, duration, bioavailability and metabo-
lism, and cognitive function assessment. To date, only one 
study has investigated the effects of soy/IFs on cognitive 
function in post-menopausal women using a food (soy milk) 
[31] rather than a supplement. There is, therefore, a need for 
additional, well-designed studies to further assess the effects 
of IFs on cognitive function.
In line with the ‘critical window hypothesis’ of HT and 
cognitive function that postulates that optimal effects are 
evident with the early initiation [35], limited evidence sug-
gests that younger post-menopausal women (< 60 years) may 
gain more cognitive benefit from soy IFs in comparison to 
their older counterparts [25]. It has also been postulated that 
the effects of soy on health may be determined by an indi-
vidual’s equol producer status [36]. S-equol, a potent ligand 
for ERβ, is an isoflavan formed exclusively via the bacte-
rial conversion of daidzein in the intestine [37] and is only 
produced by ~ 30% of western populations following a soy 
challenge [38–40]. The ability to produce equol has been 
associated with reduced VMS [41]. Furthermore, S-equol 
supplementation alleviates hot flushes [42] and S-equol 
derivatives of soy IFs are now recommended by the North 
American Menopause Society for the non-hormonal man-
agement of VMS [43], who have highlighted the need for 
further studies in this area.
The aim of this study was to investigate the effects of a 
commercially available soy drink on cognitive function and 
menopausal symptoms in post-menopausal women within 
7 years postmenopause. A secondary aim was to assess the 
relationship between equol producer status and cognitive 
function and menopausal symptoms.
Subjects and methods
Design
This 12-week parallel group, randomised, controlled trial 
was conducted between October 2015 and May 2018. All 
procedures were approved by Ulster University’s Research 
Ethics Committee (REC/15/0025) and the study was regis-
tered at http://www.clini caltr ials.gov (NCT03561662). Par-
ticipants were recruited throughout the province of Ulster 
and screening, baseline and post-intervention appointments 
were conducted before and after the 12-week interven-
tion either at the university, the participant’s home, or at 
a location convenient for the participant. The duration of 
intervention was based on previous intervention studies 
in post-menopausal women that have demonstrated that 
soy IF supplementation (60 mg/day) for 6 weeks signifi-
cantly improves frontal lobe function [26], with significant 
improvements in sustained attention and long-term episodic 
memory additionally observed when supplementation is 
extended to 12 weeks [24]. The primary outcome of the 
study was effect on cognitive function and the secondary 
outcome was effect on menopausal symptoms. Sub-analysis 
investigated the effect of the intervention based on severity 
of VMS at baseline and also investigated cognitive func-
tion and menopausal symptoms according to equol producer 
status.
Participants
Eligible participants were apparently healthy women within 
7 year postmenopause (i.e., 1–7 years since last menstrual 
period). Post-menopausal status was confirmed based on 
a serum concentration of follicle-stimulating hormone 
(FSH) > 30 mIU/ml (assessed via electrochemiluminescence 
immunoassay on a Cobas 8000 analyzer [Cobas 602 mod-
ule], Roche Diagnostics at Antrim Area hospital). Exclusion 
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criteria included: surgically induced menopause; habitual 
consumers of soya foods (> 2 serves/week); current use of 
HT or IF supplements; antibiotics use within the previous 
3 months; current use of psychoactive medication; presence 
or history of cardiovascular disease, cancer, diabetes, thy-
roid, renal or kidney disease, alcohol or drug abuse; cog-
nitive impairment as determined by a Mini-Mental State 
Examination score < 24; psychiatric distress as determined 
using a General Health Questionnaire-28 [44] score of ≥ 26; 
red–green colour blind, assessed via the Ishihara test (as 
CANTAB testing requires colour recognition); abnormal full 
blood profile (assessed via a Sysmex KX21-N, Sysmex Ltd, 
UK at Ulster University); and/or insufficient renal/hepatic 
performance assessed via kidney and liver function tests 
(assessed photometrically via a Cobas 6000 analyzer [Cobas 
C501 module], Roche Diagnostics at Causeway Hospital).
Intervention
An independent clinical trial manager used MINIM software 
[45] to randomise recruited women to one of the three treat-
ment groups with an allocation ratio of 1:1:1. Participants 
were asked to consume soy drinks  (Alpro®) providing a 
low (10 mg), medium (35 mg), or high (60 mg) dose of IFs 
daily for a period of 12 weeks and could choose from differ-
ent flavours of drink (original, unsweetened, chocolate, or 
strawberry). Limited evidence suggests that IFs consumed in 
divided doses may be more effective in alleviating menopau-
sal symptoms than a single dose [46, 47], and thus, women 
were advised to spread their intake throughout the day. The 
group that consumed the lowest dose of IFs was considered 
a low-dose control group as beneficial effects of soy IFs on 
post-menopausal health have previously been observed in 
intervention studies at much higher doses [48]; furthermore, 
it was not possible to obtain a placebo control drink. The 
previous soy/IF intervention studies on cognitive function 
in post-menopausal women have used doses ranging from 
60 to 160 mg IFs per day [24–33]. This study utilised a dose 
that was achievable in a commercially available soy drink 
and at a volume that was easily incorporated into an indi-
vidual’s daily diet. Compliance was monitored by measuring 
plasma concentrations of soy IFs. Total genistein, daidzein, 
and equol concentrations were assessed using LC–MS/MS 
by LGC Limited (Cambridgeshire, UK). Equol producers 
were defined as those with a plasma equol concentration of 
> 20 nmol/l (5 µg/l) [40].
Dietary intake, anthropometrics, and general health 
and lifestyle
Weight (kg) and height (cm) were measured at baseline 
and used to calculate BMI [weight (kg)/height (m)2]. Body 
weight was measured to the nearest 0.1  kg using Seca 
770 electronic weighing scales (Brosch Direct Ltd, Peter-
borough, United Kingdom), without footwear and heavy 
clothing. Standing body height was measured to the near-
est 0.1 cm using a Seca 220 stadiometer (Seca Ltd, Ham-
burg, Germany). The participant stood without footwear, 
with their heels together, hands and arms hanging relaxed, 
and measurements were taken with the Frankfurt plane in a 
horizontal position. Dietary intake was assessed at baseline 
and post-intervention using a 4-day food diary. Participants 
received instructions on how to complete the diary from 
a trained researcher and dietary intake was analysed using 
Nutritics nutritional analysis software [49]. A general health 
and lifestyle questionnaire were completed by participants 
at baseline and provided information on age, gender, marital 
status, education level, occupation, smoking habits, alcohol 
use, dietary habits, and physical activity.
Blood collection and processing
Fasted blood samples were collected by a trained phle-
botomist before and after intervention for the analysis of 
serum FSH and plasma IF concentrations. Participants 
were instructed to fast from 10 pm the night prior to blood 
sampling and water intake was encouraged. Fasted blood 
samples were obtained from the antecubital fossa using a 
21-gauge butterfly needle and 8 ml serum and 9 ml ethyl-
enediametetraacetic acid (EDTA) plasma vacutainer tubes 
(Greiner Bio-One GmbH, Kremsmunster, Austria). Fol-
lowing inversion, serum samples were allowed to clot for 
> 60 min and plasma samples placed in refrigeration until 
full blood profile analysis. Following this, all tubes were 
centrifuged at 2200 rpm for 15 min at 4 °C to allow the sepa-
ration of whole blood into its respective components. Fol-
lowing separation, serum and plasma samples were divided 
into aliquots and stored at − 80 °C until further analysis.
Cognitive function
Pre- and post-intervention cognitive function was assessed 
in the morning, after participants had consumed a standard, 
caffeine-free, breakfast. Cognitive function was assessed 
using the Cambridge Neuropsychological Test Automated 
Battery (CANTAB Research Suite; Cambridge Cognition, 
UK) [50]. CANTAB has been extensively validated for 
assessing brain-to-behaviour relationships in adult popula-
tions [51, 52], has proven test–retest reliability [53], and 
is deemed suitable for use with older adults [51]. The fol-
lowing tests were used: spatial working memory (SWM), 
spatial span (SSP), pattern recognition memory (PRM), 
5-choice reaction time (RTI), and match to sample visual 
search (MTS). The tests chosen activate areas of the brain 
that are associated with cognitive decline during the meno-
pausal transition and that are sensitive to hormonal changes, 
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including the hippocampus [54] and prefrontal cortex [5]. 
SWM and SSP activate the temporal and frontal lobe regions 
of the brain; PRM activates the temporal lobe, hippocam-
pus and amygdala; RTI and MTS activate the fronto-striatal 
circuitry [55]. The procedure for assessing SSP, RTI, and 
MTS is described in detail elsewhere [56]. Spatial work-
ing memory (SWM), a sensitive measure of frontal lobe 
and executive function, requires retention and manipula-
tion of visuospatial information. The test began with four 
coloured squares (boxes) shown on the screen. Participants 
were required, by selecting boxes and using a process of 
elimination, to find one blue ‘token’ in each of four boxes 
(only one token is hidden at a time) and use them to fill 
up an empty column on the right-hand side of the screen. 
Touching any box in which a token has already been found 
is an error. The trial was then repeated three times with four 
boxes and then progressed to four trials with six boxes and 
four trials with eight boxes. The colour and position of the 
boxes used are changed from trial to trial to discourage the 
use of stereotyped search strategies and a practice test was 
completed prior to testing. The outcome measure was SWM 
total errors, i.e., the number of times which a box is selected 
that is certain not to contain a token and, therefore, should 
have not been visited by the participant.
Visual memory was assessed using the Pattern Recogni-
tion Memory (PRM) test in a two-choice forced discrimina-
tion paradigm. Participants were asked to remember a series 
of 12 abstract-coloured patterns; each presented for 3 s. They 
were then presented with a series of 12 pairs of old–new pat-
terns and were asked to touch the pattern seen previously in 
each case. This procedure was repeated with a second set of 
12 patterns followed by 12 pairs of patterns for recognition. 
The outcome measure was mean correct latency, i.e., the 
mean time (milliseconds) to respond correctly.
Menopausal symptoms
The Greene Climacteric Scale [57] was used to assess men-
opausal symptoms at baseline and post-intervention. This 
21-item scale provides three main independent measures of 
psychological, somatic, and vasomotor symptoms. Partici-
pants were asked to indicate the extent to which they were 
currently bothered by the list of symptoms on a scale from 
1 ‘not at all’ up to 4 ‘extremely’.
Statistical analyses
An a priori power calculation was conducted using spatial 
working memory total error data obtained from the study 
of Thompson et al. [58]. Based on the probability of a type 
1 error (α) = 0.05 and a Power of 0.9, 41 participants were 
required in each group to be able to reject the null hypothesis 
that the population means of the treatment groups are equal. 
To allow for dropouts, we aimed to recruit 150 women to 
the study. All statistical analyses were performed using the 
Statistical Package for the Social Sciences (SPSS) with sig-
nificance set at P < 0.05 throughout (IBM SPSS Statistics for 
Windows, version 24.0, IBM Corp, Armok NY). Only those 
participants that had completed cognitive testing at both 
baseline and post-intervention were included in the analy-
sis. Intention-to-treat analysis was also performed including 
all participants randomised at baseline and did not change 
the primary outcome findings. The Shapiro–Wilk test was 
used to determine whether data followed a normal distribu-
tion and skewed variables were log-transformed to attain a 
normal distribution prior to analysis or analysed using non-
parametric statistical tests. Transformations were applied to 
SWM, SSP, PRM, RTI, and MTS data. Descriptive statistics 
were used to present participant characteristics at baseline. 
The effect of intervention on the primary outcome measures 
of cognitive function (SWM, SSP, PRM, RTI, and MTS) 
was analysed using an analysis of covariance (ANCOVA) 
with baseline measures included as covariates. The second-
ary outcome measure of menopausal symptoms was ana-
lysed using a Kruskal–Wallis test. IF concentrations were 
compared between groups using a Kruskal–Wallis test with 
post hoc analysis conducted using a Mann–Whitney U test. 
Two outliers with post-intervention genistein concentrations 
of > 800 ng/ml in the low-dose treatment group and one in 
the high-dose group (baseline genistein of 275 ng/ml) were 
removed prior to statistical analysis of IF concentrations 
between groups. Sub-analysis was conducted to determine 
if the effect of the intervention on cognitive function and 
menopausal symptoms was significantly different between 
equol producers and non-producers using a Mann–Whitney 
U test. This test and one-way ANOVA with quadratic con-
trasts were also used in sub-analysis to investigate the effect 
of the intervention on VMS stratifying women according to 
severity of VMS at baseline. Dietary intake pre- and post-
intervention was analysed using the Wilcoxin Signed-Rank 
test.
Results
A total of 101 post-menopausal women completed the study 
and were included in the final analysis. Participant progress 
through the study is illustrated in the CONSORT diagram 
[59] in Fig. 1. Baseline demographic characteristics of the 
study participants are shown in Table 1. There was no sig-
nificant difference at baseline between the groups for any of 
the characteristics presented. Table 2 shows the effect of the 
intervention on cognitive function; no significant differences 
were observed between the groups for any of the cognitive 
function outcomes measured (RTI, SSP, SWM, PRM, and 
MTS). The soy drink had no effect on menopausal symptoms 
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overall (Table 3); however, when women were stratified 
according to the severity of their VMS (hot flushes and 
night sweats) at baseline by splitting into two groups above/
below mean, women with more severe VMS at baseline in 
the medium group had a significant reduction in symptoms 
after consuming the soy drink for 12 weeks, in comparison 
to those with less severe symptoms at baseline (Table 4). 
There was a significant quadratic trend for dose (P = 0.011) 
with the observed reduction in symptoms in the medium-
dose group being significantly greater in comparison to that 
observed in women with more severe VMS at baseline in 
the low-dose control group (P = 0.018) and the high-dose 
group (P = 0.046).
Compliance, as assessed via plasma IF concentrations, 
appeared good (Table 5), albeit some women found it dif-
ficult to consume the instructed volume of soy drink in the 
high-dose group, with seven women failing to complete the 
intervention for this reason. Blood samples were available 
for IF analysis for 95 participants at baseline and 87 post-
intervention. IF concentrations were not significantly differ-
ent between groups at baseline. As expected, post-interven-
tion genistein concentration was significantly higher in the 
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Analysed 10 mg/d (n=35) Analysed 35mg/d (n=37) Analysed 60mg/d (n=29)
Enrolment
Allocated to 35mg/day (n=38)
Received allocated
intervenon (n=38)
Allocated to 10mg/day (n=39)
Received allocated
intervenon (n=39)
Disconnued intervenon (n=1)
No longer wished to parcipate
(n=1)
Disconnued intervenon (n=9)
Could not consume volume of
drink required (n=7)
Family illness (n=1)
Illness (n=1)
Fig. 1  CONSORT diagram of participant flow. A total of 394 women 
were assessed for eligibility with 279 excluded due to not meeting the 
inclusion criteria (n = 146) or not wishing to participate in the study 
(n = 133). Remaining post-menopausal women were randomised to 
receive a soy drink  (Alpro®) and asked to consume a volume pro-
viding either 10  mg (n = 39), 35  mg (n = 38) or 60  mg (n = 38) IFs 
daily. A total of 14 participants were lost to follow up owing to illness 
(n = 3) unrelated to the intervention, antibiotic use (n = 2), no longer 
wishing to participate (n = 1), family illness (n = 1) or being unable to 
consume the soy drink (n = 7). A total of 101 women completed the 
study and were included in the final analysis
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medium- (P = 0.007) and high-dose (P = 0.013) groups in 
comparison to the low-dose group. Post-intervention daid-
zein was also significantly higher in the medium- (P = 0.006) 
and high-dose (P = 0.029) groups versus the low group. 
There was no significant difference in post-intervention IF 
concentrations between the medium- and high-dose groups. 
Some 28.7% of the cohort was classified as equol produc-
ers with n = 7, n = 9, and n = 9 participants classified as 
equol producers within the low-, medium-, and high-dose 
groups, respectively. In sub-analysis, cognitive performance 
was not significantly different according to equol status 
(Table 6) albeit, within the high-dose group, spatial working 
memory improved in equol producers (change from base-
line − 9.44 ± 15.69, n = 9) in comparison to non-producers 
(2.36 ± 13.24, n = 23), though this effect did not reach sig-
nificance (P = 0.066). VMS were significantly lower in equol 
producers in comparison to non-producers at both baseline 
(3.67 ± 1.01 vs 4.49 ± 1.60, P = 0.022) and post-intervention 
(2.96 ± 1.04 vs 3.86 ± 1.67, P = 0.046).
Table 1  Baseline participant characteristics
Characteristics were not significantly different between treatment 
groups
FSH follicle-stimulating hormone, GHQ-28 General Health Ques-
tionnaire-28, LMP time since last menstrual period, METs metabolic 
equivalents, MMSE mini-mental state examination, PA physical activ-
ity
a Data on smoking, alcohol use, education, and physical activity 
were unavailable for 4 participants (n = 1, n = 2 and n = 1 in the low-, 
medium-, and high-dose groups, respectively) as they failed to com-
plete the health and lifestyle questionnaire
b Mean ± SD (all such values with the exception of smoking and edu-
cation)
Measurea Soy IF treatment group
Low (n = 35) Medium (n = 37) High (n = 29)
Age (years) 53.69 ± 3.72b 53.86 ± 3.28 53.72 ± 4.62
Height (m) 1.61 ± 0.065 1.64 ± 0.062 1.63 ± 0.073
Weight (kg) 70.32 ± 12.36 71.48 ± 13.85 72.91 ± 14.86
BMI (kg/m2) 26.97 ± 5.22 26.76 ± 5.73 27.37 ± 5.77
Non-smokers (%) 94.12 100 100
Alcohol (units/
week)
7.64 ± 6.58 11.73 ± 12.60 7.44 ± 10.21
Education level (n)
 Primary 0 1 0
 Secondary 19 13 12
 Tertiary 15 21 16
PA (METs/week) 165.17 ± 56.32 184.70 ± 57.48 192.74 ± 76.98
LMP (months) 31.97 ± 19.05 39.33 ± 21.99 39.38 ± 23.25
FSH (IU/ml) 83.02 ± 34.44 88.79 ± 28.33 85.84 ± 33.84
GHQ-28 16.91 ± 4.82 14.73 ± 5.48 15 ± 4.6
MMSE 29.17 ± 0.79 29.03 ± 1.07 29.21 ± 0.73
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Energy intake, carbohydrate, protein, and total fat intake 
were not significantly different between the low-, medium-, 
and high-dose groups at baseline or post-intervention 
(Table 7). In the high-dose group, protein and total fat intake 
(expressed as % energy intake) were significantly lower post-
intervention in comparison to baseline. Using the Goldberg 
cut-off technique [60], 12.8% and 15.7% of participants were 
identified as mis-reporters at baseline and post-intervention, 
respectively. Of these, three were within the low, two within 
the medium, and five within the high-dose groups at baseline 
with six within the low, two within the medium, and three 
within the high-dose groups post-intervention.
Discussion
In the current study, consumption of a soy drink for 
12 weeks, providing 35 or 60 mg of IFs/day, had no effect on 
visual memory, working memory, or attention, in apparently 
healthy post-menopausal women in comparison to consump-
tion of a low-dose control providing 10 mg IFs/day. We did 
not observe a significant effect for menopausal symptoms; 
albeit, sub-analysis identified a potential beneficial effect 
of soy IFs in women with more severe VMS at baseline. 
Our findings on cognitive function are in agreement with 
the previous studies that observed no beneficial effects of 
isoflavone supplementation on cognition in post-menopausal 
women [30, 32, 33]. In contrast, others have demonstrated 
an improvement in frontal lobe function (mental flexibility 
and planning) [24, 26], long-term episodic memory, sus-
tained attention [24], psychomotor performance [27], verbal/
semantic memory [25], and visual memory [29]. Variations 
in study design make it difficult to draw direct comparisons 
between the findings of our study and previous work. Mixed 
results may be reflective of the different cognitive tests used. 
Although two studies, showing beneficial effects, utilised 
CANTAB to assess cognitive function [24, 26], neither used 
the same tests as the current study. Given the wide range 
of methodologies currently available to assess cognitive 
function, there is a need to identify a standard method and 
testing suite to enable a better comparison between stud-
ies and reliably inform scientific knowledge in this area. 
Conflicting results may also be reflective of variation in the 
dose and duration of isoflavone supplementation used. Three 
studies that report improvements in cognitive function with 
soy IF supplementation have used much higher doses and/
or have intervened over a longer duration than that used in 
the current study [25, 27, 29]. Furthermore, age/time since 
menopause may be a key factor in determining response to 
soy isoflavones, with Kritz-Silverstein et al. [25] observ-
ing significant effects on a test of visumotor tracking and 
attention in younger (50–59 years) but not older women 
(60–74 years). Kreijkamp-Kaspers et al. also observed no Ta
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significant effects using the same test in a cohort of older 
post-menopausal women, aged 60–75 years [30]. In the 
longest intervention trial conducted to date, supplementa-
tion of 91 mg IFs daily for 2.5 years had no effect on global 
cognition, executive function, or verbal episodic memory in 
healthy post-menopausal women albeit, an improvement in 
a visual memory factor was observed [29]. In contrast to our 
study, there was a wide age range in this study (45–92 years) 
with almost half of the cohort > 10 years postmenopause; 
sub-analysis suggested that such women were less likely to 
show cognitive improvement and this may, therefore, have 
influenced the null findings in this study. Finally, differences 
in the makeup of the supplement used, in terms of the indi-
vidual isoflavone constituents, may account for the observed 
mixed findings on cognition. Genistein and daidzein have 
distinct biological effects, e.g., genistein is a potent inhibi-
tor of protein tyrosine kinase (PTK) [61], whereas daidzein 
is not a PTK inhibitor [62]. Genistein is now thought more 
promising as a treatment for Alzheimer’s disease [63–65].
To our knowledge, only one other study has investigated 
the effects of IFs on post-menopausal cognition in the form 
of a soy drink [31]. In this study, consumption of IFs via 
a drink (72 mg/day) or a supplement (70 mg/day) over 
16 weeks did not improve short-term memory, long-term 
memory, working memory, or selective attention as assessed 
using tests similar to those used in our study. The soy milk 
group showed a poorer performance in verbal working mem-
ory in comparison to the supplement and control groups; 
albeit this study was subject to limitations including subjec-
tive compliance, lack of power, and lack of controls, owing 
to the quasi-experimental design.
In agreement with the previous literature, 28.7% of our 
study cohort were equol producers [38–40]. Limited evi-
dence suggests that the ability to produce equol may confer 
beneficial effects on cognitive function following soy intake 
[66, 67], potentially via increased cerebral blood flow [68]. 
We did not observe any significant differences in cognitive 
performance following intervention between equol pro-
ducers and non-producers, although, within the high-dose 
group, improvements in spatial working memory in produc-
ers versus non-producers were approaching significance. Our 
findings support those of Henderson et al. [29] who observed 
a nonsignificant trend towards improved global cognition in 
consistent equol producers. Similar to Henderson’s study, 
the sample size in the current study was likely too small to 
adequately investigate the role of equol in cognitive perfor-
mance and further research in this area is warranted.
In agreement with our findings, previous studies, includ-
ing 2 that used the same scale as that in the current study 
[24, 26], have reported no effect of IF supplementation on 
menopausal symptoms [24, 26, 32]. Basaria et al. observed 
an improvement in menopausal symptoms using the men-
opause-specific quality-of-life questionnaire; however, the Ta
bl
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dose used in this study was very high (160 mg/day) [33]. 
A recent meta-analysis has demonstrated that soy IF sup-
plementation can significantly reduce hot flush frequency 
and severity in comparison to placebo, with supplements 
containing > 18.8  mg of genistein being most effective 
[12]. In support of these findings, our study has shown that 
women with more severe VMS at baseline showed a signifi-
cant improvement in symptoms following consumption of 
35 mg IFs/day (providing ~ 18 mg genistein) in comparison 
to those consuming 10 mg/day. This observation was not 
replicated in the high-dose group, possibly due to the sample 
size, and thus, further studies are required to confirm these 
findings. Our findings in the medium group are in agreement 
with an open-label crossover study that demonstrated a com-
mercial soy drink  (ViveSoy®), providing ~ 50 mg IFs per 
day for 12 weeks, improved climacteric symptoms including 
hot flushes in peri/post-menopausal women [69]. Previous 
research on the effects of soy foods on menopausal symp-
toms is limited [70] and our findings warrant further study in 
this area. In support of the role of S-equol in the alleviation 
Table 5  IF concentrations at baseline and following 12 weeks’ soy drink intervention
BLD below limit of detection
a Mean ± SD (all such values)
A,B Values with different superscript letters across a row are significantly different (Kruskal–Wallis with post hoc Mann–Whitney U test)
Treatment group Low Medium High
Baseline (n = 32) Week 12 (n = 32) Baseline (n = 35) Week 12 (n = 32) Baseline (n = 28) Week 12 (n = 23)
Genistein (ng/ml) 10.01 ± 22.07a 82.75 ± 124.62A 9.83 ± 24.25 168.71 ± 166.81B 6.40 ± 9.27 216.71 ± 305.36B
Daidzein (ng/ml) 5.03 ± 11.88 20.44 ± 30.82A 2.29 ± 4.37 39.20 ± 36.9B 2.50 ± 3.34 49.82 ± 66.49B
Equol (ng/ml) 1.76 ± 6.01 3.81 ± 8.17A BLD 9.43 ± 19.84A 0.42 ± 1.30 11.69 ± 19.23A
Table 6  Effect of soy drink intervention on cognitive performance 
stratifying women according to equol producer status
RTI five-choice reaction time measured as reaction time latency (ms), 
SSP spatial span measured as the longest sequence length recalled 
correctly, SWM spatial working memory measured as total errors 
made, PRM pattern recognition memory measured as mean correct 
latency (ms), MTS match to sample visual search measured as mean 
correct reaction time (ms)
a Defined as plasma equol concentration > 20 nmol/l (5 µg/l)
b Independent samples t test or Mann–Whitney U test for non-para-
metric data
c Mean ± SD (all such values)
Cognitive test Change from baseline Pb
Equol non-producers Equol  producersa
n = 62 n = 25
RTI 6.23 ± 54.98c − 6.23 ± 41.30 0.764
SSP 0.21 ± 1.34 0.12 ± 1.42 0.735
SWM − 1.82 ± 15.34 − 6.16 ± 16.36 0.245
PRM − 45.58 ± 533.00 − 62.66 ± 557.10 0.453
MTS − 363.39 ± 675.51 − 163.99 ± 630.38 0.234
Table 7  Dietary intake at baseline and following 12 weeks’ soy drink intervention
Nutrient intake did not differ between the groups at either baseline or post-intervention (Kruskal–Wallis test)
EI energy intake
a Wilcoxon signed-rank test comparing week 12 to baseline within groups
b Mean ± SD (all such values)
Treatment 
group
Low Medium High
Baseline 
(n = 27)
Week 12 
(n = 28)
Pa Baseline 
(n = 27)
Week 12 (n = 21) P Baseline 
(n = 24)
Week 12 
(n = 21)
P
Energy (Kcal/
day)
1532 ± 451.72b 1506 ± 526.37 0.715 1623 ± 549.91 1792.62 ± 665.34 0.845 1562 ± 501.51 1731 ± 583.89 0.163
Carbohydrate 
(g/day)
165.52 ± 47.76 154.21 ± 46.65 0.144 165.67 ± 44.26 162.43 ± 50.24 0.500 173.38 ± 63.37 170.00 ± 54.52 0.472
Protein (g) 74.74 ± 42.49 72.39 ± 24.59 0.726 75.85 ± 33.37 71.90 ± 28.28 0.184 77.21 ± 27.46 70.71 ± 32.31 0.139
Fat (g) 61.07 ± 25.96 59.86 ± 18.31 0.935 59.56 ± 16.74 65.40 ± 23.34 0.887 61.21 ± 23.32 59.00 ± 25.08 0.868
Carbohydrate 
(% EI)
44.32 ± 9.85 45.74 ± 28.91 0.068 42.52 ± 8.99 37.60 ± 7.82 0.184 44.26 ± 5.31 41.00 ± 11.35 0.744
Protein (% EI) 15.55 ± 2.55 18.28 ± 12.52 0.563 15.27 ± 3.42 15.37 ± 5.84 0.500 15.46 ± 2.13 13.59 ± 3.67 0.018
Fat (% EI) 42.76 ± 17.35 47.89 ± 25.98 0.503 42.11 ± 11.52 38.67 ± 12.85 0.112 46.94 ± 19.53 37.71 ± 13.52 0.022
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of VMS [41], equol producers in the current study had sig-
nificantly lower VMS scores throughout in comparison to 
non-equol producers.
Strengths of this study include the use of CANTAB, 
a well-validated method in digital cognitive assessment. 
CANTAB is a sensitive method to detect changes in cogni-
tive domains, including spatial memory, executive func-
tion, and information processing, in response to nutrition 
intervention trials, including soy isoflavone trials [71]. 
Despite being a more sensitive measure, one limitation of 
this method, highlighted within a recent International Life 
Sciences Institute (ILSI) review [71], is the speed/accu-
racy trade-offs associated with the more complex informa-
tion processing tasks available within computerized test 
batteries as well as training/practice effects in compari-
son to simple information processing tasks. In the current 
study, cognitive assessment was conducted 12 weeks apart, 
and thus, training/practice effects would be negligible. 
Cognitive assessment was strictly controlled with partici-
pants consuming the same standard caffeine-free breakfast 
prior to testing at both timepoints. Time since menopause 
was kept within a defined limit of < 7 years and compli-
ance was closely monitored. The main limitations of the 
study were the absence of a placebo control and the non-
blinded study design. Nonetheless, the low-dose control 
drink provided only 10 mg IFs/day, an amount well below 
that typically consumed in Asian populations (~ 25–50 mg/
day) [72] and well below the lowest dose previously used 
in intervention studies on cognitive function in post-men-
opausal women (60 mg/day) [24, 26, 27]. Given that we 
used a commercially available soy drink in the current 
intervention study, we were limited with regard to the dose 
of IFs that could be tested. Nonetheless, it is important to 
investigate the effects of soy foods in addition to IF supple-
ments as consumers may gain additional nutritional bene-
fits from consuming soy food as part of a healthy balanced 
diet [73]. Furthermore, IF pharmacokinetics are similar 
following ingestion of soy foods and IF supplements [74]. 
We did not reach our recruitment target of 41 participants/
group, largely due to participants not meeting the stringent 
inclusion criteria (of note was the substantial number of 
post-menopausal women currently on antidepressants); 
however, the study was still adequately powered (80% 
power) to detect significant effects. Reference ranges are 
not provided for the CANTAB tests used for healthy popu-
lations; however, our data concur with a previous study in 
healthy older women [75].
Our participants were apparently healthy and relatively 
early post-menopausal (< 7 years; mean 3.05 ± 1.78 years 
post-menopausal) and our findings are, therefore, not repre-
sentative of all post-menopausal women. Women > 7 years 
post-menopausal are less likely to be prone to fluctuating 
hormone levels and associated menopausal symptoms [76]. 
Furthermore, our findings cannot be extrapolated to post-
menopausal women suffering mild cognitive impairment; 
further research in this area is needed.
In conclusion, a commercially available soy drink had 
no effect on cognitive function in post-menopausal women. 
Consumption of ~ 350 ml/day (providing 35 mg IFs) for 
12 weeks significantly reduced VMS in those women with 
more severe symptoms at baseline, a finding with potential 
clinical relevance that warrants further research given the 
high prevalence of VMS in western women [77, 78].
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